alpha-Synuclein locus triplication causes Parkinson s disease

DOI: 10.1126/science.1090278
Science, 2003, 302, 841.

#	Paper	IF	Citations
2330	Yeast cells provide insight into alpha-synuclein biology and pathobiology. *Science*, **2003**, 302, 1772-5	33.3	613
2329	Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. **2003**, 40, 453-6		135
2328	Molecular pathways of neurodegeneration in Parkinson's disease. *Science*, **2003**, 302, 819-22	33.3	1382
2327	Proteolytic dysfunction in neurodegenerative disorders. **2004**, 62, 95-119		18
2326	Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. **2004**, 101, 17510-5		263
2325	Influence of different promoters on the expression pattern of mutated human alpha-synuclein in transgenic mice. **2004**, 1, 255-65		29
2324	Biomedicine. Parkinson's--divergent causes, convergent mechanisms. *Science*, **2004**, 304, 1120-2	33.3	337
2323	The ubiquitin proteasome system in synaptic and axonal degeneration: a new twist to an old cycle. **2004**, 165, 27-30		60
2322	Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. **2004**, 101, 8331-6		311
2321	Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study. **2004**, 279, 21966-75		185
2320	Glial cell inclusions and the pathogenesis of neurodegenerative diseases. **2004**, 1, 13-21		48
2319	Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. **2004**, 24, 7400-9		146
2318	Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease. **2004**, 41, 900-7		36
2317	alpha-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. **2004**, 279, 52984-90		43
2316	Lipid rafts mediate the synaptic localization of alpha-synuclein. **2004**, 24, 6715-23		393
2315	Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease. **2004**, 10, 63-72		14
2314	Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. **2004**, 18, 1615-7		67

2313	Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. **2004**, 18, 1713-5	72
2312	Beta-synuclein gene alterations in dementia with Lewy bodies. **2004**, 63, 805-11	138
2311	Molecules that cause or prevent Parkinson's disease. **2004**, 2, e401	3
2310	Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. **2004**, 17, 137-45	156
2309	Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. **2004**, 127, 768-72	118
2308	alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. **2004**, 271, 3180-9	67
2307	Stressor-related impairment of synaptic transmission in hippocampal slices from alpha-synuclein knockout mice. **2004**, 20, 3085-91	14
2306	Could a loss of alpha-synuclein function put dopaminergic neurons at risk?. **2004**, 89, 1318-24	115
2305	Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. **2004**, 6, 1054-61	697
2304	Protein aggregation and neurodegenerative disease. **2004**, 10 Suppl, S10-7	2281
2303	Genetic clues to the pathogenesis of Parkinson's disease. **2004**, 10 Suppl, S58-62	191
2302	Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. **2004**, 10, 1055-63	547
2301	Using human neural stem cells to model neurological disease. **2004**, 5, 136-44	66
2300	Biomarkers of neurodegenerative disorders: how good are they?. **2004**, 14, 347-58	67
2299	Early-onset dementia with Lewy bodies. **2004**, 14, 137-47	20
2298	The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. **2004**, 14, 703-11	210
2297	Disease modification in Parkinson's disease. **2004**, 3, 362-8	58
2296	Lewy-body formation is an aggresome-related process: a hypothesis. **2004**, 3, 496-503	235

2295	PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. **2004**, 3, 652-62	52
2294	How do Parkin mutations result in neurodegeneration?. **2004**, 14, 384-9	50
2293	Accumulation of beta- and gamma-synucleins in the ubiquitin carboxyl-terminal hydrolase L1-deficient gad mouse. **2004**, 1019, 1-9	32
2292	Molecular genetics approaches in yeast to study amyloid diseases. **2004**, 23, 49-60	35
2291	Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease. **2004**, 24, 337-42	9
2290	New aspects of genetic contributions to Parkinson's disease. **2004**, 24, 417-24	15
2289	Proteomic approach to studying Parkinson's disease. **2004**, 29, 271-88	28
2288	Neurobiology of alpha-synuclein. **2004**, 30, 1-21	80
2287	Neurodegeneration and neuroprotection in Parkinson disease. **2004**, 1, 139-54	186
2286	Chasing genes in Alzheimer's and Parkinson's disease. **2004**, 114, 413-38	39
2285	Synucleins and their relationship to Parkinson's disease. **2004**, 318, 163-74	31
2284	Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. **2004**, 318, 225-41	218
2283	Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. **2004**, 82, 163-74	106
2282	Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. **2004**, 55, 174-9	594
2281	Alpha-synuclein in Parkinson's disease: light from two new angles. **2004**, 55, 153-6	29
2280	Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. **2004**, 56, 149-62	455
2279	Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. **2004**, 19, 649-55	33
2278	Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. **2004**, 19, 796-800	60

2277	Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. **2004**, 279, 18614-22	734
2276	Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. **2004**, 43, 2871-8	95
2275	Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. **2004**, 24, 9434-40	369
2274	Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. **2004**, 101, 14966-71	332
2273	Parkinson's disease molecular mechanisms of disease. **2004**, 1, 399-405	8
2272	Population genetics for target identification. **2004**, 1, 69-74	10
2271	Genetics of neurological disorders. **2004**, 4, 317-32	13
2270	Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. **2004**, 43, 4621-33	88
2269	Genetics of Parkinson disease. **2004**, 1, 235-42	30
2268	Familial Occurrence of Dementia With Lewy Bodies. **2004**, 12, 179-188	21
2267	Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. **2004**, 24, 1888-96	334
2266	Recent advances in the pharmacology of neurological gene therapy. **2004**, 4, 91-7	18
2265	Genetic contributions to Parkinson's disease. **2004**, 46, 44-70	68
2264	Commentary on "Alpha-synuclein and mitochondria: a tangled skein". **2004**, 186, 109-11	10
2263	Phosphorylated alpha-synuclein in normal mouse brain. **2004**, 572, 227-32	30
2262	Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. **2004**, 576, 363-8	210
2261	Deletion of multimerin-1 in alpha-synuclein-deficient mice. **2004**, 83, 1176-8	51
2260	Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. **2004**, 27, 691-7	151

2259	Genes, proteins, and neurotoxins involved in Parkinson's disease. **2004**, 73, 151-77	144
2258	Problems and solutions for circuits and synapses in Parkinson's disease. **2004**, 43, 165-8	15
2257	Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. **2004**, 44, 601-7	2228
2256	Alpha-synuclein and transgenic mouse models. **2004**, 17, 123-30	163
2255	No evidence for tau duplications in frontal temporal dementia families showing genetic linkage to the tau locus in which tau mutations have not been found. **2004**, 363, 99-101	7
2254	Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson's disease. **2004**, 367, 97-100	23
2253	Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. **2004**, 25, 761-9	103
2252	A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. **2004**, 10, 1023-31	100
2251	Yeast genetics targets lipids in Parkinson's disease. **2004**, 20, 273-7	26
2250	Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. **2004**, 364, 1167-9	1579
2249	Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. **2004**, 364, 1169-71	869
2248	Parkinson's disease and dementia with Lewy bodies: a difference in dose?. **2004**, 364, 1105-7	70
2247	Alpha-synuclein and chaperones in dementia with Lewy bodies. **2005**, 64, 1058-66	50
2246	Genetics of Parkinson's disease. **2005**, 18, 363-9	145
2245	How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. **2005**, 18, 706-11	56
2244	Does proteasome [corrected] inhibition decrease or accelerate toxin-induced dopaminergic neurodegeneration?. **2005**, 97, 457-60	6
2243	Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. **2005**, 10, 235-44	27
2242	Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration. **2005**, 33, 578-81	82

2241	Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease. **2005**, 33, 586-90	35
2240	Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies. **2005**, 109, 343-54	13
2239	Molecular genetic pathways in Parkinson's disease: a review. **2005**, 109, 355-64	30
2238	Methionine oxidation, alpha-synuclein and Parkinson's disease. **2005**, 1703, 157-69	134
2237	Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. **2005**, 1066, 181-221	83
2236	Environmental toxins and alpha-synuclein in Parkinson's disease. **2005**, 31, 273-82	14
2235	The genetic epidemiology of neurodegenerative disease. **2005**, 115, 1449-57	403
2234	Animal models of multiple system atrophy. **2005**, 28, 501-6	71
2233	Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. **2005**, 93, 1304-13	69
2232	Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity. **2005**, 93, 1542-50	24
2231	Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. **2005**, 94, 839-49	78
2230	Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. **2005**, 95, 1259-76	129
2229	Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. **2005**, 25, 304-14	61
2228	Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. **2005**, 17, 73-80	68
2227	Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. **2005**, 8, 657-63	511
2226	PARK11 is not linked with Parkinson's disease in European families. **2005**, 13, 193-7	21
2225	Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving. **2005**, 29, 763-5	61
2224	A haplotype map of the human genome. **2005**, 437, 1299-320	4818

2223	PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly. **2005**, 272, 4023-33	58
2222	Neurogenetics: insights into degenerative diseases and approaches to schizophrenia. **2005**, 5, 3-14	9
2221	The role of alpha-synuclein in neurodegenerative diseases. **2005**, 105, 311-31	136
2220	Phylogenomic approaches to common problems encountered in the analysis of low copy repeats: the sulfotransferase 1A gene family example. **2005**, 5, 22	17
2219	Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. **2005**, 137B, 5-16	175
2218	Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. **2005**, 57, 439-43	43
2217	A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. **2005**, 57, 429-34	78
2216	Multiple regions of alpha-synuclein are associated with Parkinson's disease. **2005**, 57, 535-41	206
2215	G2019S LRRK2 mutation in French and North African families with Parkinson's disease. **2005**, 58, 784-7	172
2214	Viral vectors as tools to model and treat neurodegenerative disorders. **2005**, 7, 530-9	42
2213	Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. **2005**, 80, 247-59	72
2212	Genetic testing in Parkinson's disease. **2005**, 20, 1-10	38
2211	Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years. **2005**, 20, 479-484	26
2210	Alpha-synuclein mRNA expression in sporadic Parkinson's disease. **2005**, 20, 620-3	44
2209	Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. **2005**, 20, 1191-4	63
2208	Parkinson's disease: a broken nosology. **2005**, 20 Suppl 12, S2-4	17
2207	Alpha-synuclein dysfunction in Lewy body diseases. **2005**, 20 Suppl 12, S37-44	64
2206	Treatment of dementia with Lewy bodies and Parkinson's disease dementia. **2005**, 20 Suppl 12, S77-82	26

2205	Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. **2005**, 110, 298-305	52
2204	The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. **2005**, 112, 1249-54	22
2203	Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. **2005**, 112, 1487-502	1
2202	Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. **2005**, 112, 1613-24	144
2201	Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis. **2005**, 7, 59-67	63
2200	Genetics of parkinsonism. **2005**, 5, 397-404	10
2199	Interaction of myocilin with gamma-synuclein affects its secretion and aggregation. **2005**, 25, 1009-33	27
2198	Pathophysiology: biochemistry of Parkinson's disease. **2005**, 598-611	
2197	A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders. **2005**, 222-226	
2196	Disorders of the mitochondrial respiratory chain. **2005**, 909-926	
2195	Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues. **2005**, 1, 107-20	3
2194	Towards a Molecular Classification of Neurodegenerative Disease. **2005**, 11-23	
2193	Phenotypical Characterization of Genetic Mouse Models of Parkinson Disease. **2005**, 183-192	4
2192	Genetics of parkinsonism. **2005**, 586-597	1
2191	Phenotype/genotype correlations in Parkinson's disease. **2005**, 153-164	
2190	Dieldrin induces ubiquitin-proteasome dysfunction in alpha-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death. **2005**, 315, 69-79	73
2189	Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. **2005**, 14, 71-84	218
2188	Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. **2005**, 14, 3549-56	68

2187	Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. **2005**, 25, 3801-12	229
2186	A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. **2005**, 14, 3407-23	92
2185	Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. **2005**, 11, 539-49	32
2184	Neurodegenerative disorders: Parkinson's disease and Huntington's disease. **2005**, 76, 1058-63	59
2183	The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. **2005**, 14, 1231-41	216
2182	Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. **2005**, 102, 4294-9	322
2181	A combinatorial code for the interaction of alpha-synuclein with membranes. **2005**, 280, 31664-72	153
2180	The E46K mutation in alpha-synuclein increases amyloid fibril formation. **2005**, 280, 7800-7	284
2179	Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants. **2005**, 280, 43179-87	128
2178	Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. **2005**, 25, 10689-99	194
2177	A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. **2005**, 280, 22670-8	198
2176	Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. **2005**, 280, 9678-90	103
2175	Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. **2005**, 25, 6016-24	618
2174	The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. **2005**, 280, 23727-34	255
2173	Aneuploid neurons are functionally active and integrated into brain circuitry. **2005**, 102, 6143-7	137
2172	Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. **2005**, 102, 2162-7	363
2171	Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. **2005**, 280, 30649-52	152
2170	p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. **2005**, 280, 5703-15	150

2169	Neural activity controls the synaptic accumulation of alpha-synuclein. **2005**, 25, 10913-21	203
2168	Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. **2005**, 14, 1709-25	295
2167	The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. **2006**, 43, 557-62	32
2166	Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. **2005**, 280, 42655-42668	206
2165	Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. **2005**, 170, 47-59	94
2164	Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. **2005**, 128, 2654-64	159
2163	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. **2005**, 128, 2786-96	283
2162	Genetics of Parkinson's disease: LRRK2 on the rise. **2005**, 128, 2760-2	78
2161	Molecular pathogenesis of Parkinson's disease. **2005**, 14, 2749-55	162
2160	Toxin-induced models of Parkinson's disease. **2005**, 2, 484-94	535
2159	Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. **2005**, 308, 78-84	28
2158	Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. **2005**, 76, 478-92	85
2157	Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. **2005**, 76, 672-80	453
2156	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. **2005**, 14, 2063-73	348
2155	Genetics of Parkinson's disease. **2005**, 37, 86-96	64
2154	The proteomics of neurodegeneration. **2005**, 5, 259-70	29
2153	A topological model of the interaction between alpha-synuclein and sodium dodecyl sulfate micelles. **2005**, 44, 329-39	108
2152	Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. **2005**, 128, 3000-11	217

2151	Mitochondrial inhibition and oxidative stress: reciprocating players in neurodegeneration. **2005**, 7, 1117-39	68
2150	Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. **2005**, 44, 8251-9	76
2149	Molecular pathophysiology of Parkinson's disease. **2005**, 28, 57-87	982
2148	Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. **2005**, 351, 1081-100	201
2147	Stem cells may reshape the prospect of Parkinson's disease therapy. **2005**, 134, 34-51	45
2146	Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?. **2005**, 134, 18-23	90
2145	Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. **2005**, 134, 109-18	195
2144	Effects of nitration on the structure and aggregation of alpha-synuclein. **2005**, 134, 84-102	127
2143	Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death. **2005**, 139, 137-52	56
2142	Gene dosage and pathogenesis of Parkinson's disease. **2005**, 11, 91-6	80
2141	The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1. **2005**, 11, 488-95	46
2140	Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. **2005**, 20, 64-73	32
2139	Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. **2005**, 20, 401-11	37
2138	Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. **2005**, 20, 898-906	101
2137	Unaltered alpha-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion. **2005**, 374, 189-91	14
2136	Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. **2005**, 375, 112-6	57
2135	SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy. **2005**, 381, 74-9	50
2134	Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. **2005**, 381, 294-8	91

2133	Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. **2005**, 382, 297-9	13
2132	Subcellular localisation of recombinant alpha- and gamma-synuclein. **2005**, 28, 326-34	65
2131	Phosphorylated tau and the neurodegenerative foldopathies. **2005**, 1739, 298-310	101
2130	Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. **2005**, 332, 233-40	64
2129	Single particle detection and characterization of synuclein co-aggregation. **2005**, 333, 1202-10	46
2128	Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. **2005**, 337, 1133-8	127
2127	The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. **2005**, 122, 633-44	164
2126	Parkinson's disease: from causes to mechanisms. **2005**, 328, 131-42	39
2125	Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. **2005**, 65, 405-13	60
2124	Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. **2005**, 192, 274-87	86
2123	Ubiquitin-proteasome system and Parkinson's diseases. **2005**, 191 Suppl 1, S17-27	159
2122	Lewy bodies in Parkinson's disease: protectors or perpetrators?. **2005**, 195, 1-6	21
2121	Controversy: is Parkinson's disease a single disease entity? Yes. **2005**, 11 Suppl 1, S31-7	18
2120	Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease. **2005**, 11, 341-7	13
2119	Yeast as a model for medical and medicinal research. **2005**, 26, 265-73	152
2118	Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. **2005**, 46, 857-68	456
2117	Nosology of Parkinson's disease: looking for the way out of a quagmire. **2005**, 47, 479-82	80
2116	Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. **2005**, 2, 14	254

2115	Drosophila models of neurodegenerative disease. **2005**, 2, 438-46	83
2114	Genetic mouse models of parkinsonism: strengths and limitations. **2005**, 2, 495-503	131
2113	Constitutional aneuploidy in the normal human brain. **2005**, 25, 2176-80	251
2112	Parkinson's disease as a disorder of the aging. **2005**, 2, 299-305	2
2111	Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. **2005**, 19, 533-42	883
2110	Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. **2005**, 11, 80-8	122
2109	Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. **2005**, 7, 672-84	49
2108	The biochemistry of Parkinson's disease. **2005**, 74, 29-52	536
2107	The aggregation and fibrillation of alpha-synuclein. **2006**, 39, 628-34	384
2106	Management of Parkinson's disease dementia : practical considerations. **2006**, 23, 807-22	16
2105	Modulatory neurotransmitter systems and behavior: towards zebrafish models of neurodegenerative diseases. **2006**, 3, 235-47	188
2104	Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. **2006**, 20, 477-505	90
2103	Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. **2006**, 103, 4246-51	221
2102	Copper(II) binding by fragments of alpha-synuclein containing M1-D2- and -H50-residues; a combined potentiometric and spectroscopic study. **2006**, 5068-76	52
2101	Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. **2006**, 15, 3012-23	395
2100	Screening for genetic modifiers of amyloid toxicity in yeast. **2006**, 412, 201-22	14
2099	Existing dopaminergic therapies for Parkinson disease. **2006**, 16, 1613-1625	12
2098	A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. **2006**, 79, 439-48	424

2097	Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. **2006**, 168, 947-61		127
2096	Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. **2006**, 26, 11915-22		322
2095	Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. *Science*, **2006**, 313, 324-8	33.3	1084
2094	Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. **2006**, 90, 4692-700		207
2093	[Genetics of prevalent neurodegenerative disorders]. **2006**, 126, 662-70		4
2092	Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. **2006**, 20, 419-25		541
2091	Characterization of oligomers during alpha-synuclein aggregation using intrinsic tryptophan fluorescence. **2006**, 45, 2752-60		139
2090	Of flies and man: Drosophila as a model for human complex traits. **2006**, 7, 339-67		71
2089	Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. **2006**, 45, 10947-56		66
2088	Current strategies for the treatment of Alzheimer's disease and other tauopathies. **2006**, 10, 665-76		19
2087	Small molecule inhibitors of alpha-synuclein filament assembly. **2006**, 45, 6085-94		301
2086	Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. **2006**, 20, 2302-12		87
2085	Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism. **2006**, 45, 6956-66		65
2084	Small molecule oxidation products trigger disease-associated protein misfolding. **2006**, 39, 611-9		92
2083	Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation. **2006**, 45, 15610-6		67
2082	Synuclein proteins of the pufferfish Fugu rubripes: sequences and functional characterization. **2006** , 45, 2599-607		17
2081	Interactions between fatty acids and alpha-synuclein. **2006**, 47, 1714-24		41
2080	Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease. **2006**, 1, 420-4		25

2079	Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. **2006**, 198, 382-90	125
2078	Hero versus antihero: the multiple roles of alpha-synuclein in neurodegeneration. **2006**, 199, 238-42	18
2077	Getting back to basics. **2006**, 126, 11-5	0
2076	Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. **2006**, 341, 1088-95	80
2075	Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. **2006**, 349, 162-6	335
2074	Identification of human alpha-synuclein specific single chain antibodies. **2006**, 349, 1198-205	28
2073	alpha-Synuclein protects SH-SY5Y cells from dopamine toxicity. **2006**, 349, 1294-300	32
2072	Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. **2006**, 351, 631-8	148
2071	Upregulation of alpha-synuclein in neurons and glia in inflammatory demyelinating disease. **2006**, 31, 597-612	36
2070	A novel mechanism of interaction between alpha-synuclein and biological membranes. **2006**, 360, 386-97	43
2069	LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. **2006**, 12, 76-82	78
2068	Understanding the molecular causes of Parkinson's disease. **2006**, 12, 521-8	240
2067	Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease. **2006**, 48, 329-40	37
2066	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. **2006**, 12, 309-13	2
2065	Parkinson's disease and family history. **2006**, 12, 399-409	39
2064	Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. **2006**, 27, 530-45	122
2063	Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. **2006**, 51, 29-42	421
2062	Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. **2006**, 52, 33-8	360

2061	Genomic rearrangements and gene copy-number alterations as a cause of nervous system disorders. **2006**, 52, 103-21	244
2060	Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. **2006**, 142, 1245-53	85
2059	Diagnosis and treatment of Parkinson disease: molecules to medicine. **2006**, 116, 1744-54	461
2058	A vaccine for Parkinson disease?. **2006**, 1, 21-23	
2057	Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. **2006**, 17, 383-91	49
2056	Genetically Engineered Mouse Models of Neurodegenerative Disorders. **2006**, 371-408	
2055	Parkinson's disease and genetics. **2006**, 12, 240-4	5
2054	A novel P755L mutation in LRRK2 gene associated with Parkinson's disease. **2006**, 17, 1859-62	15
2053	Cognitive change in Parkinson disease. **2006**, 20, 302-10	45
2052	Chaperone Suppression of Aggregated Protein Toxicity. **2006**, 137-164	1
2051	Pilot study of the Human Proteome Organisation Brain Proteome Project: applying different 2-DE techniques to monitor proteomic changes during murine brain development. **2006**, 6, 4899-913	30
2050	Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein. **2006**, 24, 55-64	69
2049	Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. **2006**, 24, 3153-62	126
2048	Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein. **2006**, 96, 950-9	10
2047	Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. **2006**, 97, 1071-7	95
2046	Embryonic stem cell-derived neuron models of Parkinson's disease exhibit delayed neuronal death. **2006**, 98, 45-56	19
2045	Parkinsonism genes: culprits and clues. **2006**, 99, 1062-72	92
2044	Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. **2006**, 99, 1188-96	72

2043	Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. **2007**, 101, 132-41	80
2042	Alpha-synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids. **2007**, 101, 201-11	63
2041	Parkinson's disease: the genetics of a heterogeneous disorder. **2006**, 13, 616-27	38
2040	DNA microarray and proteomic strategies for understanding alcohol action. **2006**, 30, 700-8	13
2039	Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. **2006**, 2, 249-53	263
2038	Amyloid double trouble. **2006**, 38, 11-2	32
2037	Genome structural variation and sporadic disease traits. **2006**, 38, 974-6	63
2036	Common deletions and SNPs are in linkage disequilibrium in the human genome. **2006**, 38, 82-5	303
2035	APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. **2006**, 38, 24-6	928
2034	Hereditary pancreatitis caused by triplication of the trypsinogen locus. **2006**, 38, 1372-4	159
2033	Mendelian disorders deserve more attention. **2006**, 7, 277-82	168
2032	Genetics of Parkinson disease: paradigm shifts and future prospects. **2006**, 7, 306-18	567
2031	Ubiquitin-protein ligase parkin and its role in the development of Parkinson's disease. **2006**, 71, 851-60	13
2030	Ageing and neuronal vulnerability. **2006**, 7, 278-94	728
2029	A century-old debate on protein aggregation and neurodegeneration enters the clinic. **2006**, 443, 774-9	554
2028	Global variation in copy number in the human genome. **2006**, 444, 444-54	3306
2027	Segmental duplication density decrease with distance to human-mouse breaks of synteny. **2006**, 14, 216-21	4
2026	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. **2006**, 14, 322-31	134

2025	14-3-3eta is a novel regulator of parkin ubiquitin ligase. **2006**, 25, 211-21	99
2024	RNA knockdown as a potential therapeutic strategy in Parkinson's disease. **2006**, 13, 517-24	33
2023	NMR mapping of copper binding sites in alpha-synuclein. **2006**, 1764, 5-12	94
2022	Role of selection in fixation of gene duplications. **2006**, 239, 141-51	152
2021	Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. **2006**, 26, 41-50	535
2020	A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease. **2006**, 105-9	16
2019	Yeast as a drug discovery platform in Huntington's and Parkinson's diseases. **2006**, 1, 258-69	47
2018	Overexpression of alpha-synuclein following methamphetamine: is it good or bad?. **2006**, 1074, 191-7	19
2017	Molecular genetics of Parkinson□ disease. **2006**, 42, 858-871	1
2016	Secondary structure and dynamics of micelle bound beta- and gamma-synuclein. **2006**, 15, 1162-74	45
2015	Role of DJ-1 in Parkinson's disease. **2006**, 29, 215-25	73
2014	Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. **2006**, 1, 151-70	293
2013	Genes and the environment in neurodegeneration. **2006**, 26, 341-67	81
2012	Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. **2006**, 26, 781-802	89
2011	Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. **2006**, 113, 331-7	14
2010	alpha-Synuclein promoter RsaI T-to-C polymorphism and the risk of Parkinson's disease. **2006**, 113, 1425-33	15
2009	Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson's disease. **2006**, 113, 1903-8	10
2008	Reverse genetics for proteomics: from proteomic discovery to scientific content. **2006**, 113, 1033-40	3

2007	Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. **2006**, 111, 101-8	45
2006	Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. **2006**, 112, 115-26	68
2005	Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. **2006**, 112, 237-51	158
2004	Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. **2006**, 7, 1-11	176
2003	Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. **2006**, 173, 223-33	57
2002	Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. **2006**, 6, 261-281	251
2001	The diagnosis of Parkinson's disease. **2006**, 5, 75-86	476
2000	Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. **2006**, 5, 355-63	263
1999	Pathophysiology of synuclein aggregation in Lewy body disease. **2006**, 127, 188-202	61
1998	Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. **2006**, 176, 198-215	71
1997	Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. **2006**, 21, 305-13	81
1996	Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. **2006**, 22, 404-20	262
1995	Identification of gene expression changes in transgenic C. elegans overexpressing human alpha-synuclein. **2006**, 22, 477-86	66
1994	Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. **2006**, 23, 198-205	114
1993	Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. **2006**, 23, 522-32	65
1992	Role of nitric oxide in Parkinson's disease. **2006**, 109, 33-41	127
1991	Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset. **2006**, 21, 534-9	42
1990	Recessive Parkinson's disease. **2006**, 21, 885-93	28

1989	Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. **2006**, 21, 728-9	20
1988	No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease. **2006**, 21, 731-2	6
1987	Familial essential tremor with apparent autosomal dominant inheritance: should we also consider other inheritance modes?. **2006**, 21, 1368-74	49
1986	Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. **2006**, 21, 1703-8	127
1985	Ubiquitin-proteasome system and Parkinson's disease. **2006**, 21, 1806-23	153
1984	Identification of a risk haplotype of the alpha-synuclein gene in Japanese with sporadic Parkinson's disease. **2006**, 21, 2157-64	2
1983	Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. **2006**, 59, 298-309	281
1982	Interface between tauopathies and synucleinopathies: a tale of two proteins. **2006**, 59, 449-58	204
1981	Genetics of Parkinson's disease and parkinsonism. **2006**, 60, 389-98	252
1980	Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. **2006**, 129, 686-94	129
1979	The genetics of Parkinson disease: Implications for neurological care. **2006**, 2, 136-46	127
1978	Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. **2006**, 8, 784-92	225
1977	Untangling the tau gene association with neurodegenerative disorders. **2006**, 15 Spec No 2, R188-95	90
1976	Gaucher disease and the synucleinopathies. **2006**, 2006, 78549	35
1975	Role of ubiquitylation in cellular membrane transport. **2006**, 86, 669-707	180
1974	Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. **2006**, 15, 3002-11	67
1973	The role of chaperones in Parkinson's disease and prion diseases. **2006**, 221-58	13
1972	Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. **2006**, 15, 1151-8	185

1971	Dequalinium-induced protofibril formation of alpha-synuclein. **2006**, 281, 3463-72	21
1970	Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. **2006**, 103, 5917-22	44
1969	DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling. **2006**, 15, 743-9	144
1968	Familial occurrence of dementia and parkinsonism: a systematic review. **2006**, 22, 288-95	19
1967	Structural variants: changing the landscape of chromosomes and design of disease studies. **2006**, 15 Spec No 1, R57-66	190
1966	Lewy bodies. **2006**, 103, 1661-8	329
1965	RNAi therapy for neurodegenerative diseases. **2006**, 75, 73-92	20
1964	Current perspectives in dementia with Lewy bodies. **2006**, 2, 461-472	1
1963	6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. **2006**, 281, 9824-31	39
1962	Alpha-synuclein expression modulates microglial activation phenotype. **2006**, 26, 10558-63	112
1961	Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. **2006**, 281, 29739-52	842
1960	Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. **2006**, 26, 3685-96	72
1959	Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. **2006**, 26, 3942-50	257
1958	Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. **2006**, 20, 2050-7	74
1957	Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. **2006**, 281, 334-40	140
1956	Different species of alpha-synuclein oligomers induce calcium influx and seeding. **2007**, 27, 9220-32	590
1955	Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. **2007**, 130, 799-815	155
1954	Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. **2007**, 282, 5862-70	146

1953	A novel pathway for transcriptional regulation of alpha-synuclein. **2007**, 21, 596-607	43
1952	Investigation of alpha-synuclein fibril structure by site-directed spin labeling. **2007**, 282, 24970-9	200
1951	Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. **2007**, 104, 12524-9	155
1950	Parkinson's Disease: Genetics and Pathogenesis. **2007**,	
1949	Copy number variants and common disorders: filling the gaps and exploring complexity in genome-wide association studies. **2007**, 3, 1787-99	157
1948	Parkinson's disease: genetics and beyond. **2007**, 5, 99-113	20
1947	Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. **2007**, 104, 18259-64	134
1946	A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. **2007**, 130, 2277-91	50
1945	Translational considerations for CNS gene therapy. **2007**, 7, 305-18	13
1944	Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease. **2007**, 2, 447-55	4
1943	Merging mouse transcriptome analyses with Parkinson's disease linkage studies. **2007**, 14, 79-89	6
1942	Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. **2007**, 16, 651-66	59
1941	Gene-expression profiling in Parkinson□ disease: discovery of valid biomarkers, molecular targets and biochemical pathways. **2007**, 2, 29-38	7
1940	Technology insight: therapeutic RNA interference--how far from the neurology clinic?. **2007**, 3, 394-404	33
1939	Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease. **2007**, 77, 179-217	10
1938	Parkinson Disease: Molecular Insights. **2007**, 221-239	
1937	Genetic and Environmental Factors in Neurodegenerative Diseases. **2007**, 89-114	1
1936	Genetics of Parkinson's Disease. **2007**, 663-697	3

1935	Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. **2007**, 282, 31621-30	70
1934	Genetics of Parkinson disease. **2007**, 9, 801-11	77
1933	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. **2007**, 30, 1-32	
1932	DEMENTIA WITH LEWY BODIES. **2007**, 13, 69-86	0
1931	Emerging Blueprint of Genome Suggests Structural Rearrangements May Explain Many Sporadic Cases of Disease. **2007**, 7, 46-47	
1930	Impact of recent genetic findings in Parkinson's disease. **2007**, 20, 453-64	73
1929	Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. **2007**, 18, 273-5	111
1928	The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies. **2007**, 60, 17-28; discussion 28-30	45
1927	Protein aggregation mechanisms in synucleinopathies: commonalities and differences. **2007**, 66, 965-74	56
1926	Chapter 8 Synuclein and Synucleinopathies. **2007**, 30, 186-215	4
1925	Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. **2007**, 30, 244-50	439
1924	Exploring the relationship between essential tremor and Parkinson's disease. **2007**, 13, 67-76	145
1923	Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. **2007**, 13, 340-2	27
1922	Association of alpha-synuclein gene haplotypes with Parkinson's disease. **2007**, 13, 343-7	14
1921	LRRK2: a link between familial and sporadic Parkinson's disease?. **2007**, 55, 107-10	12
1920	Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. **2007**, 28, 1421-35	129
1919	Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. **2007**, 28, 1709-17	47
1918	Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates. **2007**, 144, 743-53	62

1917	Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models. **2007**, 357, 596-602	60
1916	Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. **2007**, 357, 1096-9	22
1915	Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. **2007**, 204, 421-32	36
1914	Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. **2007**, 204, 583-8	106
1913	Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. **2007**, 204, 619-30	92
1912	Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. **2007**, 208, 1-25	397
1911	A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. **2007**, 131, 1235-47	652
1910	Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. **2007**, 368, 1132-44	127
1909	Residual structure, backbone dynamics, and interactions within the synuclein family. **2007**, 372, 689-707	125
1908	Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein. **2007**, 374, 454-64	59
1907	Brain CHIP: removing the culprits in neurodegenerative disease. **2007**, 13, 32-8	79
1906	Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant. **2007**, 50, 119-29	84
1905	Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. **2007**, 424, 78-82	81
1904	MAPT gene duplications are not a cause of frontotemporal lobar degeneration. **2007**, 424, 61-5	14
1903	Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. **2007**, 581, 4711-7	71
1902	No gene is an island: the flip-flop phenomenon. **2007**, 80, 531-8	402
1901	Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells. **2007**, 171, 2000-11	81
1900	Genetics of parkinsonism. **2007**, 13 Suppl 3, S233-41	42

1899	Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies. **2007**, 4, 769-81		61
1898	Oxidative stress and the pathogenesis of neurodegenerative disorders. **2007**, 82, 297-325		290
1897	Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors. **2007**, 46, 12522-9		44
1896	Caenorhabditis elegans as a model system for Parkinson's disease. **2007**, 4, 199-217		34
1895	Relevance of Copy Number Variation to Human Genetic Disease. **2007**,		
1894	Role of different regions of alpha-synuclein in the assembly of fibrils. **2007**, 46, 13322-30		83
1893	Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. **2007**, 9, 553-61		91
1892	Role of mitochondrial dysfunction in Parkinson's disease: Implications for treatment. **2007**, 24, 95-105		16
1891	Determination of alpha-synuclein concentration in human plasma using ELISA. **2007**, 67, 431-5		46
1890	Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. *Science*, **2007**, 317, 516-9	33.3	844
1889	Distinguishing Lewy body dementias from Alzheimer's disease. **2007**, 7, 1499-516		22
1888	Autosomal dominant Parkinson's disease and the route to new therapies. **2007**, 7, 649-56		2
1887	Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. **2007**, 7, 1693-729		15
1886	Genetics of Parkinson's disease and parkinsonism. **2007**, 7, 657-66		24
1885	Parkinson's disease: animal models. **2007**, 83, 265-87		9
1884	Genetic aspects of Parkinson's disease. **2007**, 83, 217-44		2
1883	Protein-handling dysfunction in Parkinson's disease. **2007**, 83, 571-90		
1882	Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. **2007**, 18, 115-36		43

1881	Clinical features, pathophysiology and treatment of dementia associated with Parkinson's disease. **2007**, 83, 401-19	9
1880	Isomers of human alpha-synuclein stabilized by disulfide bonds exhibit distinct structural and aggregative properties. **2007**, 46, 602-9	15
1879	Gene therapy for Parkinson's disease. **2007**, 7, 957-60	9
1878	Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. **2007**, 16, 1-14	199
1877	Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. **2007**, 27, 3338-46	235
1876	Gamma-synuclein and the progression of cancer. **2007**, 21, 3419-30	76
1875	GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. **2007**, 46, 1868-77	198
1874	Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation. **2007**, 46, 4499-509	83
1873	Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein. **2007**, 46, 472-82	43
1872	Lewy Body Disorders. **2007**, 267-343	3
1871	Current Concepts on the Etiology and Pathogenesis of Parkinson Disease. **2007**, 105-127	
1870	Environmental exposures and gene regulation in disease etiology. **2007**, 115, 1264-70	182
1869	Clinical Overview and Phenomenology of Movement Disorders. **2007**, 1-42	2
1868	Protein Aggregation Disorders. **2007**, 111-123	2
1867	Dementia with Lewy Bodies. 472-489	
1866	Partial tandem duplication of GRIA3 in a male with mental retardation. **2007**, 143A, 1448-55	29
1865	Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. **2007**, 55, 1178-88	126
1864	The ups and downs of alpha-synuclein mRNA expression. **2007**, 22, 293-5	41

1863	Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification. **2007**, 22, 1708-14	13
1862	Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. **2007**, 22, 932-7	14
1861	Clinical diagnostic criteria for dementia associated with Parkinson's disease. **2007**, 22, 1689-707; quiz 1837	1968
1860	Multiplex ligation-dependent probe amplification assay for simultaneous detection of Parkinson's disease gene rearrangements. **2007**, 22, 2274-8	16
1859	The pathogenesis of cell death in Parkinson's disease--2007. **2007**, 22 Suppl 17, S335-42	170
1858	Update on the genetics of Parkinson's disease. **2007**, 22 Suppl 17, S343-50	125
1857	RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. **2007**, 85, 351-63	107
1856	Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro. **2007**, 85, 1547-57	39
1855	Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. **2007**, 85, 1819-25	70
1854	Optimizing human post-mortem brain tissue gene expression profiling in Parkinson's disease and other neurodegenerative disorders: from target "fishing" to translational breakthroughs. **2007**, 85, 3013-24	20
1853	Role of the ubiquitin proteasome system in Parkinson's disease. **2007**, 8 Suppl 1, S13	80
1852	Dietary restriction modulates alpha-synuclein expression in the aging rat cortex and hippocampus. **2007**, 61, 790-4	12
1851	The proteomic approach in Parkinson's disease. **2007**, 1, 1428-35	7
1850	Mutational and selective effects on copy-number variants in the human genome. **2007**, 39, S22-9	193
1849	Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. **2007**, 8, 639-46	335
1848	Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. **2007**, 8, 101-12	3692
1847	The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element. **2007**, 12, 222-3	135
1846	17p11.2p12 triplication and del(17)q11.2q12 in a severely affected child with dup(17)p11.2p12 syndrome. **2007**, 72, 47-58	17

1845	Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D. **2007**, 26, 863-74		92
1844	Pathological biochemistry of alpha-synucleinopathy. **2007**, 27, 474-8		27
1843	The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. **2007**, 27, 494-506		297
1842	Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. **2007**, 103, 17-37		373
1841	Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. **2007**, 14, 7-11		47
1840	Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1. **2007**, 274, 346-55		14
1839	Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. **2007**, 274, 1862-77		139
1838	Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. **2007**, 1168, 83-9		25
1837	An investigation into the lipid-binding properties of alpha-, beta- and gamma-synucleins in human brain and cerebrospinal fluid. **2007**, 1170, 103-11		8
1836	Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. **2007**, 114, 34-55		38
1835	Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. **2007**, 128, 378-82		51
1834	Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?. **2007**, 25, 134-49		316
1833	Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases. **2007**, 25, 446-54		45
1832	Autophagy and neurodegeneration: when the cleaning crew goes on strike. **2007**, 6, 352-61		389
1831	Molecular biology. miRNAs in neurodegeneration. *Science*, **2007**, 317, 1179-80	33.3	146
1830	Interactions between metals and alpha-synuclein--function or artefact?. **2007**, 274, 3766-74		40
1829	Model fusion, the next phase in developing animal models for Parkinson's disease. **2007**, 11, 219-40		55
1828	LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. **2007**, 32, 1700-8		56

1827	Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms. **2007**, 32, 1646-54	40
1826	Predominant neuritic pathology induced by viral overexpression of alpha-synuclein in cell culture. **2007**, 27, 505-15	16
1825	In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. **2007**, 114, 1559-67	96
1824	Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. **2007**, 113, 253-63	32
1823	alpha-Synucleinopathy models and human neuropathology: similarities and differences. **2008**, 115, 87-95	101
1822	Research into neurodegenerative disease: an entangled web of mice and men. **2008**, 115, 1-4	5
1821	Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. **2007**, 8, 95-102	34
1820	Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. **2007**, 8, 71-81	23
1819	Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene. **2007**, 23, 53-7	23
1818	ATP depletion is the major cause of MPP+ induced dopamine neuronal death and worm lethality in alpha-synuclein transgenic C. elegans. **2007**, 23, 329-35	36
1817	Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. **2007**, 47, 285-99	90
1816	Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. **2007**, 32, 217-27	37
1815	Dequalinium-induced cell death of yeast expressing alpha-synuclein-GFP fusion protein. **2008**, 33, 1393-400	8
1814	Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?. **2008**, 14, 329-41	21
1813	Recent advances in the genetics of dementia with lewy bodies. **2008**, 8, 187-9	14
1812	RNA interference mediated silencing of alpha-synuclein in MN9D cells and its effects on cell viability. **2008**, 24, 96-104	9
1811	Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease. **2008**, 10, 10-6	27
1810	Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. **2008**, 34, 17-22	127

1809	Structural genomic variation in ischemic stroke. **2008**, 9, 101-8	26
1808	Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. **2008**, 116, 37-46	63
1807	Genes associated with Parkinson syndrome. **2008**, 255 Suppl 5, 8-17	69
1806	Exploring gene-environment interactions in Parkinson's disease. **2008**, 123, 257-65	83
1805	Exploiting the proteome to improve the genome-wide genetic analysis of epistasis in common human diseases. **2008**, 124, 19-29	73
1804	In vivo silencing of alpha-synuclein using naked siRNA. **2008**, 3, 19	86
1803	Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease. **2008**, 86, 496-503	37
1802	Transcriptional regulation of mesencephalic dopaminergic neurons: the full circle of life and death. **2008**, 23, 319-28	69
1801	Glial reactions in Parkinson's disease. **2008**, 23, 474-83	550
1800	Susceptibility genes in movement disorders. **2008**, 23, 927-934	2
1799	Neuronal gene expression correlates of Parkinson's disease with dementia. **2008**, 23, 1588-95	38
1798	Discovery and characterization of three novel synuclein genes in zebrafish. **2008**, 237, 2490-5	41
1797	Genomewide SNP assay reveals mutations underlying Parkinson disease. **2008**, 29, 315-22	44
1796	Alpha-synuclein promoter haplotypes and dementia in Parkinson's disease. **2008**, 147, 403-7	15
1795	Genetic association between alpha-synuclein and idiopathic Parkinson's disease. **2008**, 147B, 1222-30	54
1794	Genomic investigation of alpha-synuclein multiplication and parkinsonism. **2008**, 63, 743-50	269
1793	Neurofibrillary tau pathology modulated by genetic variation of alpha-synuclein. **2008**, 64, 348-52	15
1792	A critical evaluation of the Braak staging scheme for Parkinson's disease. **2008**, 64, 485-91	279

1791	A simple method for comparing microarray genotype data between brain and other tissues. **2008**, 173, 315-7	2
1790	The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. **2008**, 131, 1969-78	427
1789	Molecular determinants of the aggregation behavior of alpha- and beta-synuclein. **2008**, 17, 887-98	84
1788	Contribution of disturbed iron metabolism to the pathogenesis of Parkinson□ disease. **2008**, 3, 447-461	1
1787	The use of cell-free systems to characterize parkinson's disease-related gene products. **2008**, 597-627	1
1786	□Synuclein, CSP□SNAREs and Neuroprotection in vivo. **2008**, 295-308	
1785	Viral Vectors: A Potent Approach to Generate Genetic Models of Parkinson's Disease. **2008**, 269-284	
1784	The Bac Transgenic Approach to Study Parkinson's Disease in Mice. **2008**, 247-268	0
1783	The Dynamics of □Synuclein at the Nerve Terminal. **2008**, 237-246	1
1782	Yeast as a model for studying human neurodegenerative disorders. **2008**, 3, 325-38	59
1781	Copy number variant analysis of human embryonic stem cells. **2008**, 26, 1484-9	42
1780	Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. **2008**, 67, 793-802	57
1779	Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. **2008**, 82, 283-9	403
1778	Advances in the genetics of Parkinson's disease. **2008**, 29, 21-34	20
1777	Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. **2008**, 118, 320-7	63
1776	Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?. **2008**, 7, 129-51	69
1775	Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. **2008**, 275, 5748-57	25
1774	Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. **2008**, 275, 5767-73	109

1773	Mitochondrial dysfunction and oxidative damage in the molecular pathology of Parkinson disease. **2008**, 42, 720-728	10
1772	Modeling synucleinopathies in genetically modified animals: Successes and failures. **2008**, 42, 747-761	1
1771	Systematic assessment of copy number variant detection via genome-wide SNP genotyping. **2008**, 40, 1199-203	174
1770	A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. **2008**, 11, 301-8	113
1769	Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. **2008**, 104, 1504-25	168
1768	Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. **2008** , 105, 1656-67	124
1767	FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T. **2008**, 106, 121-33	23
1766	Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. **2008**, 106, 529-40	57
1765	Mitochondrial alterations in Parkinson's disease: new clues. **2008**, 107, 317-28	101
1764	Controlling the mass action of alpha-synuclein in Parkinson's disease. **2008**, 107, 303-16	75
1763	Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells. **2008**, 107, 1722-9	69
1762	Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. **2008**, 27, 947-57	113
1761	The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. **2008**, 28, 2459-73	59
1760	Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. **2008**, 34, 255-71	88
1759	Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. **2008**, 8, 1	32
1758	N-terminal region of alpha-synuclein is essential for the fatty acid-induced oligomerization of the molecules. **2008**, 582, 3693-700	38
1757	Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data. **2008**, 45, 1290-301	15
1756	Generation of a alpha-synuclein-based rat model of Parkinson's disease. **2008**, 30, 8-18	31

1755	Transcriptional dysregulation in a transgenic model of Parkinson disease. **2008**, 29, 515-28	54
1754	Superoxide dismutase overexpression protects dopaminergic neurons in a Drosophila model of Parkinson's disease. **2008**, 30, 65-73	81
1753	Fas-associated factor 1 and Parkinson's disease. **2008**, 31, 309-15	26
1752	Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. **2008**, 3, e1376	264
1751	Neuropathology of Parkinson's Disease. **2008**, 35-48	4
1750	Molecular and cellular biology of synucleins. **2008**, 270, 225-317	73
1749	Concentration dependence of alpha-synuclein fibril length assessed by quantitative atomic force microscopy and statistical-mechanical theory. **2008**, 95, 4871-8	54
1748	Clinical utility of contemporary molecular cytogenetics. **2008**, 9, 71-86	68
1747	Red blood cells are the major source of alpha-synuclein in blood. **2008**, 5, 55-9	325
1746	Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. **2008**, 22, 1327-34	209
1745	Copper(II) binding to alpha-synuclein, the Parkinson's protein. **2008**, 130, 6898-9	187
1744	Widespread duplications in the genomes of laboratory stocks of Dictyostelium discoideum. **2008**, 9, R75	56
1743	Genetics of Parkinson's Disease. **2008**, 9-33	0
1742	Guiding protein aggregation with macromolecular crowding. **2008**, 47, 8993-9006	138
1741	Protein Folding and Aggregation in in vitro Models of Parkinson's Disease. **2008**, 575-595	11
1740	Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains. **2008**, 375, 1394-404	133
1739	An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. **2008**, 377, 136-47	92
1738	Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein. **2008**, 380, 444-50	88

1737	Brain prostaglandin formation is increased by alpha-synuclein gene-ablation during global ischemia. **2008**, 432, 243-7	30
1736	Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. **2008**, 436, 52-6	53
1735	Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease. **2008**, 439, 129-33	66
1734	Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. **2008**, 439, 125-8	128
1733	Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases. **2008**, 29, 408-17	61
1732	Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. **2008**, 29, 574-85	129
1731	Synuclein activates microglia in a model of Parkinson's disease. **2008**, 29, 1690-701	322
1730	Will stem cell biology generate new therapies for Parkinson's disease?. **2008**, 58, 659-61	25
1729	Mitochondria in neuroplasticity and neurological disorders. **2008**, 60, 748-66	688
1728	Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. **2008**, 152, 913-23	114
1727	Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. **2008**, 14, 465-70	44
1726	Viral vectors, animal models and new therapies for Parkinson's disease. **2008**, 14 Suppl 2, S169-71	14
1725	Alpha-synuclein and autophagy as common steps in neurodegeneration. **2008**, 14 Suppl 2, S180-4	28
1724	Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. **2008**, 29, 1472-8	67
1723	Progress in Parkinson's disease-where do we stand?. **2008**, 85, 376-92	140
1722	Alpha-synuclein and Parkinson's disease: a proteomic view. **2008**, 5, 239-48	26
1721	Cell systems and the toxic mechanism(s) of alpha-synuclein. **2008**, 209, 5-11	141
1720	In vivo gene delivery for development of mammalian models for Parkinson's disease. **2008**, 209, 89-100	32

1719	Gazing into the future: Parkinson's disease gene therapeutics to modify natural history. **2008**, 209, 101-13	8
1718	Parkinson patient fibroblasts show increased alpha-synuclein expression. **2008**, 212, 307-13	68
1717	The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. **2008**, 212, 235-8	31
1716	Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. **2008**, 213, 315-25	282
1715	Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies. **2008**, 1782, 764-74	82
1714	Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. **2008**, 1778, 1112-9	40
1713	Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease. **2008**, 365, 833-9	18
1712	The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. **2008**, 27, 336-49	279
1711	alpha-Synuclein: a therapeutic target for Parkinson's disease?. **2008**, 58, 271-80	31
1710	Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. **2008**, 28, 2471-84	144
1709	Trypsinogen copy number mutations in patients with idiopathic chronic pancreatitis. **2008**, 6, 82-8	65
1708	Membrane-induced folding of the cAMP-regulated phosphoprotein endosulfine-alpha. **2008**, 47, 12357-64	15
1707	Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. **2008**, 47, 9678-87	205
1706	Proteome response to the panneural expression of human wild-type alpha-synuclein: a Drosophila model of Parkinson's disease. **2008**, 7, 3911-21	19
1705	Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration. **2008**, 2, 465-78	18
1704	Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. **2008**, 47, 12614-25	105
1703	Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. **2008**, 105, 728-33	238
1702	The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. **2008**, 105, 14503-8	549

1701	Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. **2008**, 283, 3316-3328	125
1700	Human genes involved in copy number variation: mechanisms of origin, functional effects and implications for disease. **2008**, 123, 17-26	53
1699	A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. **2008**, 25, 301-8	35
1698	Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. **2008**, 17, 1988-93	98
1697	Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. **2009**, 132, 1093-101	168
1696	Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease?. **2008**, 16, 52-62	37
1695	Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. **2008**, 19, 1093-103	116
1694	GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. **2008**, 105, 10907-12	205
1693	Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. **2008**, 22, 3509-14	31
1692	Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. **2008**, 28, 7687-98	327
1691	Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. **2008**, 283, 23179-88	101
1690	alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. **2008**, 283, 20288-98	88
1689	Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. **2008**, 283, 23731-8	167
1688	Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. **2008**, 283, 10992-1003	182
1687	Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease. **2008**, 283, 9863-70	47
1686	Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. **2008**, 28, 4250-60	115
1685	A Drosophila model for LRRK2-linked parkinsonism. **2008**, 105, 2693-8	213
1684	The genetics and molecular biology of alpha-synuclein. **2008**, 89, 313-9	1

1683	C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. **2008**, 4, e1000027	295
1682	Amyloidogenesis of natively unfolded proteins. **2008**, 5, 260-87	147
1681	Animal Models of Parkinson's Disease to Aid Drug Discovery and Development. **2008**, 159-205	1
1680	Biologic models of neurodegenerative disorders. **2008**, 89, 173-88	3
1679	Molecular cytogenetics and cytogenomics of brain diseases. **2008**, 9, 452-65	65
1678	Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. **2008**, 6, e29	73
1677	Reduced purifying selection prevails over positive selection in human copy number variant evolution. **2008**, 18, 1711-23	64
1676	Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. **2008**, 36, e38	122
1675	wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. **2008**, 36, e41	21
1674	A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. **2008**, 17, 2997-3009	122
1673	alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease. **2008**, 283, 6979-87	43
1672	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. **2008**, 17, 3631-42	242
1671	Using leucine zipper to facilitate alpha-synuclein assembly. **2008**, 22, 3165-74	10
1670	Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. **2008**, 28, 465-72	121
1669	Novel suppressors of alpha-synuclein toxicity identified using yeast. **2008**, 17, 3784-95	54
1668	Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. **2008**, 28, 12305-17	154
1667	Two polymorphisms in NEDD4L gene and essential hypertension in Chinese Hans - a population-based case-control study. **2008**, 30, 87-94	17
1666	Progress in the pathogenesis and genetics of Parkinson's disease. **2008**, 363, 2215-27	59

1665 Contemplating effects of genomic structural variation. **2008**, 10, 639-47 65

1664 Amyloidogenic metal-binding proteins: new investigative pathways. **2008**, 36, 1299-303 5

1663 Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies. **2008**, 67, 984-93 39

1662 Protein stability and aggregation in Parkinson's disease. **2008**, 413, 1-13 37

1661 Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. **2008**, 67, 1084-96 38

1660 Neurodegenerative disorders. 39-89 0

1659 Heme Gene Controller May Be a New Path To Treatment of Parkinson Disease. **2008**, 8, 16-18

1658 Regulation of alpha-synuclein expression by liver X receptor ligands in vitro. **2008**, 19, 1685-9 25

1657 Drug Targeting of □Synuclein Oligomerization in Synucleinopathies. **2008**, 2, 1177391X0800200 3

1656 Paraquat-induced Neurodegeneration: a Model of Parkinson's Disease Risk Factors. **2008**, 207-217 1

1655 Yeast Cells as a Discovery Platform for Parkinson's Disease and other Protein Misfolding Diseases. **2008**, 505-536

1654 Neuroprotective and Neurotoxic Properties of □Synuclein in Cell Culture Models of Dopaminergic Degeneration. **2008**, 475-490

1653 DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. **2008**, 3, e1884 104

1652 Using yeast as a model system for the genetic dissection of □ynuclein toxicity. **2008**, 433-448

1651 Environmental exposures and gene regulation in disease etiology. **2008**, 13, 269-81 20

1650 Genomic and Proteomic Biomarker Discovery in Neurological Disease. **2008**, 3, 73-86 5

1649 Neurogenetics of dementia. 27-44

1648 Parkinson□ Disease: Alpha-Synuclein and Neurodegeneration. **2009**, 461-467

1647	Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. **2009**, 117, 117-21	49
1646	Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. **2009**, 4, e5777	264
1645	Live imaging of synaptic vesicle release and retrieval in dopaminergic neurons. **2009**, 3, 3	26
1644	Repression of alpha-synuclein expression and toxicity by microRNA-7. **2009**, 106, 13052-7	493
1643	Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disorders. **2009**, 89, 57-65	16
1642	Detecting morphologically distinct oligomeric forms of alpha-synuclein. **2009**, 284, 11048-58	72
1641	Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. **2009**, 23, 2820-30	199
1640	Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. **2009**, 29, 3365-73	282
1639	Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. **2009**, 9, 1189-97	25
1638	The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. **2009**, 11, 2167-87	8
1637	Is Parkinson's disease a prion disorder?. **2009**, 106, 12571-2	205
1636	TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. **2009**, 284, 20329-39	512
1635	Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. **2009**, 284, 7425-9	165
1634	Genomic duplication resulting in increased copy number of genes encoding the sister chromatid cohesion complex conveys clinical consequences distinct from Cornelia de Lange. **2009**, 46, 626-34	44
1633	Aneuploidy: from a physiological mechanism of variance to Down syndrome. **2009**, 89, 887-920	86
1632	Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. **2009**, 284, 2598-2602	160
1631	Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. **2009**, 284, 7940-50	77
1630	Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. **2009**, 119, 3257-65	128

1629	Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. **2009**, 284, 10211-22		104
1628	No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration. **2009**, 28, 471-5		6
1627	BAC to degeneration bacterial artificial chromosome (BAC)-mediated transgenesis for modeling basal ganglia neurodegenerative disorders. **2009**, 89, 37-56		7
1626	The paradoxical cell biology of alpha-Synucle. **2009**, 48, 159-72		9
1625	Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons. **2009**, 17, 1517-26		16
1624	Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. **2009**, 18, 3274-85		90
1623	Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. **2009**, 10, 1226-60		61
1622	Molecular pathology of Lewy body diseases. **2009**, 10, 724-45		76
1621	Neuronal aneuploidy in health and disease: a cytomic approach to understand the molecular individuality of neurons. **2009**, 10, 1609-27		34
1620	Novel therapeutic modalities to address nondrugable protein interaction targets. **2009**, 34, 142-58		31
1619	Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. *Science*, **2009**, 323, 124-7	33.3	259
1618	Evaluation of the X-linked high-grade myopia locus (MYP1) with cone dysfunction and color vision deficiencies. **2009**, 50, 1552-8		20
1617	A common copy number variation on chromosome 6 association with the gene expression level of endothelin 1 in transformed B lymphocytes from three racial groups. **2009**, 2, 483-8		7
1616	{alpha}-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. **2009**, 20, 3725-39		80
1615	Molecular pathogenesis of Parkinson disease: insights from genetic studies. **2009**, 11, e22		217
1614	Elucidation of the complex structure and origin of the human trypsinogen locus triplication. **2009**, 18, 3605-14		18
1613	Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy. **2009**, 34, 113-20		40
1612	Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. **2009**, 35, 385-98		320

1611	Copy-number variation: the end of the human genome?. **2009**, 27, 448-54	44
1610	Protein disorder in the human diseasome: unfoldomics of human genetic diseases. **2009**, 10 Suppl 1, S12	105
1609	Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology. **2009**, 1250, 232-41	26
1608	Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA--a key player in the pathogenesis of Parkinson's disease. **2009**, 1256, 19-33	7
1607	Molecular cytogenetic characterization of two cases with constitutional distal 11q duplication/triplication. **2009**, 149A, 1516-22	12
1606	No pathogenic rearrangement within the DISC 1 gene in psychosis. **2009**, 150B, 148-50	2
1605	Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. **2008**, 64 Suppl 2, S111-21	23
1604	SNCA variants are associated with increased risk for multiple system atrophy. **2009**, 65, 610-4	232
1603	Modeling Parkinson's disease. **2009**, 66, 432-6	29
1602	Aspects of observing and claiming allele flips in association studies. **2010**, 34, 266-74	32
1601	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. **2009**, 30, 1054-61	52
1600	LRRK2 gene variation and its contribution to Parkinson disease. **2009**, 30, 1153-60	62
1599	Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms. **2009**, 1, 360-70	65
1598	Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. **2009**, 87, 1283-95	96
1597	Neurochemical biomarkers in the differential diagnosis of movement disorders. **2009**, 24, 1411-26	31
1596	Alpha-synuclein and familial Parkinson's disease. **2009**, 24, 1125-31	32
1595	Expanding the clinical phenotype of SNCA duplication carriers. **2009**, 24, 1811-9	103
1594	ATP13A2 variants in early-onset Parkinson's disease patients and controls. **2009**, 24, 2104-11	54

1593	Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population. **2009**, 24, 2411-4	15
1592	From genes to proteins in mendelian Parkinson's disease: an overview. **2009**, 292, 1893-901	7
1591	Genomewide association study for susceptibility genes contributing to familial Parkinson disease. **2009**, 124, 593-605	363
1590	Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. **2009**, 14, 478-500	216
1589	Recent advances in using Drosophila to model neurodegenerative diseases. **2009**, 14, 1008-20	26
1588	Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. **2009**, 117, 63-73	126
1587	Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?. **2009**, 256 Suppl 3, 286-92	9
1586	Modulation of alpha-synuclein aggregation by dopamine: a review. **2009**, 34, 1838-46	90
1585	Population genetic models of duplicated genes. **2009**, 137, 19-37	51
1584	Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. **2009**, 11, 239-51	53
1583	The therapeutic potential of microRNAs in nervous system damage, degeneration, and repair. **2009**, 11, 153-61	37
1582	Modelling Parkinson's disease in Drosophila. **2009**, 11, 268-80	60
1581	Clearance and phosphorylation of alpha-synuclein are inhibited in methionine sulfoxide reductase a null yeast cells. **2009**, 39, 323-32	30
1580	Genetics of ischemic stroke: inheritance of a sporadic disorder. **2009**, 9, 19-27	5
1579	An update on essential tremor. **2009**, 9, 273-7	37
1578	Mutant alpha-synuclein overexpression mediates early proinflammatory activity. **2009**, 16, 238-54	115
1577	Versatile somatic gene transfer for modeling neurodegenerative diseases. **2009**, 16, 329-42	10
1576	Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function. **2009**, 9, 4284-97	60

1575	Dominant negative factors in health and disease. **2009**, 218, 409-18	22
1574	Charge neutralization and collapse of the C-terminal tail of alpha-synuclein at low pH. **2009**, 18, 1531-40	75
1573	Structural characterization of alpha-synuclein in an aggregation prone state. **2009**, 18, 1840-6	78
1572	Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. **2009**, 4, 34	65
1571	alpha-Synuclein and neuronal cell death. **2009**, 4, 9	257
1570	Neuronal cell replacement in Parkinson's disease. **2009**, 266, 358-71	45
1569	Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. **2009**, 41, 308-15	451
1568	Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. **2009**, 41, 316-23	242
1567	The impact of copy number variation on local gene expression in mouse hematopoietic stem and progenitor cells. **2009**, 41, 430-7	103
1566	Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. **2009**, 41, 1303-7	1045
1565	Genome-wide association study reveals genetic risk underlying Parkinson's disease. **2009**, 41, 1308-12	1469
1564	Evidence for a common pathway linking neurodegenerative diseases. **2009**, 41, 1261-2	36
1563	Computational methods for discovering structural variation with next-generation sequencing. **2009** , 6, S13-20	421
1562	Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. **2009**, 10, 218-34	125
1561	Clinical utility of array CGH for the detection of chromosomal imbalances associated with mental retardation and multiple congenital anomalies. **2009**, 1151, 157-66	96
1560	Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. **2009**, 19, 91-107	117
1559	Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease. **2009**, 108, 932-44	50
1558	Inducible over-expression of wild type alpha-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. **2009**, 109, 1348-62	80

1557	Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP. **2009**, 109, 1483-96	44
1556	On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft. **2009**, 110, 400-11	92
1555	The Parkinson disease-associated A30P mutation stabilizes alpha-synuclein against proteasomal degradation triggered by heme oxygenase-1 over-expression in human neuroblastoma cells. **2009**, 110, 719-33	52
1554	Functional dissection of the alpha-synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. **2009**, 110, 1479-90	40
1553	The ubiquitin ligase E6-AP promotes degradation of alpha-synuclein. **2009**, 110, 1955-64	47
1552	Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. **2009**, 111, 1075-93	84
1551	alpha-Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH-SY5Y) cells. **2009**, 111, 1192-201	85
1550	Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. **2009**, 16, 174-82	65
1549	EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. **2009**, 16, 777-85	37
1548	Perspectives on recent advances in the understanding and treatment of Parkinson's disease. **2009**, 16, 1090-9	53
1547	High-throughput methods for SNP genotyping. **2009**, 578, 245-54	46
1546	Analysis of the □synuclein gene dosage variation associated with autosomal dominant form of Parkinson□ disease. **2009**, 45, 504-506	
1545	Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. **2009**, 48, 9427-36	61
1544	Intrinsic Disorder in Proteins Associated with Neurodegenerative Diseases. **2009**, 21-75	6
1543	Evidence that alpha-synuclein does not inhibit phospholipase D. **2009**, 48, 1077-83	25
1542	miR-23 regulation of lamin B1 is crucial for oligodendrocyte development and myelination. **2009**, 2, 178-88	138
1541	A cellular model to monitor proteasome dysfunction by alpha-synuclein. **2009**, 48, 8014-22	40
1540	Structural insights on physiological functions and pathological effects of alpha-synuclein. **2009**, 23, 329-40	113

1539	Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration. **2009**, 11, 369-99	182
1538	Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. **2009**, 1,	216
1537	Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. **2009**, 41, 2015-24	133
1536	Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. **2009**, 218, 235-46	245
1535	Targets for neuroprotection in Parkinson's disease. **2009**, 1792, 676-87	125
1534	Molecular mechanisms of alpha-synuclein neurodegeneration. **2009**, 1792, 616-24	156
1533	Genetic models of Parkinson disease. **2009**, 1792, 604-15	42
1532	Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. **2009**, 1792, 651-63	178
1531	Genetic susceptibility in Parkinson's disease. **2009**, 1792, 597-603	30
1530	Mendelian forms of Parkinson's disease. **2009**, 1792, 587-96	122
1529	A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. **2009**, 1792, 664-75	76
1528	Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. **2009**, 1790, 615-28	72
1527	Protein aggregation as a paradigm of aging. **2009**, 1790, 980-96	78
1526	Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. **2009**, 1788, 1271-8	126
1525	The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers. **2009**, 378, 872-6	30
1524	Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. **2009**, 385, 434-8	34
1523	Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants. **2009**, 386, 165-9	14
1522	Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. **2009**, 387, 149-52	118

1521	Threonine 53 in alpha-synuclein is conserved in long-living non-primate animals. **2009**, 387, 602-5	16
1520	beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein. **2009**, 387, 682-7	18
1519	Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. **2009**, 390, 1229-34	26
1518	The genetics of Parkinson's syndromes: a critical review. **2009**, 19, 254-65	168
1517	Alterations of the microRNA network cause neurodegenerative disease. **2009**, 32, 199-206	373
1516	Recent insights into the molecular genetics of dementia. **2009**, 32, 451-61	47
1515	Neurobiology and treatment of Parkinson's disease. **2009**, 30, 41-7	168
1514	Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. **2009**, 159, 501-13	76
1513	Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. **2009**, 160, 796-804	91
1512	Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. **2009**, 15, 721-7	43
1511	Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. **2009**, 387, 771-85	79
1510	E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. **2009**, 388, 1022-32	81
1509	Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. **2009**, 390, 775-90	281
1508	Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid. **2009**, 394, 94-107	43
1507	Tryptophan fluorescence reveals structural features of alpha-synuclein oligomers. **2009**, 394, 826-33	91
1506	Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. **2009**, 9, 289-98	53
1505	GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. **2009**, 454, 209-11	18
1504	Inhibition of lysosomal functions reduces proteasomal activity. **2009**, 456, 15-9	47

1503	Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. **2009**, 459, 16-8	24
1502	A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. **2009**, 461, 196-201	51
1501	Desipramine induced changes in the norepinephrine transporter, alpha- and gamma-synuclein in the hippocampus, amygdala and striatum. **2009**, 467, 86-9	13
1500	Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. **2009**, 30, 1127-32	150
1499	Copy number variation in human health, disease, and evolution. **2009**, 10, 451-81	804
1498	Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration. **2009**, 96, 540-51	53
1497	Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. **2009**, 109, 102-12	81
1496	Genomewide association studies and human disease. **2009**, 360, 1759-68	564
1495	Protein misfolding and aggregation in Parkinson's disease. **2009**, 11, 2119-34	71
1494	Neurodegeneration in Parkinson's disease: genetics enlightens physiopathology. **2009**, 215-21	2
1493	Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. **2004**, 13, 3245-52	124
1492	The emerging role of autophagy in Parkinson's disease. **2009**, 2, 29	65
1491	Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. **2009**, 2, 5	190
1490	Drosophila models of neurodegenerative diseases. **2009**, 4, 315-42	157
1489	A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration. **2009**, 106, 2097-103	151
1488	Parkinson's disease: from monogenic forms to genetic susceptibility factors. **2009**, 18, R48-59	668
1487	Decreased alpha-synuclein expression in the aging mouse substantia nigra. **2009**, 220, 359-65	33
1486	Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. **2009**, 175, 736-47	127

1485	Synuclein Structure and Function in Parkinson's Disease. **2009**, 159-174	2
1484	Toxic effects of dopamine metabolism in Parkinson's disease. **2009**, 15 Suppl 1, S35-8	52
1483	Parkin gene therapy. **2009**, 15 Suppl 1, S43-5	8
1482	Does autophagy worsen or improve the survival of dopaminergic neurons?. **2009**, 15 Suppl 4, S24-7	13
1481	Neuroprotection in Parkinson's disease. **2009**, 15 Suppl 4, S41-3	12
1480	Parkinson's disease. **2009**, 373, 2055-66	1541
1479	Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. **2009**, 106, 20051-6	615
1478	Etiology and pathogenesis of Parkinson disease. **2009**, 27, 583-603, v	83
1477	Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. **2009**, 10, 483-99	250
1476	Structural chromosomal variations in neurological diseases. **2009**, 15, 245-53	8
1475	[Pathogenesis of sporadic Parkinson's disease: contribution of genetic and environmental risk factors]. **2009**, 49, 885-7	6
1474	Parkinson's Disease: Genomic Perspectives. **2009**, 1233-1242	
1473	Synucleins. **2009**, 833-837	3
1472	Targeting the progression of Parkinson's disease. **2009**, 7, 9-36	54
1471	Long tandem repeats as a form of genomic copy number variation: structure and length polymorphism of a chromosome 5p repeat in control and schizophrenia populations. **2009**, 19, 64-71	22
1470	Early-onset familial lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study. **2009**, 68, 73-82	29
1469	Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. **2009**, 68, 515-24	91
1468	Convergence of multiple hits that could underlie Parkinson's disease. **2009**, 4, 525-529	

1467	Bases moléculaires de la maladie de Parkinson. **2010**, 7, 1-9	
1466	Maladie de Parkinson idiopathique´: aspects cliniques, diagnostiques et thérapeutiques. **2010**, 7, 1-30	
1465	Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. **2010**, 3, 194-208	147
1464	Biomarkers of Alzheimer's and Parkinson's Disease. **2010**, 89-117	
1463	The genetics of Parkinson disease. **2010**, 23, 228-42	214
1462	Lysosomal degradation of alpha-synuclein in vivo. **2010**, 285, 13621-9	252
1461	Modeling human diseases in Caenorhabditis elegans. **2010**, 5, 1261-76	135
1460	Structural variation in the human genome and its role in disease. **2010**, 61, 437-55	827
1459	microRNAs in Sporadic Alzheimer's Disease and Related Dementias. **2010**, 91-98	1
1458	α-Synuclein: membrane interactions and toxicity in Parkinson's disease. **2010**, 26, 211-33	399
1457	Analysis of copy number variations of BS69 in multiple types of hematological malignancies. **2010**, 89, 959-64	8
1456	Astrocytes and therapeutics for Parkinson's disease. **2010**, 7, 413-23	172
1455	Interaction of baicalein and copper with α-synuclein: Electrochemical approach to Parkinson's Disease. **2010**, 648, 151-155	20
1454	Analysis of exon dosage using MLPA in South African Parkinson's disease patients. **2010**, 11, 305-12	38
1453	The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease. **2010**, 15, 1312-21	39
1452	Editorial: apoptosis in the aging brain. **2010**, 15, 1285-91	4
1451	Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease. **2010**, 117, 1019-25	30
1450	Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells. **2010**, 26, 205-10	35

1449	Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. **2010**, 1, 273-92	23
1448	Implications of copy number variation in people with chromosomal abnormalities: potential for greater variation in copy number state may contribute to variability of phenotype. **2010**, 4, 1-9	7
1447	Implications of copy number variation in people with chromosomal abnormalities: potential for greater variation in copy number state may contribute to variability of phenotype. **2010**, 4, 1-9	9
1446	Establishment of stably transfected rat neuronal cell lines expressing alpha-synuclein GFP fusion proteins. **2010**, 41, 80-8	7
1445	Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models. **2010**, 41, 210-8	84
1444	Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations. **2010**, 42, 85-95	19
1443	Overexpression of alpha-synuclein down-regulates BDNF expression. **2010**, 30, 939-46	45
1442	Dominant-positive HSF1 decreases alpha-synuclein level and alpha-synuclein-induced toxicity. **2010**, 37, 1875-81	24
1441	Comparison of newly generated doublecortin-immunoreactive neuronal progenitors in the main olfactory bulb among variously aged gerbils. **2010**, 35, 1599-608	5
1440	Are synucleinopathies prion-like disorders?. **2010**, 9, 1128-38	191
1439	Cognition, language, and clinical pathological features of non-Alzheimer's dementias: an overview. **2010**, 43, 438-52	57
1438	VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. **2010**, 37, 330-8	64
1437	Dysfunctional mitochondria uphold calpain activation: contribution to Parkinson's disease pathology. **2010**, 37, 723-30	43
1436	Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease. **2010**, 40, 113-9	49
1435	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. **2010**, 39, 229-41	56
1434	Neurodegenerative disorders: insights from the nematode Caenorhabditis elegans. **2010**, 40, 4-11	69
1433	Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. **2010**, 40, 29-39	49
1432	CSF from Parkinson disease patients differentially affects cultured microglia and astrocytes. **2010**, 11, 151	15

1431	Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. **2010**, 11, 41	38
1430	Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. **2010**, 11, 57	133
1429	Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. **2010**, 3, 12	199
1428	RNAi therapeutics for CNS disorders. **2010**, 1338, 112-21	35
1427	Parkin dosage mutations in patients with early-onset sporadic and familial Parkinson's disease in Chinese: an independent pathogenic role. **2010**, 1358, 30-8	11
1426	Neuroimaging for Lewy body disease: is the in vivo molecular imaging of □synuclein neuropathology required and feasible?. **2010**, 65, 28-55	35
1425	Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. **2010**, 22, 821-7	69
1424	Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease. **2010**, 584, 1571-6	81
1423	A Saccharomyces cerevisiae strain unable to store neutral lipids is tolerant to oxidative stress induced by □synuclein. **2010**, 49, 1755-64	15
1422	Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. **2010**, 31, 685-91	49
1421	Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. **2010**, 31, 763-80	341
1420	Non-apoptotic cell death in Caenorhabditis elegans. **2010**, 239, 1337-51	18
1419	C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. **2010**, 239, 1282-95	91
1418	Using Drosophila to Reveal Insight into Protein Misfolding Diseases. **2010**, 191-211	
1417	Alteration of the □Synuclein Folding Landscape by a Mutation Related to Parkinson□ Disease. **2010**, 122, 3547-3550	4
1416	Alteration of the alpha-synuclein folding landscape by a mutation related to Parkinson's disease. **2010**, 49, 3469-72	55
1415	Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. **2010**, 32, 227-235	57
1414	Hsp70 molecular chaperones and Parkinson's disease. **2010**, 93, 218-28	60

1413	Sensitive and specific detection of □synuclein in human plasma. **2010**, 88, 2693-700	20
1412	Clues to how alpha-synuclein damages neurons in Parkinson's disease. **2010**, 25 Suppl 1, S27-31	51
1411	The behavior of alpha-synuclein in neurons. **2010**, 25 Suppl 1, S21-6	34
1410	Parkinson's disease: 10 years of progress, 1997-2007. **2010**, 25 Suppl 1, S2-14	29
1409	Clinical course of the first Asian family with Parkinsonism related to SNCA triplication. **2010**, 25, 2871-5	28
1408	In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease. **2010**, 188, 151-64	7
1407	Production of a monoclonal antibody, against human □synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the □synuclein locus. **2010**, 192, 268-76	11
1406	Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. **2010**, 5, 14	43
1405	The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein. **2010**, 5, 20	28
1404	Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. **2010**, 5, 43	77
1403	ER stress response plays an important role in aggregation of □synuclein. **2010**, 5, 56	65
1402	Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons. **2010**, 5, 9	35
1401	The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease. **2010**, 64, 241-50	30
1400	The impact of human copy number variation on a new era of genetic testing. **2010**, 117, 391-8	41
1399	Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. **2010**, 74, 97-109	374
1398	Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. **2010**, 113, 27-41	109
1397	Ectopic expression of □synuclein affects the migration of neural stem cells in mouse subventricular zone. **2010**, 115, 854-63	16
1396	Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. **2010**, 114, 419-29	63

1395	Over-expression of alpha-synuclein in the nervous system enhances axonal degeneration after peripheral nerve lesion in a transgenic mouse strain. **2010**, 114, 1007-18	20
1394	□Synuclein expression is induced by depolarization and cyclic AMP in enteric neurons. **2010**, 115, 694-706	21
1393	Simple is good: yeast models of neurodegeneration. **2010**, 10, 970-9	65
1392	Protein aggregation in Parkinson's disease. **2010**, 122, 82-7	22
1391	Mysterious oligomerization of the amyloidogenic proteins. **2010**, 277, 2940-53	151
1390	Review: the ubiquitin-proteasome system: contributions to cell death or survival in neurodegeneration. **2010**, 36, 113-24	23
1389	Copy number variations of the human histamine H4 receptor gene are associated with systemic lupus erythematosus. **2010**, 163, 935-40	29
1388	Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations. **2010**, 161, 527-35	18
1387	Prion-like mechanisms in neurodegenerative diseases. **2010**, 11, 155-9	524
1386	Gene-environment interactions in Parkinson's disease: the importance of animal modeling. **2010**, 88, 467-74	59
1385	Inhibition of mitochondrial fusion by □synuclein is rescued by PINK1, Parkin and DJ-1. **2010**, 29, 3571-89	375
1384	Missing pieces in the Parkinson's disease puzzle. **2010**, 16, 653-61	521
1383	Genome-wide association studies: the key to unlocking neurodegeneration?. **2010**, 13, 789-94	72
1382	The evolution of gene duplications: classifying and distinguishing between models. **2010**, 11, 97-108	833
1381	The epidemiology of dementia associated with Parkinson's disease. **2010**, 20, 633-9	181
1380	Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. **2010**, 32, 10-7	57
1379	Gene copy number variation and common human disease. **2010**, 77, 201-13	85
1378	Microtubule depolymerization potentiates alpha-synuclein oligomerization. **2010**, 1, 5	49

1377 Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease. **2010**, 4, 140 49

1376 Effects of Various Flavonoids on the Synuclein Fibrillation Process. **2010**, 2010, 650794 67

1375 Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. **2010**, 5, e8784 173

1374 Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. **2010**, 5, e9052 69

1373 The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy. **2010**, 5, e10014 34

1372 A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. **2010**, 5, e11464 98

1371 Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. **2010**, 5, e12122 101

1370 Membrane Permeabilization by Oligomeric Synuclein: In Search of the Mechanism. **2010**, 5, e14292 105

1369 CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. **2010**, 5, e15522 216

1368 Cerebrospinal fluid biomarkers for dementia with lewy bodies. **2010**, 2010, 536538 19

1367 Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. **2010**, 183, 3-20 16

1366 Protein homeostasis and aging in neurodegeneration. **2010**, 190, 719-29 261

1365 Parkinson's disease: insights from pathways. **2010**, 19, R21-7 137

1364 Autosomal recessive mutations in the development of Parkinson's disease. **2010**, 4, 713-21 11

1363 {alpha}-Synuclein gene duplication impairs reward learning. **2010**, 107, 15992-4 26

1362 Identification of epistatic effects using a protein-protein interaction database. **2010**, 19, 4345-52 21

1361 Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. **2010**, 19, 1633-50 198

1360 Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. **2010**, 285, 12726-34 347

1359	Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. **2010**, 30, 6355-9	293
1358	Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation. **2010**, 21, 2128-37	94
1357	Classification of pathogenic or benign status of CNVs detected by microarray analysis. **2010**, 10, 717-21	10
1356	Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. **2010**, 133, 172-88	142
1355	Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. **2010**, 10, 1035-50	10
1354	Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. **2010**, 332, 849-57	134
1353	Human beta-synuclein rendered fibrillogenic by designed mutations. **2010**, 285, 38555-67	15
1352	Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. **2010**, 285, 17648-61	88
1351	A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. **2010**, 30, 8083-95	228
1350	Regulation of Weibel-Palade body exocytosis by alpha-synuclein in endothelial cells. **2010**, 285, 21416-25	24
1349	Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. **2010**, 21, 251-72	44
1348	The impact of genetic research on our understanding of Parkinson's disease. **2010**, 183, 21-41	26
1347	SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. **2010**, 67, 1350-6	129
1346	Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection. **2010**, 133, 2313-30	59
1345	Unravelling the role of defective genes. **2010**, 183, 43-57	6
1344	Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. **2010**, 1, e2	89
1343	Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. **2010**, 3, 386-96	47
1342	Basi molecolari del morbo di Parkinson. **2010**, 10, 1-9	

1341	SPECT and PET in Atypical Parkinsonism. **2010**, 5, 65-74	
1340	Morbo di Parkinson idiopatico: aspetti clinici, diagnostici e terapeutici. **2010**, 10, 1-29	
1339	Problems associated with fluid biomarkers for Parkinson's disease. **2010**, 4, 671-81	13
1338	Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. **2010**, 30, 6838-51	761
1337	Genetics of Parkinson's Disease□An Overview. **2010**, 15-39	0
1336	□Synuclein and Parkinson's Disease. **2010**, 34, 40-53	1
1335	PARK2: Parkin Mutations Responsible for Familial Parkinson's Disease. **2010**, 34, 54-65	
1334	Development of Parkinson's disease biomarkers. **2010**, 10, 1811-25	7
1333	Effects of curvature and composition on □synuclein binding to lipid vesicles. **2010**, 99, 2279-88	238
1332	Molecular mechanisms of pathogenesis of Parkinson's disease. **2010**, 281, 229-66	48
1331	Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, □synuclein aggregation, oxidative damage and behavioral changes. **2010**, 3, 35	52
1330	Role of epigenetics in Alzheimer's and Parkinson's disease. **2010**, 2, 671-82	84
1329	Prion-like disorders: blurring the divide between transmissibility and infectivity. **2010**, 123, 1191-201	231
1328	Differential effects of wild-type and A53T mutant isoform of alpha-synuclein on the mitochondrial proteome of differentiated SH-SY5Y cells. **2010**, 9, 2390-401	27
1327	Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy. **2010**, 7, 565-78	14
1326	The conformation and the aggregation kinetics of □synuclein depend on the proline residues in its C-terminal region. **2010**, 49, 9345-52	48
1325	Quantification of □synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. **2010**, 4, 683-99	101
1324	Human Gene Mutation: Mechanisms and Consequences. **2010**, 319-363	5

1323	Pathogenesis of Parkinson's disease: emerging role of molecular chaperones. **2010**, 16, 27-36	64
1322	No evidence for prion protein gene locus multiplication in Creutzfeldt-Jakob disease. **2010**, 472, 16-8	4
1321	FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients. **2010**, 479, 22-5	43
1320	Endogenous catecholamine enhances the dysfunction of unfolded protein response and alpha-synuclein oligomerization in PC12 cells overexpressing human alpha-synuclein. **2010**, 66, 124-30	20
1319	DnaK/DnaJ/GrpE of Hsp70 system have differing effects on alpha-synuclein fibrillation involved in Parkinson's disease. **2010**, 46, 275-9	12
1318	Role of small oligomers on the amyloidogenic aggregation free-energy landscape. **2010**, 395, 134-54	25
1317	Towards multiparametric fluorescent imaging of amyloid formation: studies of a YFP model of alpha-synuclein aggregation. **2010**, 395, 627-42	62
1316	Lipid rafts: keys to neurodegeneration. **2010**, 82, 7-17	98
1315	Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. **2010**, 1802, 11-9	108
1314	Mitochondrial dysfunction in Parkinson's disease. **2010**, 1802, 29-44	383
1313	Inflammation in transgenic mouse models of neurodegenerative disorders. **2010**, 1802, 889-902	74
1312	Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. **2010**, 1802, 322-30	75
1311	Pathological roles of MAPK signaling pathways in human diseases. **2010**, 1802, 396-405	1455
1310	New insights into the role of mitochondrial dysfunction and protein aggregation in Parkinson's disease. **2010**, 1802, 935-41	48
1309	Lack of involvement of alpha-synuclein in unconditioned anxiety in mice. **2010**, 209, 234-40	27
1308	Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. **2010**, 391, 461-6	50
1307	Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation. **2010**, 391, 1415-20	15
1306	alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. **2010**, 16, 228-31	30

1305	Alpha-synuclein, lipids and Parkinson's disease. **2010**, 49, 420-8	136
1304	Parkinson's disease: Exit toxins, enter genetics. **2010**, 90, 146-56	38
1303	Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. **2010**, 31, 953-68	160
1302	Selective noradrenergic vulnerability in □synuclein transgenic mice. **2010**, 31, 2103-14	43
1301	Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. **2010**, 65, 66-79	739
1300	Genetic animal models of Parkinson's disease. **2010**, 66, 646-61	602
1299	Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice. **2010**, 167, 261-76	8
1298	□Synuclein and dopamine at the crossroads of Parkinson's disease. **2010**, 33, 559-68	188
1297	Protein carbonyl and the methionine sulfoxide reductase system. **2010**, 12, 405-15	45
1296	The propagation of prion-like protein inclusions in neurodegenerative diseases. **2010**, 33, 317-25	336
1295	Next-generation sequencing in aging research: emerging applications, problems, pitfalls and possible solutions. **2010**, 9, 315-23	77
1294	Molecular and clinical prodrome of Parkinson disease: implications for treatment. **2010**, 6, 309-17	132
1293	Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases. **2010**, 3, 839-915	140
1292	Paraquat. **2010**, 1771-1827	19
1291	Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption. **2010**, 221, 86-97	24
1290	ASIP Outstanding Investigator Award Lecture. New approaches to the pathology and genetics of neurodegeneration. **2010**, 176, 2058-66	14
1289	Protein metabolism and lifespan in Caenorhabditis elegans. **2010**, 694, 81-107	2
1288	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. **2010**, 133, 2032-44	203

1287	Genetics and Genomics of Dementia. **2010**, 687-699	
1286	Genetics and Genomics of Parkinson's Disease. **2010**, 700-711	1
1285	Parkinson Disease: Genetics. **2010**, 425-430	
1284	What have we learned from Drosophila models of Parkinson's disease?. **2010**, 184, 3-16	25
1283	Genetic basis of Parkinson disease. **2010**, 28, E7	30
1282	Copy number variation in Parkinson's disease. **2010**, 2, 62	20
1281	Gene therapy in Parkinson's disease: rationale and current status. **2010**, 24, 177-92	49
1280	The yin and yang of amyloid: insights from synuclein and repeat domain of Pmel17. **2011**, 13, 20066-75	19
1279	Can synuclein be targeted in novel therapies for Parkinson's disease?. **2011**, 11, 917-9	9
1278	The synucleins are a family of redox-active copper binding proteins. **2011**, 50, 37-47	60
1277	Allostery in a disordered protein: oxidative modifications to synuclein act distally to regulate membrane binding. **2011**, 133, 7152-8	99
1276	Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. **2011**, 286, 14168-77	75
1275	Rabs, SNAREs and synuclein--membrane trafficking defects in synucleinopathies. **2011**, 67, 268-81	25
1274	Inverted genomic segments and complex triplication rearrangements are mediated by inverted repeats in the human genome. **2011**, 43, 1074-81	147
1273	Tremors. **2011**, 389-414	
1272	Chaperone-Mediated Autophagy and Parkinson's Disease. **2011**, 101-138	
1271	Chaperone and Anti-Chaperone Properties of Synuclein: Implications for Development, Aging, and Neurodegenerative Disease. **2011**, 139-177	
1270	Mitochondrial Fission-Fusion and Parkinson Disease: A Dynamic Question of Compensatory Networks. **2011**, 197-213	1

1269	Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. **2011**, 15, 83-102	24
1268	Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. **2011**, 63, 439-44	104
1267	Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. **2011**, 306, 1-8	46
1266	Parkinson's disease: genetics and pathogenesis. **2011**, 6, 193-222	519
1265	Copy number variations of EphA3 are associated with multiple types of hematologic malignancies. **2011**, 11, 50-3	26
1264	Development of advanced therapies based on viral vector-mediated overexpression of therapeutic molecules and knockdown of disease-related genes for Parkinson's disease. **2011**, 2, 37-50	4
1263	Mechanism of membrane interaction and disruption by □synuclein. **2011**, 133, 19366-75	162
1262	Impact of □ fatty acids in Parkinson's disease. **2011**, 10, 453-63	80
1261	A feedforward loop links Gaucher and Parkinson's diseases?. **2011**, 146, 9-11	10
1260	Clan genomics and the complex architecture of human disease. **2011**, 147, 32-43	268
1259	Essential tremor--not just a shake. **2011**, 57, 127-34	1
1258	The hexapeptide PGVTAV suppresses neurotoxicity of human □synuclein aggregates. **2011**, 408, 334-8	7
1257	Gelsolin co-occurs with Lewy bodies in vivo and accelerates □synuclein aggregation in vitro. **2011**, 412, 32-8	7
1256	Human □synuclein modulates vesicle trafficking through its interaction with prenylated Rab acceptor protein 1. **2011**, 412, 526-31	40
1255	Cell death pathology: perspective for human diseases. **2011**, 414, 451-5	46
1254	MicroRNAs in Parkinson's disease. **2011**, 42, 127-30	95
1253	Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies. **2011**, 42, 327-40	11
1252	Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. **2011**, 42, 131-41	51

1251	□Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. **2011**, 32, 622-9	27
1250	Rho GTPase regulation of □synuclein and VMAT2: implications for pathogenesis of Parkinson's disease. **2011**, 48, 29-37	25
1249	The anti-Parkinsonian drug selegiline delays the nucleation phase of □synuclein aggregation leading to the formation of nontoxic species. **2011**, 405, 254-73	68
1248	Structured regions of □synuclein fibrils include the early-onset Parkinson's disease mutation sites. **2011**, 411, 881-95	128
1247	Neuroprotective and nootropic drug noopept rescues □synuclein amyloid cytotoxicity. **2011**, 414, 699-712	14
1246	Animal Models of Neurodegenerative Diseases. **2011**, 49-101	
1245	TDP-43 toxicity in yeast. **2011**, 53, 238-45	25
1244	Caenorhabditis elegans as a model system for identifying effectors of □synuclein misfolding and dopaminergic cell death associated with Parkinson's disease. **2011**, 53, 220-5	24
1243	LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. **2011**, 8, 267-80	572
1242	Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?. **2011**, 17, 730-6	20
1241	Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. **2011**, 94, 1-19	127
1240	Biomarker-based dissection of neurodegenerative diseases. **2011**, 95, 520-34	66
1239	Genetic players in multiple system atrophy: unfolding the nature of the beast. **2011**, 32, 1924.e5-14	33
1238	Exogenous □synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. **2011**, 72, 57-71	931
1237	Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice. **2011**, 180, 280-92	43
1236	Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). **2011**, 195, 128-37	21
1235	Dynamic modeling of □synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy. **2011**, 199, 303-17	17
1234	[Role of genetics in the etiology of synucleinopathies]. **2011**, 46 Suppl 1, 3-11	

1233	[Clinical characteristics of the neurological forms of Gaucher's disease]. **2011**, 137 Suppl 1, 6-11	4
1232	Autophagic pathways in Parkinson disease and related disorders. **2011**, 13, e8	71
1231	Pharmacological therapy in Parkinson's disease: focus on neuroprotection. **2011**, 17, 345-67	23
1230	Prions. **2011**, 3, a006833	367
1229	Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. **2011**, 63, 411-36	616
1228	Elevated levels of -synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. **2011**, 7, 215-22	126
1227	Identifying the genetic components underlying the pathophysiology of movement disorders. **2011**, 4, 81-92	1
1226	Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice. **2011**, 20, 181-8	33
1225	Genetic mutations and mitochondrial toxins shed new light on the pathogenesis of Parkinson's disease. **2011**, 2011, 979231	8
1224	Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. **2010**, 2011, 617472	41
1223	Bridging molecular genetics and biomarkers in lewy body and related disorders. **2011**, 2011, 842475	5
1222	Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. **2011**, 2011, 708404	43
1221	-Synuclein Transgenic Drosophila As a Model of Parkinson's Disease and Related Synucleinopathies. **2010**, 2011, 212706	21
1220	Contribution of Alanine-76 and Serine Phosphorylation in -Synuclein Membrane Association and Aggregation in Yeasts. **2011**, 2011, 392180	19
1219	Toxin-induced and genetic animal models of Parkinson's disease. **2010**, 2011, 951709	42
1218	Drosophila models of Parkinson's disease: discovering relevant pathways and novel therapeutic strategies. **2011**, 2011, 520640	44
1217	Mitochondrial contribution to Parkinson's disease pathogenesis. **2011**, 2011, 159160	75
1216	-Synuclein Alters Toll-Like Receptor Expression. **2011**, 5, 80	119

1215	Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. **2011**, 4, 67-80	75
1214	Alzheimer Disease and Type 2 Diabetes: Different Pathologies and Same Features. **2011**,	2
1213	TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. **2011**, 7, 234-43	29
1212	Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease. **2011**, 6, e19622	20
1211	Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease. **2011**, 6, e15946	32
1210	Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma. **2011**, 6, e17177	14
1209	Assessment of Synuclein secretion in mouse and human brain parenchyma. **2011**, 6, e22225	118
1208	Tau enhances Synuclein aggregation and toxicity in cellular models of synucleinopathy. **2011**, 6, e26609	94
1207	Parkinson disease: diagnostic relevance of elevated levels of soluble Synuclein oligomers in cerebrospinal fluid. **2011**, 6, 159-163	1
1206	Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies. **2011**, 70, 264-80	42
1205	Transmission of prion strains in a transgenic mouse model overexpressing human A53T mutated Synuclein. **2011**, 70, 377-85	28
1204	Modelling early responses to neurodegenerative mutations in mice. **2011**, 39, 933-8	13
1203	Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. **2011**, 34, 92-6	88
1202	SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate Synuclein and are susceptible to oxidative stress. **2011**, 6, e26159	200
1201	[108th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Progress in dementia research--dementia disorders and protein; (3) alpha-synuclein, alpha-synucleinopathies, and dementia]. **2011**, 100, 2476-81	
1200	DNA methylation in neurodegenerative disorders: a missing link between genome and environment?. **2011**, 80, 1-14	38
1199	Exome sequencing in Parkinson's disease. **2011**, 80, 104-9	15
1198	Neurodegenerative disease and adult neurogenesis. **2011**, 33, 1139-51	301

1197	Hyperphosphorylated Tau in an -synuclein-overexpressing transgenic model of Parkinson's disease. **2011**, 33, 1598-610	92
1196	LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study. **2011**, 37, 777-90	37
1195	A neuroprotective role for angiogenin in models of Parkinson's disease. **2011**, 116, 334-41	51
1194	N-terminal deletion does not affect -synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast. **2011**, 119, 389-97	14
1193	The oxysterol 27-hydroxycholesterol regulates -synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease. **2011**, 119, 1119-36	58
1192	Modulation of -synuclein aggregation by dopamine in the presence of MPTP and its metabolite. **2011**, 278, 1688-98	27
1191	Priorities in Parkinson's disease research. **2011**, 10, 377-93	317
1190	A deadly spread: cellular mechanisms of -synuclein transfer. **2011**, 18, 1425-33	107
1189	-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. **2011**, 41, 71-82	35
1188	Familial Parkinson disease mutations influence -synuclein assembly. **2011**, 43, 715-24	54
1187	Age and -synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. **2011**, 44, 215-22	20
1186	The role of the C-terminus of human -synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers. **2011**, 585, 561-6	49
1185	The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of -synuclein oligomers with distinct biochemical, morphological, and functional properties. **2011**, 50, 428-37	99
1184	Altered expression of autophagic genes in the peripheral leukocytes of patients with sporadic Parkinson's disease. **2011**, 1394, 105-11	51
1183	Comparing Behavioral Assessment of Sensorimotor Function in Rat and Mouse Models of Parkinson Disease and Stroke. **2011**, 325-335	
1182	Mitochondrial pathology in Parkinson's disease. **2011**, 78, 872-81	56
1181	Molecular insights into Parkinson's disease. **2011**, 3, 7	37
1180	What genetics tells us about the causes and mechanisms of Parkinson's disease. **2011**, 91, 1161-218	422

1179	□Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. **2011**, 121, 715-25	616
1178	Epidemiology and etiology of Parkinson's disease: a review of the evidence. **2011**, 26 Suppl 1, S1-58	707
1177	Lack of alpha-synuclein modulates microglial phenotype in vitro. **2011**, 36, 994-1004	28
1176	RNAi: a potential new class of therapeutic for human genetic disease. **2011**, 130, 583-605	71
1175	Changes in the solubility and phosphorylation of □synuclein over the course of Parkinson's disease. **2011**, 121, 695-704	78
1174	Glial dysfunction in the pathogenesis of □synucleinopathies: emerging concepts. **2011**, 121, 675-93	149
1173	The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. **2011**, 12, 59-64	47
1172	Genetic variability in SNCA and Parkinson's disease. **2011**, 12, 283-93	25
1171	Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells. **2011**, 118, 397-406	26
1170	The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. **2011**, 118, 493-507	47
1169	Increased expression of □synuclein in aged human brain associated with neuromelanin accumulation. **2011**, 118, 1575-83	28
1168	Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder. **2011**, 11, 73-83	54
1167	Parkinson's disease mouse models in translational research. **2011**, 22, 401-19	52
1166	Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. **2011**, 68, 721-33	64
1165	Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. **2011**, 68, 2643-54	26
1164	Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy?. **2011**, 43, 60-7	47
1163	Next-generation sequencing reveals regional differences of the □synuclein methylation state independent of Lewy body disease. **2011**, 13, 310-20	48
1162	Aggregation of □synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis. **2011**, 43, 391-405	62

1161	Investigation of copy-number variations of C8orf4 in hematological malignancies. **2011**, 28 Suppl 1, S647-52	8
1160	Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration. **2011**, 44, 13-27	23
1159	Oxidative stress partially contributes to iron-induced -synuclein aggregation in SK-N-SH cells. **2011**, 19, 435-42	45
1158	Neuroprotective upregulation of endogenous -synuclein precedes ubiquitination in cultured dopaminergic neurons. **2011**, 19, 592-602	12
1157	Dopamine and paraquat enhance -synuclein-induced alterations in membrane conductance. **2011**, 20, 387-401	16
1156	Lipid classes and fatty acid patterns are altered in the brain of -synuclein null mutant mice. **2011**, 46, 121-30	14
1155	Alzheimer's genetics in the GWAS era: a continuing story of 'replications and refutations'. **2011**, 11, 246-53	28
1154	Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. **2011**, 12, 79	26
1153	Pros and cons of a prion-like pathogenesis in Parkinson's disease. **2011**, 11, 74	13
1152	Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. **2011**, 8, 44	69
1151	Inference of chromosome-specific copy numbers using population haplotypes. **2011**, 12, 194	2
1150	ClipCrop: a tool for detecting structural variations with single-base resolution using soft-clipping information. **2011**, 12 Suppl 14, S7	35
1149	The landscape of inherited and de novo copy number variants in a Plasmodium falciparum genetic cross. **2011**, 12, 457	16
1148	Conserved core of amyloid fibrils of wild type and A30P mutant -synuclein. **2011**, 20, 387-95	33
1147	Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human -synuclein. **2011**, 89, 1091-102	107
1146	The most cited works in Parkinson's disease. **2011**, 26, 380-90	43
1145	New animal models of Parkinson's disease. **2011**, 26, 1198-1205	31
1144	Milestones in PD genetics. **2011**, 26, 1042-8	130

1143	Parkinson's disease, proteins, and prions: milestones. **2011**, 26, 1056-71	33
1142	Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by □synuclein triplication (Iowa kindred). **2011**, 26, 2134-6	27
1141	Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. **2011**, 26, 2283-6	18
1140	Parkinson's disease and □synuclein expression. **2011**, 26, 2160-8	149
1139	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. **2011**, 70, 964-73	144
1138	Gene Dosage and Duplication. **2011**, 57-76	1
1137	Characterization of three synuclein genes in Xenopus laevis. **2011**, 240, 2028-33	11
1136	Synphilin suppresses □synuclein neurotoxicity in a Parkinson's disease Drosophila model. **2011**, 49, 392-402	19
1135	Characterization of copy number-stable regions in the human genome. **2011**, 32, 947-55	17
1134	The association between Parkinson's disease and melanoma. **2011**, 128, 2251-60	105
1133	Intrinsically disordered proteins may escape unwanted interactions via functional misfolding. **2011**, 1814, 693-712	52
1132	Enzyme-linked immunosorbent assays for □synuclein with species and multimeric state specificities. **2011**, 199, 249-57	23
1131	Demise of the flies: why Drosophila models still matter. **2011**, 100, 483-98	4
1130	Genetic mouse models of neurodegenerative diseases. **2011**, 100, 419-82	33
1129	The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. **2011**, 2, e196	42
1128	In vivo application of an RNAi strategy for the selective suppression of a mutant allele. **2011**, 22, 27-34	16
1127	Genetic and clinical analysis in a Chinese parkinsonism-predominant spinocerebellar ataxia type 2 family. **2011**, 56, 330-4	4
1126	Cyclin-G-associated kinase modifies □synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. **2011**, 20, 1478-87	47

1125	A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. **2011**, 20, R158-62	60
1124	Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action. **2011**, 20, 4475-90	39
1123	Structural and morphological characterization of aggregated species of □synuclein induced by docosahexaenoic acid. **2011**, 286, 22262-74	82
1122	Genetic therapy for the nervous system. **2011**, 20, R28-41	58
1121	Copy number variations in candidate genes in neovascular age-related macular degeneration. **2011**, 52, 3129-35	24
1120	□Synuclein in Parkinson disease and other neurodegenerative disorders. **2011**, 49, 403-8	59
1119	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. **2011**, 20, 345-53	178
1118	Clinical overview and phenomenology of movement disorders. **2011**, 1-35	4
1117	Current concepts on the etiology and pathogenesis of Parkinson disease. **2011**, 93-118	0
1116	The association between the copy-number variations of ZMAT4 and hematological malignancy. **2011**, 16, 20-3	5
1115	Parkinson's disease and dementia: a longitudinal study (DEMPARK). **2011**, 37, 168-76	35
1114	Direct interaction of □synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease. **2011**, 19, 86-96	19
1113	Prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy. **2011**, 8, 25-34	19
1112	Detecting common copy number variants in high-throughput sequencing data by using JointSLM algorithm. **2011**, 39, e65	54
1111	□Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. **2011**, 286, 43933-43943	53
1110	E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. **2011**, 286, 35104-18	93
1109	Phosphorylated □synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. **2011**, 25, 4127-37	146
1108	Alpha-synuclein populates both elongated and broken helix states on small unilamellar vesicles. **2011**, 286, 21450-7	76

1107	Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of □synuclein. **2011**, 31, 14508-20	268
1106	Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. **2011**, 286, 28080-8	130
1105	Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation. **2011**, 286, 26687-701	28
1104	Investigation of modifier genes within copy number variations in Rett syndrome. **2011**, 56, 508-15	23
1103	Parkinson's disease induced pluripotent stem cells with triplication of the □synuclein locus. **2011**, 2, 440	328
1102	In vivo demonstration that alpha-synuclein oligomers are toxic. **2011**, 108, 4194-9	1004
1101	□Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-□B-mediated pathway. **2011**, 21, 435-43	35
1100	Study on effect of □Synuclein enhanced survival rate of rat primary cultured neuron. **2011**,	
1099	Pathways towards an effective immunotherapy for Parkinson's disease. **2011**, 11, 1703-15	21
1098	Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. **2011**, 286, 20710-26	423
1097	Role of Rab GTPases in membrane traffic and cell physiology. **2011**, 91, 119-49	1006
1096	Environmental exposure, obesity, and Parkinson's disease: lessons from fat and old worms. **2011**, 119, 20-8	18
1095	Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. **2011**, 9, e1000614	321
1094	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. **2011**, 20, 3933-42	107
1093	Neuroinflammation and □synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. **2011**, 119, 807-14	227
1092	Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. **2011**, 7, e1002141	387
1091	Alpha-synuclein functions in the nucleus to protect against hydroxyurea-induced replication stress in yeast. **2011**, 20, 3401-14	25
1090	Sumoylation inhibits alpha-synuclein aggregation and toxicity. **2011**, 194, 49-60	169

1089	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. **2012**, 21, 4996-5009	145
1088	An extracellular mechanism that can explain the neurotoxic effects of β-synuclein aggregates in the brain. **2012**, 3, 297	30
1087	Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples. **2012**, 78, 1016-24	51
1086	The mitochondrial chaperone protein TRAP1 mitigates α-synuclein toxicity. **2012**, 8, e1002488	105
1085	Genetics of Parkinson's disease. **2012**, 2, a008888	739
1084	Prion-like spread of protein aggregates in neurodegeneration. **2012**, 209, 889-93	153
1083	The role of SNPs in the α-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. **2012**, 13, 83-93	22
1082	Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins. **2012**, 287, 2971-83	60
1081	Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease. **2012**, 32, 2142-53	53
1080	Mutant protein A30P α-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics. **2012**, 287, 11526-32	54
1079	Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. **2012**, 287, 29301-11	86
1078	Disruption of protein quality control in Parkinson's disease. **2012**, 2, a009423	98
1077	Inflammation and adaptive immunity in Parkinson's disease. **2012**, 2, a009381	171
1076	Animal models of Parkinson's disease: vertebrate genetics. **2012**, 2,	86
1075	α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. **2012**, 21, 495-510	25
1074	Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. **2012**, 21, 2420-31	69
1073	α-Synuclein levels modulate Huntington's disease in mice. **2012**, 21, 485-94	31
1072	Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein. **2012**, 287, 28243-62	121

1071	The homocysteine-inducible endoplasmic reticulum (ER) stress protein Herp counteracts mutant α-synuclein-induced ER stress via the homeostatic regulation of ER-resident calcium release channel proteins. **2012**, 21, 963-77		53
1070	Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome. **2012**, 287, 27567-79		58
1069	Very low rate of gene conversion in the yeast genome. **2012**, 29, 3817-26		18
1068	α-synuclein, LRRK2 and their interplay in Parkinson's disease. **2012**, 7, 145-153		30
1067	Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1. **2012**, 2, 262		13
1066	Role of Mitochondria in Parkinson's Disease and Huntington's Disease. **2012**, 415-431		
1065	Single gene variants in risk and protection: a new view on the genetic etiology of Parkinson's disease. **2012**, 2, 235-237		
1064	Emerging Role for Copper-Bound α-Synuclein in Parkinson's Disease Etiology. **2012**, 307-338		1
1063	Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast depends on genetic context. **2012**, 21, 2432-49		48
1062	NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease. **2012**, 32, 14465-77		67
1061	Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science*, **2012**, 338, 949-53	33.3	1524
1060	Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. **2012**, 32, 15227-42		119
1059	Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra. **2012**, 72, 906-17		8
1058	Vaccination for Parkinson's disease. **2012**, 18 Suppl 1, S11-3		66
1057	Role of mendelian genes in "sporadic" Parkinson's disease. **2012**, 18 Suppl 1, S66-70		98
1056	Molecular pathways in sporadic PD. **2012**, 18 Suppl 1, S71-3		31
1055	Dynamic modelling of protein and oxidative metabolisms simulates the pathogenesis of Parkinson's disease. **2012**, 6, 65-72		19
1054	Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. **2012**, 287, 33691-705		41

1053	Neuropathologic substrates of Parkinson disease dementia. **2012**, 72, 587-98	316
1052	O-GlcNAc modification prevents peptide-dependent acceleration of □synuclein aggregation. **2012**, 13, 2665-70	42
1051	Therapeutic effects of human mesenchymal and hematopoietic stem cells on rotenone-treated parkinsonian mice. **2013**, 91, 62-72	12
1050	Tremor-ataxia with central hypomyelination (TACH): dystonia as a new clinical feature. **2012**, 27, 1829-30	23
1049	Overcoming obstacles in Parkinson's disease. **2012**, 27, 1606-11	28
1048	Tremor-ataxia with central hypomyelination (TACH): Dystonia as a new clinical feature. **2012**, 27, 1831-1832	4
1047	DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer. **2012**, 138, 1463-74	43
1046	Iron accumulation in Parkinson's disease. **2012**, 119, 1511-4	36
1045	The Parkinson's disease-related genes act in mitochondrial homeostasis. **2012**, 36, 2034-43	42
1044	Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease. **2012**, 61, 899-906	21
1043	MicroRNAs in Neurodegenerative Disorders. **2012**, 1, 214-218	1
1042	Parkinson's disease: gene therapies. **2012**, 2, a009431	68
1041	Does a prion-like mechanism play a major role in the apparent spread of □synuclein pathology?. **2012**, 4, 48	5
1040	Genetics of immunological and inflammatory components in age-related macular degeneration. **2012**, 20, 27-36	65
1039	Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention. **2012**, 47, 282-96	71
1038	Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits. **2012**, 7, 245-59	14
1037	Review: quantifying mitochondrial dysfunction in complex diseases of aging. **2012**, 67, 1022-35	93
1036	Structural intermediates during □synuclein fibrillogenesis on phospholipid vesicles. **2012**, 134, 5090-9	112

1035	Mechanisms underlying altered striatal synaptic plasticity in old A53T-αsynuclein overexpressing mice. **2012**, 33, 1792-9	32
1034	DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. **2012**, 33, 629.e5-629.e18	52
1033	Aberrant striatal synaptic plasticity in monogenic parkinsonisms. **2012**, 211, 126-35	13
1032	αsynuclein phosphorylation and truncation are normal events in the adult human brain. **2012**, 200, 106-19	79
1031	Lewy-like aggregation of αsynuclein reduces protein phosphatase 2A activity in vitro and in vivo. **2012**, 207, 288-97	41
1030	Long-term polarization of microglia upon αsynuclein overexpression in nonhuman primates. **2012**, 208, 85-96	52
1029	An approach to finding brain-situated mutations in sporadic Parkinson's disease. **2012**, 18, 82-5	6
1028	Can Parkinson's disease pathology be propagated from one neuron to another?. **2012**, 97, 205-19	83
1027	The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?. **2012**, 96, 190-207	97
1026	A prolyl oligopeptidase inhibitor, KYP-2047, reduces αsynuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. **2012**, 166, 1097-113	84
1025	Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. **2012**, 166, 1586-99	155
1024	Control of autophagy as a therapy for neurodegenerative disease. **2011**, 8, 108-17	334
1023	An update on the management of juvenile and young-onset Parkinson's disease. **2012**, 7, 581-593	1
1022	Unfolded protein stress in the endoplasmic reticulum and mitochondria: a role in neurodegeneration. **2012**, 4, 5	59
1021	Proteolytic cleavage of extracellular αsynuclein by plasmin: implications for Parkinson disease. **2012**, 287, 24862-72	48
1020	Alternative αsynuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. **2012**, 3, 1084	98
1019	Phosphorylation of αsynuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. **2012**, 287, 7098-109	57
1018	Potential role of αsynuclein in neurodegeneration: studies in a rat animal model. **2012**, 122, 812-22	20

1017	-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. **2012**, 109, 16119-24	31
1016	Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. **2012**, 31, 3038-62	388
1015	Mitochondrial dynamics and neuronal fate in Parkinson's disease. **2012**, 12, 428-37	42
1014	Use of viral vectors to create animal models for Parkinson's disease. **2012**, 48, 189-201	49
1013	-Synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. **2012**, 73, 173-7	36
1012	-synuclein misfolding and Parkinson's disease. **2012**, 1822, 261-85	406
1011	Biophysics of -synuclein membrane interactions. **2012**, 1818, 162-71	141
1010	Folding and misfolding of alpha-synuclein on membranes. **2012**, 1818, 1013-8	132
1009	-Synuclein modulates neurite outgrowth by interacting with SPTBN1. **2012**, 424, 497-502	25
1008	Genetically engineered mouse models of Parkinson's disease. **2012**, 88, 13-32	35
1007	Gene expression in the Parkinson's disease brain. **2012**, 88, 302-12	31
1006	SUMOylation in carcinogenesis. **2012**, 316, 113-25	116
1005	Bioinorganic chemistry of copper coordination to alpha-synuclein: Relevance to Parkinson's disease. **2012**, 256, 2188-2201	101
1004	Polyglutamine neurodegeneration: expanded glutamines enhance native functions. **2012**, 22, 251-5	61
1003	An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. **2012**, 12, 71	96
1002	Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. **2012**, 24, 244102	46
1001	Molecular insights into Parkinson's disease. **2012**, 107, 125-88	59
1000	Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. **2012**, 13, 453-64	89

999	Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease. **2012**, 123, 932-43	56
998	Genetics and epigenetics of Parkinson's disease. **2012**, 2012, 489830	104
997	Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. **2012**, 32, 17775-87	125
996	Nanobodies as structural probes of protein misfolding and fibril formation. **2012**, 911, 533-58	13
995	Role of Ser129 phosphorylation of □synuclein in melanoma cells. **2013**, 126, 696-704	19
994	Alpha-synuclein pore forming activity upon membrane association. **2012**, 1818, 2876-83	66
993	Evolution of neurodegeneration. **2012**, 22, R753-61	15
992	Structural basis behind the interaction of Zn□+ with the protein □synuclein and the A□peptide: a comparative analysis. **2012**, 117, 334-41	40
991	Mitochondria and programmed cell death in Parkinson's disease: apoptosis and beyond. **2012**, 16, 883-95	116
990	Stem Cells and Parkinson's Disease. **2012**,	
989	Biology of mitochondria in neurodegenerative diseases. **2012**, 107, 355-415	117
988	Parkinson's disease. **2012**, 65, 389-455	184
987	Cell cycle activation and aneuploid neurons in Alzheimer's disease. **2012**, 46, 125-35	87
986	The "Janus-faced role" of autophagy in neuronal sickness: focus on neurodegeneration. **2012**, 46, 513-21	21
985	Systems Biology of Parkinson's Disease. **2012**,	6
984	The robust electrochemical detection of a Parkinson's disease marker in whole blood sera. **2012**, 3, 3468	55
983	Drosophila as a model to study mitochondrial dysfunction in Parkinson's disease. **2012**, 2,	69
982	□Synuclein in Parkinson's disease. **2012**, 2, a009399	625

981	Drug Repositioning Efforts by Nonprofit Foundations. **2012**, 389-431	
980	Identification of key pathways and transcription factors related to Parkinson disease in genome wide. **2012**, 39, 10881-7	11
979	Implications of gene copy-number variation in health and diseases. **2012**, 57, 6-13	108
978	Peculiarities of copper binding to alpha-synuclein. **2012**, 29, 825-42	26
977	Exosomal cell-to-cell transmission of alpha synuclein oligomers. **2012**, 7, 42	545
976	Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. **2012**, 7, e43099	35
975	Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. **2012**, 7, e36199	89
974	Genetic copy number variation and general cognitive ability. **2012**, 7, e37385	19
973	The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. **2012**, 7, e38545	64
972	Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. **2012**, 7, e39465	186
971	Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. **2012**, 7, e39953	52
970	Evaluation of the role of SNCA variants in survival without neurological disease. **2012**, 7, e42877	7
969	Quantitative analysis of synuclein solubility in living cells using split GFP complementation. **2012**, 7, e43505	19
968	Covalent synuclein dimers: chemico-physical and aggregation properties. **2012**, 7, e50027	30
967	pha-synuclein levels in blood plasma from LRRK2 mutation carriers. **2012**, 7, e52312	30
966	Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. **2012**, 2012, 437025	22
965	Postmortem Interval Influences Synuclein Expression in Parkinson Disease Brain. **2012**, 2012, 614212	11
964	Non-coding RNA and pseudogenes in neurodegenerative diseases: "The (un)Usual Suspects". **2012**, 3, 231	34

963	Cytoprotective effect of chlorogenic acid against -synuclein-related toxicity in catecholaminergic PC12 cells. **2012**, 51, 122-7	34
962	Genetics of Parkinson's disease - a clinical perspective. **2012**, 5, 33-41	10
961	Alzheimer's disease and related dementias. 17-31	
960	Parkinsonism. 83-102	
959	Parkinson's disease. 197-213	
958	Environmental-genetic interactions in the pathogenesis of Parkinson's disease. **2012**, 21, 123-8	33
957	MicroRNAs in Neurotoxicity. **2012**, 2012, 870150	31
956	Tyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's disease. **2012**, 11, 469-81	13
955	Synucleinopathies and Tauopathies. **2012**, 829-843	4
954	Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?. **2012**, 2, 249-67	52
953	Genetics of Neurodegenerative Diseases. **2012**, 719-736	0
952	Therapeutic Applications of Induced Pluripotent Stem Cells in Parkinson Disease. **2012**, 409-420	
951	-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. **2012**, 287, 15345-64	375
950	Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. **2012**, 20, 1265-9	15
949	Population genetic nature of copy number variation. **2012**, 838, 209-23	17
948	In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy. **2012**, 32, 9992-8	28
947	Regulation of -synuclein expression in Down syndrome. **2012**, 90, 1589-96	5
946	The neuropathology of genetic Parkinson's disease. **2012**, 27, 831-42	184

945	Microdeletion and microduplication syndromes. **2012**, 838, 29-75	47
944	Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. **2012**, 32, 4240-6	212
943	The genetics and neuropathology of Parkinson's disease. **2012**, 124, 325-38	222
942	Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. **2012**, 123, 653-69	111
941	Synaptic dysfunction in Parkinson's disease. **2012**, 970, 553-72	161
940	What have studies of genomic disorders taught us about our genome?. **2012**, 838, 1-27	10
939	Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. **2012**, 32, 9248-64	134
938	Modeling Parkinson's disease using induced pluripotent stem cells. **2012**, 12, 237-42	57
937	PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway. **2012**, 47, 582-94	20
936	Increased expression of α-synuclein by SNCA duplication is associated with resistance to toxic stimuli. **2012**, 47, 249-55	11
935	Genetic testing in neurological diseases. **2012**, 259, 1249-54	5
934	α-synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. **2012**, 119, 739-46	56
933	Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. **2012**, 120, 37-45	72
932	The neuropathology, pathophysiology and genetics of multiple system atrophy. **2012**, 38, 4-24	179
931	Deletion of alpha-synuclein decreases impulsivity in mice. **2012**, 11, 137-46	30
930	Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. **2012**, 279, 1000-13	120
929	α-synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson's disease. **2012**, 22, 280-94	41
928	A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice. **2012**, 45, 591-600	21

927	Neurochemistry and the non-motor aspects of PD. **2012**, 46, 508-26	66
926	Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of □synuclein in midbrain dopamine neurons. **2012**, 45, 939-53	185
925	MicroRNAs in Parkinson's disease. **2012**, 46, 279-84	120
924	Dysregulated dopamine storage increases the vulnerability to □synuclein in nigral neurons. **2012**, 47, 367-77	47
923	GSM-900MHz at low dose temperature-dependently downregulates □synuclein in cultured cerebral cells independently of chaperone-mediated-autophagy. **2012**, 292, 136-44	15
922	MicroRNAs in neurodegenerative diseases and their therapeutic potential. **2012**, 133, 142-50	161
921	Voltage-gated calcium channels and Parkinson's disease. **2012**, 133, 324-33	25
920	The role of □synuclein in neurodegeneration □An update. **2012**, 3,	12
919	Proteinopathies, neurodegenerative disorders with protein aggregation-based pathology. **2012**, 46, 362-374	36
918	Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T □synuclein mutation. **2012**, 1, 2	20
917	Synaptic vesicle trafficking and Parkinson's disease. **2012**, 72, 134-44	70
916	Pseudo-heterozygous rearrangement mutation of parkin. **2012**, 27, 552-5	2
915	No evidence for differential methylation of □synuclein in leukocyte DNA of Parkinson's disease patients. **2012**, 27, 590-1	35
914	Molecular mechanism of active zone organization at vertebrate neuromuscular junctions. **2012**, 45, 1-16	23
913	A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. **2012**, 119, 297-312	28
912	Variant in the 3' region of SNCA associated with Parkinson's disease and serum □synuclein levels. **2012**, 259, 497-504	24
911	De novo triplication of 11q12.3 in a patient with developmental delay and distinctive facial features. **2013**, 6, 15	4
910	The role of amyloidogenic protein oligomerization in neurodegenerative disease. **2013**, 91, 653-64	29

909	Tackling neurodegenerative diseases: animal models of Alzheimer disease and Parkinson disease. **2013**, 35, 425-440	9
908	Prion-like propagation of protein aggregation and related therapeutic strategies. **2013**, 10, 371-82	31
907	Recent advances in RNA interference therapeutics for CNS diseases. **2013**, 10, 473-85	19
906	Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. **2013**, 248, 541-5	47
905	Sumoylation in neurodegenerative diseases. **2013**, 70, 2123-38	87
904	Parkinson's disease dementia: convergence of synuclein, tau and amyloid- pathologies. **2013**, 14, 626-36	495
903	The role of autophagy in neurodegenerative disease. **2013**, 19, 983-97	1302
902	Comparison of motor performance, brain biochemistry and histology of two A30P synuclein transgenic mouse strains. **2013**, 231, 157-68	8
901	Conformational templating of synuclein aggregates in neuronal-glial cultures. **2013**, 8, 17	52
900	Advances in the genetics of Parkinson disease. **2013**, 9, 445-54	353
899	Recognizing genetic forms of parkinsonism. **2013**, 3, 379-390	1
898	Alpha-synuclein: one key opens many locks. **2013**, 28, 1176-8	
897	Synuclein overexpression represses 14-3-3 transcription. **2013**, 51, 1000-9	14
896	Human Gene Mutation in Inherited Disease. **2013**, 1-48	1
895	Induction of CNS synuclein pathology by fibrillar and non-amyloidogenic recombinant synuclein. **2013**, 1, 38	67
894	Synuclein and neuronal cell death. **2013**, 47, 466-83	82
893	The role of glia in synucleinopathies. **2013**, 47, 575-86	52
892	Function and dysfunction of synuclein: probing conformational changes and aggregation by single molecule fluorescence. **2013**, 47, 622-31	22

891	Basal Ganglia Disorders. **2013**, 1-39	
890	Vesicular integrity in Parkinson's disease. **2013**, 13, 362	24
889	Circadian clocks and neurodegenerative diseases: time to aggregate?. **2013**, 23, 880-7	67
888	Can parkin be a target for future treatment of Parkinson's disease?. **2013**, 17, 1133-44	10
887	Microglial activation and antioxidant responses induced by the Parkinson's disease protein □synuclein. **2013**, 8, 94-117	121
886	Structures of the E46K mutant-type □synuclein protein and impact of E46K mutation on the structures of the wild-type □synuclein protein. **2013**, 4, 498-508	47
885	The genetics of Parkinson's disease: progress and therapeutic implications. **2013**, 28, 14-23	248
884	Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. **2013**, 127, 438-52	69
883	Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. **2013**, 28, 1740-4	24
882	Can we clinically diagnose dementia with Lewy bodies yet?. **2013**, 2, 4	37
881	Loss of vesicular dopamine release precedes tauopathy in degenerative dopaminergic neurons in a Drosophila model expressing human tau. **2013**, 125, 711-25	24
880	A prognostic view on the application of individualized genomics in Parkinson's disease. **2013**, 1, 52-57	11
879	Hsp90 inhibits □synuclein aggregation by interacting with soluble oligomers. **2013**, 425, 4614-28	74
878	SUMO and Parkinson's disease. **2013**, 15, 737-59	36
877	Next generation sequencing for neurological diseases: new hope or new hype?. **2013**, 115, 948-53	19
876	Lewy body-like □synuclein aggregates resist degradation and impair macroautophagy. **2013**, 288, 15194-210	209
875	Parkinson's disease: is it all in the genes?. **2013**, 28, 1027-9	3
874	Site-specific differences in proteasome-dependent degradation of monoubiquitinated □synuclein. **2013**, 20, 1207-13	32

873	Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. **2013**, 12, 3543-58		106
872	Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. *Science*, **2013**, 342, 983-7	33.3	341
871	Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems. **2013**, 3, 1569-610		23
870	A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats. **2013**, 136, 412-32		90
869	TRAP1 rescues PINK1 loss-of-function phenotypes. **2013**, 22, 2829-41		74
868	Axon degeneration in Parkinson's disease. **2013**, 246, 72-83		279
867	Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease. **2013**, 4, e545		157
866	Effects of cytoprotective antioxidants on lymphocytes from representative mitochondrial neurodegenerative diseases. **2013**, 21, 969-78		15
865	Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies. **2013**, 1, 79		58
864	Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease. **2013**, 10, e121-8		20
863	YY1 binds to α-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression. **2013**, 58, 711-9		26
862	Therapeutic prospects for Parkinson disease. **2013**, 74, 337-47		99
861	Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics. **2013**, 4, 486-97		31
860	Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo. **2013**, 20, 233-44		18
859	The function of α-synuclein. **2013**, 79, 1044-66		475
858	Biomarkers, mechanisms, and potential prevention of catecholamine neuron loss in Parkinson disease. **2013**, 68, 235-72		22
857	Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. **2013**, 125, 491-511		102
856	Prion-like spreading of pathological α-synuclein in brain. **2013**, 136, 1128-38		551

855	Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates -synuclein toxicity in neurons. *Science*, **2013**, 342, 979-83	33.3	188
854	Membrane-bound -synuclein interacts with glucocerebrosidase and inhibits enzyme activity. **2013**, 108, 56-64		79
853	Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. **2013**, 241, 148-55		32
852	Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?. **2013**, 120, 197-210		14
851	100 years of Lewy pathology. **2013**, 9, 13-24		691
850	The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to -synuclein toxicity in Parkinson's disease models. **2013**, 20, 465-77		47
849	Biomarkers for the diagnosis and management of Parkinson's disease. **2013**, 7, 71-83		5
848	Inflammation and -synuclein's prion-like behavior in Parkinson's disease--is there a link?. **2013**, 47, 561-74		148
847	-Synuclein oligomers and clinical implications for Parkinson disease. **2013**, 73, 155-69		209
846	Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progression. **2013**, 137, 1-21		10
845	Convergent gene loss following gene and genome duplications creates single-copy families in flowering plants. **2013**, 110, 2898-903		231
844	Selective expression of -synuclein-immunoreactivity in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig rectum and human colon. **2013**, 521, 657-76		18
843	Synucleins: are they two-edged swords?. **2013**, 91, 161-6		38
842	A peroxisome biogenesis deficiency prevents the binding of alpha-synuclein to lipid droplets in lipid-loaded yeast. **2013**, 438, 452-6		14
841	A flash in the pan: dissecting dynamic amyloid intermediates using fluorescence. **2013**, 587, 1096-105		12
840	Neuroprotective changes of thalamic degeneration-related gene expression by acupuncture in an MPTP mouse model of parkinsonism: microarray analysis. **2013**, 515, 329-38		18
839	Detection of copy number changes in genes associated with Parkinson's disease in Iranian patients. **2013**, 551, 75-8		23
838	-Synuclein mutations cluster around a putative protein loop. **2013**, 546, 67-70		33

837	The identification of dysfunctional crosstalk of pathways in Parkinson disease. **2013**, 515, 159-62	7
836	G□□ique de la maladie de Parkinson. **2013**, 4, 3-10	0
835	Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling. **2013**, 541, 116-9	17
834	Expression of human E46K-mutated □synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. **2013**, 240, 44-56	52
833	RNA interference targeting □synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells. **2013**, 1521, 59-67	35
832	Large □synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. **2013**, 110, 4087-92	181
831	Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. **2013**, 47, 1081-92	56
830	An intact membrane is essential for small extracellular vesicle-induced modulation of □synuclein fibrillization. **2020**, 10, e12034	3
829	Comparative proteomic analysis highlights metabolic dysfunction in □synucleinopathy. **2020**, 6, 40	4
828	Proteomic analysis of subcellular compartments containing disseminated alpha-synuclein seeds. **2021**, 170, 341-349	
827	Genetic Risk Profiling in Parkinson's Disease and Utilizing Genetics to Gain Insight into Disease-Related Biological Pathways. **2020**, 21,	9
826	The Emerging Role of the Lysosome in Parkinson's Disease. **2020**, 9,	16
825	Discovery of new epigenomics-based biomarkers and the early diagnosis of neurodegenerative diseases. **2020**, 61, 101069	2
824	Fibrillar form of □synuclein-specific scFv antibody inhibits □synuclein seeds induced aggregation and toxicity. **2020**, 10, 8137	4
823	Membrane trafficking in health and disease. **2020**, 13,	25
822	Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis. **2020**, 8, 63	22
821	Decreased Vacuolar Ca Storage and Disrupted Vesicle Trafficking Underlie Alpha-Synuclein-Induced Ca Dysregulation in. **2020**, 11, 266	3
820	Structural analyses and force fields comparison for NACore (68-78) and SubNACore (69-77) fibril segments of Parkinson's disease. **2020**, 26, 132	2

819	Intramitochondrial proteostasis is directly coupled to -synuclein and amyloid -1-42 pathologies. **2020**, 295, 10138-10152	14
818	Lipids: Key Players That Modulate -Synuclein Toxicity and Neurodegeneration in Parkinson's Disease. **2020**, 21,	16
817	Alteration in the Expression of Parkinson-Related Genes in Rat Hippocampus by Exercise and Morphine Treatments. **2020**, 56, 502-508	
816	Parkinson's disease. **2020**, 377-412	2
815	Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates. **2020**, 21,	39
814	Parkinson's disease associated mutation E46K of -synuclein triggers the formation of a distinct fibril structure. **2020**, 11, 2643	31
813	Structures of -synuclein filaments from multiple system atrophy. **2020**, 585, 464-469	195
812	Changes in the Oligodendrocyte Progenitor Cell Proteome with Ageing. **2020**, 19, 1281-1302	18
811	-Synuclein-112 Impairs Synaptic Vesicle Recycling Consistent With Its Enhanced Membrane Binding Properties. **2020**, 8, 405	10
810	Anti-aggregation Effects of Phenolic Compounds on -synuclein. **2020**, 25,	6
809	TDP-1/TDP-43 potentiates human -Synuclein (HASN) neurodegeneration in Caenorhabditis elegans. **2020**, 1866, 165876	8
808	The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease. **2020**, 10,	4
807	Microglia clear neuron-released -synuclein via selective autophagy and prevent neurodegeneration. **2020**, 11, 1386	113
806	Animal Model for Prodromal Parkinson's Disease. **2020**, 21,	5
805	Initiation and propagation of -synuclein aggregation in the nervous system. **2020**, 15, 19	80
804	Unravelling the effect of (-(carboxyethyl)lysine on the conformation, dynamics and aggregation propensity of -synuclein. **2020**, 11, 3332-3344	5
803	miR-30b protects nigrostriatal dopaminergic neurons from MPP(+)-induced neurotoxicity via SNCA. **2020**, 10, e01567	10
802	Targeting -synuclein for PD Therapeutics: A Pursuit on All Fronts. **2020**, 10,	25

801 Transcriptomic signatures of brain regional vulnerability to Parkinson's disease. **2020**, 3, 101 24

800 The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases. **2020**, 21, 21

799 Synuclein filaments from transgenic mouse and human synucleinopathy-containing brains are major seed-competent species. **2020**, 295, 6652-6664 10

798 Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of Synuclein in Mouse Brain. **2020**, 21, 15

797 Salient Features of Monomeric Alpha-Synuclein Revealed by NMR Spectroscopy. **2020**, 10, 6

796 MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax. **2020**, 35, 627-635 14

795 Genetic Analysis of in an Early-Onset Parkinson's Disease Cohort. **2020**, 11, 523 6

794 Parkinson's Disease and the Gut: Future Perspectives for Early Diagnosis. **2020**, 14, 626 8

793 Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders. **2020**, 190, 111297 11

792 Protein Structure and Function in Aging and Age-Related Diseases. **2020**, 3-26

791 [Genetic testing for Parkinson's disease: indication and practical implementation]. **2020**, 88, 601-608

790 Therapeutic Potential of Baicalein in Parkinson Disease: Focus on Inhibition of Synuclein Oligomerization and Aggregation. **2020**, 2

789 In silico analysis: structural insights about inter-protofilaments interactions for synuclein (50 7) fibrils and its familial mutation. **2020**, 46, 867-878 4

788 Functional Impact of the G279S Substitution in the Adenosine A-Receptor (AR-G279S), a Mutation Associated with Parkinson's Disease. **2020**, 98, 250-266 5

787 Automated phenotyping and lifespan assessment of a model of Parkinson's disease. **2020**, 4, 38-44 4

786 Parkinson's disease: etiopathogenesis and treatment. **2020**, 91, 795-808 120

785 SUMOylation in Synuclein Homeostasis and Pathology. **2020**, 12, 167 7

784 Genomics of human neurological disorders. **2020**, 145-156

783	In Silico Study of the Mechanism of Binding of the N-Terminal Region of Synuclein to Synaptic-Like Membranes. **2020**, 10,	3
782	APOE4 exacerbates synuclein pathology and related toxicity independent of amyloid. **2020**, 12,	40
781	PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape. **2020**, 25,	30
780	CRSCNV: A Cross-Model-Based Statistical Approach to Detect Copy Number Variations in Sequence Data. **2020**, 8, 2302-2312	1
779	Chemical Chaperones as Novel Drugs for Parkinson's Disease. **2020**, 26, 408-421	15
778	A Role of Cholesterol in Modulating the Binding of Synuclein to Synaptic-Like Vesicles. **2020**, 14, 18	10
777	The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease. **2020**, 35, 551-554	3
776	Genetic causes of PD: A pathway to disease modification. **2020**, 170, 108022	15
775	Is insulin-like growth factor-1 involved in Parkinson's disease development?. **2020**, 18, 70	10
774	RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease. **2020**, 98, 730-738	2
773	Identifying inducers of BDNF gene expression from pharmacologically validated compounds; antipyretic drug dipyrone increases BDNF mRNA in neurons. **2020**, 524, 957-962	4
772	Mechanisms of alpha-synuclein toxicity: An update and outlook. **2020**, 252, 91-129	28
771	Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles. **2019**, 13, 1399	37
770	WITHDRAWN: Genetics of Parkinson's disease. **2020**, 101471	
769	The Non-amyloidal Component Region of Synuclein Is Important for Synuclein Transport Within Axons. **2019**, 13, 540	7
768	iPSC modeling of young-onset Parkinson's disease reveals a molecular signature of disease and novel therapeutic candidates. **2020**, 26, 289-299	51
767	Protein Quality Control Pathways at the Crossroad of Synucleinopathies. **2020**, 10, 369-382	12
766	Vesicular Dysfunction and the Pathogenesis of Parkinson's Disease: Clues From Genetic Studies. **2019**, 13, 1381	14

765	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease. **2020**, 25,	14
764	Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. **2020**, 137, 104782	116
763	The contribution of Parkin, PINK1 and DJ-1 genes to selective neuronal degeneration in Parkinson's disease. **2020**, 52, 3256-3268	18
762	Intracerebral seeding of amyloid-□and tau pathology in mice: Factors underlying prion-like spreading and comparisons with □synuclein. **2020**, 112, 1-27	17
761	The N-terminal Acetylation of □Synuclein Changes the Affinity for Lipid Membranes but not the Structural Properties of the Bound State. **2020**, 10, 204	22
760	The □synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure. **2020**, 117, 3592-3602	57
759	Cerium Oxide Nanoparticles Rescue □Synuclein-Induced Toxicity in a Yeast Model of Parkinson's Disease. **2020**, 10,	20
758	S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease. **2020**, 15, e0232019	4
757	Promiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies. **2020**, 21,	29
756	Animal models for preclinical Parkinson's research: An update and critical appraisal. **2020**, 252, 27-59	10
755	Saliva in Health and Disease. **2020**,	2
754	Endosomal sorting pathways in the pathogenesis of Parkinson's disease. **2020**, 252, 271-306	8
753	Selective neuronal vulnerability in Parkinson's disease. **2020**, 252, 61-89	12
752	Generation of a human induced pluripotent stem cell line derived from a Parkinson's disease patient carrying SNCA duplication. **2020**, 45, 101828	0
751	Combining data integration and molecular dynamics for target identification in □Synuclein-aggregating neurodegenerative diseases: Structural insights on Synaptojanin-1 (Synj1). **2020**, 18, 1032-1042	2
750	Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. **2020**, 27, 2781-2796	46
749	Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. **2020**, 141, 104876	36
748	Enhanced Susceptibility of PINK1 Knockout Rats to □Synuclein Fibrils. **2020**, 437, 64-75	7

747	Pathways of protein synthesis and degradation in PD pathogenesis. **2020**, 252, 217-270	3
746	Introducing Virtual Oligomerization Inhibition to Identify Potent Inhibitors of A Oligomerization. **2020**, 16, 3920-3935	4
745	Investigation of the Dissociation Mechanism of Single-Walled Carbon Nanotube on Mature Amyloid- Fibrils at Single Nanotube Level. **2020**, 124, 3459-3468	6
744	Analysis of synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies. **2020**, 2, fcaa010	12
743	Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells. **2020**, 2020, 1061470	9
742	Modelling neurodegenerative disease using brain organoids. **2021**, 111, 60-66	11
741	Vesicle trafficking and lipid metabolism in synucleinopathy. **2021**, 141, 491-510	15
740	Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients. **2021**, 36, 434-441	4
739	Molecular characteristics of porcine alpha-synuclein splicing variants. **2021**, 180, 121-133	1
738	RAB39B's role in membrane traffic, autophagy, and associated neuropathology. **2021**, 236, 1579-1592	5
737	Genetics of synucleins in neurodegenerative diseases. **2021**, 141, 471-490	6
736	Nutraceuticals in neurodegenerative diseases. **2021**, 249-270	2
735	Characterization of Small-Molecule-Induced Changes in Parkinson's-Related Trafficking via the Nedd4 Ubiquitin Signaling Cascade. **2021**, 28, 14-25.e9	7
734	Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human Synuclein BAC Transgenic Rats. **2021**, 36, 716-728	2
733	Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication. **2021**, 11, 354-366	2
732	Upregulation of Cellular Palmitoylation Mitigates Synuclein Accumulation and Neurotoxicity. **2021**, 36, 348-359	11
731	Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. **2021**, 11, 71-92	7
730	Disorders of synaptic vesicle fusion machinery. **2021**, 157, 130-164	16

729 Common Marmoset Model of -Synuclein Propagation. **2021**, 2322, 131-139 0

728 Lewy Body Disease. **2021**, 18-41

727 Etiology and pathogenesis of Parkinson disease. **2021**, 121-163.e16 1

726 Metabotropic glutamate receptor 5 inhibits -synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease. **2021**, 18, 23 15

725 Attack of the Oligomers -Alpha-synuclein amyloid oligomers and their pathogenic roles. **2021**, 129-158

724 Cellular and synaptic mechanisms for Parkinson's disease-related chronic pain. **2021**, 17, 1744806921999025 3

723 The Mechanism of Physical Activity-induced Amelioration of Parkinson's Disease: A Narrative Review. **2021**, 12, 192-202 9

722 Adeno-Associated Virus Expression of -Synuclein as a Tool to Model Parkinson's Disease: Current Understanding and Knowledge Gaps. **2021**, 12, 1120-1137 1

721 Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. **2021**, 291-310

720 Hijacking Endocytosis and Autophagy in Extracellular Vesicle Communication: Where the Inside Meets the Outside. **2020**, 8, 595515 8

719 Measurement of GCase Activity in Cultured Cells. **2021**, 2322, 47-52

718 Reverse engineering Lewy bodies: how far have we come and how far can we go?. **2021**, 22, 111-131 47

717 Tremors. **2021**, 296-326.e16

716 Clinical overview and phenomenology of movement disorders. **2021**, 1-51.e27 0

715 Parkinson's disease. **2021**, 1-171 1

714 Interaction between Parkin and -Synuclein in -Mediated Parkinson's Disease. **2021**, 10, 8

713 [Reconstruction of gene network associated with Parkinson disease for gene targets search]. **2021**, 67, 222-230 1

712 The Membrane Interactions of Synuclein: Physiology and Pathology. **2021**, 16, 465-485 12

711	CheSPI: Chemical shift Secondary structure Population Inference.	
710	Dysregulation of PGC-1□Dependent Transcriptional Programs in Neurological and Developmental Disorders: Therapeutic Challenges and Opportunities. **2021**, 10,	5
709	Seeded assembly in ́vitro does not replicate the structures of □synuclein filaments from multiple system atrophy. **2021**, 11, 999-1013	36
708	Invertebrate Models Untangle the Mechanism of Neurodegeneration in Parkinson's Disease. **2021**, 10,	5
707	Cellular and molecular pathophysiology in the progression of Parkinson's disease. **2021**, 36, 815-827	7
706	Exogenous Alpha-Synuclein Evoked Parkin Downregulation Promotes Mitochondrial Dysfunction in Neuronal Cells. Implications for Parkinson's Disease Pathology. **2021**, 13, 591475	9
705	Development of an □synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models. **2021**, 4, 232	5
704	□synuclein impairs autophagosome maturation through abnormal actin stabilization. **2021**, 17, e1009359	15
703	Recent Force Field Strategies for Intrinsically Disordered Proteins. **2021**, 61, 1037-1047	24
702	Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. **2021**, 10,	20
701	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. **2021**, 53, 294-303	31
700	stLFRsv: A Germline Structural Variant Analysis Pipeline Using Co-barcoded Reads. **2021**, 12, 636239	1
699	Biomarkers and the Role of □Synuclein in Parkinson's Disease. **2021**, 13, 645996	5
698	Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers. **2021**, 12, 1438-1448	4
697	Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences. **2021**, 10,	11
696	[illegible] **2021**, 86, 324-340	
695	Fatty Acid-Binding Protein 3 Expression in the Brain and Skin in Human Synucleinopathies. **2021**, 13, 648982	1
694	Investigating the relationship between the SNCA gene and cognitive abilities in idiopathic Parkinson's disease using machine learning. **2021**, 11, 4917	3

693	-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. **2021**, 6,	15
692	SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models. **2021**, 13, e13076	12
691	Presynaptic accumulation of -synuclein causes synaptopathy and progressive neurodegeneration in. **2021**, 3, fcab049	2
690	A conformational switch driven by phosphorylation regulates the activity of the evolutionarily conserved SNARE Ykt6. **2021**, 118,	5
689	On the Role of Normal Aging Processes in the Onset and Pathogenesis of Diseases Associated with the Abnormal Accumulation of Protein Aggregates. **2021**, 86, 275-289	2
688	Structural insights into -synuclein monomer-fibril interactions. **2021**, 118,	13
687	Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson's Disease. **2021**, 15, 626128	6
686	A New Rise of Non-Human Primate Models of Synucleinopathies. **2021**, 9,	3
685	Novel insights in the pathophysiology of -synuclein dysregulation on D2 receptor activity contributing to the vulnerability of dopamine neurons.	
684	Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy Body diseases.	
683	Nurr1 repression mediates cardinal features of Parkinson's disease in -synuclein transgenic mice. **2021**, 30, 1469-1483	1
682	A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson disease (PASADENA): rationale, design and baseline data.	3
681	Grafts Derived from an -Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease. **2021**, 11, 515-528	1
680	Association of Glycolysis-Enhancing -1 Blockers With Risk of Developing Parkinson Disease. **2021**, 78, 407-413	12
679	Clinical Insights into Mitochondrial Neurodevelopmental and Neurodegenerative Disorders: Their Biosignatures from Mass Spectrometry-Based Metabolomics. **2021**, 11,	2
678	Identification of Two Novel Peptides That Inhibit -Synuclein Toxicity and Aggregation. **2021**, 14, 659926	1
677	Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges. **2021**, 22,	
676	Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of -Synuclein and Cholesterol. **2021**, 15, 658244	2

675	The Contribution of Microglia to Neuroinflammation in Parkinson's Disease. **2021**, 22,	22
674	Role of SNAREs in Neurodegenerative Diseases. **2021**, 10,	8
673	Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N-arylbenzdiimidazole ligand□ rescue of Parkinson□-associated cell toxicity.	1
672	Neurons and Glia Interplay in □Synucleinopathies. **2021**, 22,	9
671	Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice. **2021**, 101, 207-220	3
670	Templated □Synuclein Inclusion Formation Is Independent of Endogenous Tau. **2021**, 8,	3
669	Single Nuclei Sequencing of Human Putamen Oligodendrocytes Reveals Altered Heterogeneity and Disease-Associated Changes in Parkinson□ Disease and Multiple System Atrophy.	3
668	Metabolic Study of Stable Isotope Labeled Indolinone Derivative in Hepatocyte Cell by UPLC/Q TOF MS. **2021**, 32, 1538-1544	3
667	Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies. **2021**, 41, 101896	20
666	Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain. **2021**, 1759, 147372	4
665	The Pathogenesis of Parkinson's Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes?. **2021**, 12, 666737	12
664	Ellagic Acid Inhibits □Synuclein Aggregation at Multiple Stages and Reduces Its Cytotoxicity. **2021**, 12, 1919-1930	6
663	Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression. **2021**, 152, 105289	8
662	Retrogradely transmitted □synuclein is taken up by the endophilin-independent endocytosis in the C.´elegans neural circuit. **2021**, 552, 176-182	1
661	In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129. **2021**, 152, 105291	9
660	"Janus-Faced" □Synuclein: Role in Parkinson's Disease. **2021**, 9, 673395	3
659	Oligomerization of Lrrk controls actin severing and □synuclein neurotoxicity in vivo. **2021**, 16, 33	2
658	Low-Expressing Synucleinopathy Mouse Models Based on Oligomer-Forming Mutations and C-Terminal Truncation of □Synuclein. **2021**, 15, 643391	1

657	Ronin overexpression induces cerebellar degeneration in a mouse model of ataxia. **2021**, 14,	0
656	CheSPI: chemical shift secondary structure population inference. **2021**, 75, 273-291	3
655	Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. **2021**, 12, 681369	3
654	Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease. **2021**, 22,	10
653	Molecular basis of proteinopathies: Etiopathology of dementia and motor disorders. **2021**, 75, 456-473	
652	NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease. **2021**,	0
651	The Genetics of Parkinson's Disease and Implications for Clinical Practice. **2021**, 12,	13
650	Photodynamic treatment modulates various GTPase and cellular signalling pathways in Tauopathy. **2021**, 1-13	
649	□synuclein pathogenesis in hiPSC models of Parkinson's disease. **2021**, 5, NS20210021	1
648	The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T □Synuclein Toxicity in Dopaminergic Neurons In Vivo. **2021**, 22,	6
647	An Emerging Role for Phosphoinositides in the Pathophysiology of Parkinson's Disease. **2021**, 11, 1725-1750	
646	Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. **2021**, 41, 2841-2886	3
645	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. **2021**, 7, 65	12
644	Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models. **2021**, 87, 153578	4
643	Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease. **2021**, 155, 105368	5
642	Advances in protein-protein interaction network analysis for Parkinson's disease. **2021**, 155, 105395	4
641	Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. **2021**, 8, 655123	2
640	Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases. **2021**, 142, 449-474	0

639	Parkinson's Disease Genetics and Pathophysiology. **2021**, 44, 87-108	19
638	Rat Models of Vocal Deficits in Parkinson's Disease. **2021**, 11,	2
637	Modulation of the Interactions Between -Synuclein and Lipid Membranes by Post-translational Modifications. **2021**, 12, 661117	2
636	Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough. **2021**, 13, 702639	12
635	Recalling the pathology of Parkinson's disease; lacking exact figure of prevalence and genetic evidence in Asia with an alarming outcome: A time to step-up. **2021**, 100, 659-677	2
634	A comprehensive analysis of copy number variation in a Turkish dementia cohort. **2021**, 15, 48	
633	Aberrant Expression of Circulating MicroRNA Leads to the Dysregulation of Alpha-Synuclein and Other Pathogenic Genes in Parkinson's Disease. **2021**, 9, 695007	5
632	Analysis of mutations associated with Parkinson disease in patients of the Krasnoyarsk region. **2021**, 26, 15-22	
631	Genetic Analysis and Literature Review of Variants in Parkinson's Disease. **2021**, 13, 648151	1
630	-Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability. **2021**, 7, 76	1
629	Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease. **2021**,	3
628	Disease-, region- and cell type specific diversity of -synuclein carboxy terminal truncations in synucleinopathies. **2021**, 9, 146	1
627	Clan genomics: From OMIM phenotypic traits to genes and biology. **2021**, 185, 3294-3313	9
626	Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. **2021**, 58, 5517-5532	1
625	Lewy Body-like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and -Synuclein Mutations. **2021**, 90, 490-505	12
624	The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses. **2021**, 22,	10
623	-Synuclein Decreases the Abundance of Proteasome Subunits and Alters Ubiquitin Conjugates in Yeast. **2021**, 10,	1
622	Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display -Synuclein Pathology and Abnormal Mitochondrial Morphology. **2021**, 10,	1

621	Association between □2-Adrenoreceptor Medications and Risk of Parkinson's Disease: A Meta-Analysis. **2021**, 57,	2
620	Evidence of Inflammation in Parkinson's Disease and Its Contribution to Synucleinopathy.. **2022**, 15, 1-14	0
619	Structural and Functional Insights into □Synuclein Fibril Polymorphism. **2021**, 11,	6
618	Alpha-synuclein alters the faecal viromes of rats in a gut-initiated model of Parkinson's disease. **2021**, 4, 1140	1
617	Midbrain organoids with an gene triplication model key features of synucleinopathy. **2021**, 3, fcab223	6
616	Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and □Synucleinopathy. **2021**, 11,	0
615	Activated microglia facilitate the transmission of □synuclein in Parkinson's disease. **2021**, 148, 105094	8
614	Balanced Solvent Model for Intrinsically Disordered and Ordered Proteins. **2021**, 61, 5141-5151	2
613	Neurodegenerative disorders and the current state, pathophysiology and management of Parkinson's disease. **2021**,	
612	□Synuclein inhibits Snx3-retromer retrograde trafficking of the conserved membrane-bound proprotein convertase Kex2 in the secretory pathway of Saccharomyces cerevisiae. **2021**,	1
611	Alpha-Synuclein and Lipids: The Elephant in the Room?. **2021**, 10,	2
610	Targeting □synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease. **2021**,	2
609	All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration. **2021**, 10,	2
608	A humanized version of Foxp2 affects ultrasonic vocalization in adult female and male mice. **2021**, 20, e12764	2
607	Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings. **2021**, 12, 648588	3
606	Spontaneous nucleation and fast aggregate-dependent proliferation of □synuclein aggregates within liquid condensates at physiological pH.	5
605	The 10-Repeat 3'-UTR VNTR Polymorphism in the Gene May Confer Protection Against Parkinson's Disease: A Meta-analysis. **2021**, 12, 757601	
604	Pathways to Parkinson's disease: a spotlight on 14-3-3 proteins. **2021**, 7, 85	0

603	The AKT modulator A-443654 reduces -synuclein expression and normalizes ER stress and autophagy. **2021**, 297, 101191	0
602	Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction. **2021**, 106, 12-25	1
601	Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease. **2022**, 17, 38-44	0
600	Molecular and Genetic Therapies. **2022**, 225-246	
599	Molecular foundations of prion strain diversity. **2021**, 72, 22-31	4
598	Neuroprotective mechanisms of red clover and soy isoflavones in Parkinson's disease models. **2021**, 12, 11987-12007	0
597	Targeted attenuation of elevated histone marks at SNCA alleviates -synuclein in Parkinson's disease. **2021**, 13, e12188	14
596	Potential therapeutic effects of polyphenols in Parkinson's disease: and pre-clinical studies. **2021**, 16, 234-241	11
595	Comprehensive Perspectives on Experimental Models for Parkinson's Disease. **2021**, 12, 223-246	2
594	Bad News, Good News The demographics and genetic and environmental risk factors for Parkinson's disease. **2021**, 11-32	
593	A population scale analysis of rare SNCA variation in the UK Biobank. **2021**, 148, 105182	1
592	Observation of an -synuclein liquid droplet state and its maturation into Lewy body-like assemblies. **2021**, 13, 282-294	25
591	Parkinson's Disease. 194-223	9
590	Multiple System Atrophy. 242-252	5
589	The Ubiquitin Proteasome System in Parkinson's Disease. 169-194	1
588	Novel gene therapeutic strategies for neurodegenerative diseases. **2005**, 147-71	3
587	Immunotherapy Strategies for Lewy Body and Parkinson's Diseases. **2009**, 599-613	1
586	Factors Affecting the Fibrillation of -Synuclein, a Natively Unfolded Protein. **2006**, 265-285	4

585	Progress in Understanding the Mechanisms of Neuronal Dysfunction and Degeneration in Parkinson's Disease. **2007**, 49-59	1
584	α-Synuclein Aggregation and Parkinson's Disease. **2007**, 61-110	2
583	Alzheimer's Disease, Parkinson's Disease, and Frontotemporal Dementias: Different Manifestations of Protein Misfolding. **2008**, 123-131	1
582	Novel Therapeutic Target in PD: Experimental Models. **2008**, 57-73	1
581	Genetic Models of Parkinson's Disease. **2021**, 37-84	1
580	Inhibition of α-Synuclein Aggregation by Antioxidants and Chaperones in Parkinson's Disease. **2009**, 175-206	4
579	Modeling Nonmotor Symptoms of Parkinson's Disease in Genetic Mouse Models. **2009**, 483-491	3
578	Gene- and cell-based approaches for neurodegenerative disease. **2010**, 671, 117-30	7
577	Synaptic Dysfunction in Parkinson's Disease: From Protein Misfolding to Functional Alterations. **2011**, 257-267	0
576	Modelling and Simulation of Brain Energy Metabolism: Energy and Parkinson's Disease. **2012**, 19-38	3
575	Alpha Synuclein in Parkinson's Disease. **2014**, 691-726	1
574	Integrating genetic, functional genomic, and bioinformatics data in a systems biology approach to complex diseases: application to schizophrenia. **2007**, 401, 337-64	8
573	Modeling dopamine neuron degeneration in Caenorhabditis elegans. **2011**, 793, 129-48	24
572	Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo. **2006**, 133-41	6
571	Genetic causes of Parkinson's disease: extending the pathway. **2006**, 181-9	4
570	Progress in familial Parkinson's disease. **2006**, 191-204	14
569	In Vitro Modeling of Complex Neurological Diseases. **2017**, 1-19	2
568	Therapeutic Potential of Small Interfering RNA for Brain Diseases. **2009**, 275-295	1

567	Aetiopathogenesis. **2014**, 57-81	3
566	The Use of Biomarkers for Prediction and Prevention of Alzheimer and Parkinson Diseases. **2013**, 95-140	2
565	Modeling of Human Parkinson Disease in Fly. **2019**, 279-310	1
564	Mitochondrial Proteins in the Development of Parkinson's Disease. **2019**, 1158, 17-44	2
563	Microglia in Parkinson's Disease. **2019**, 1175, 335-353	56
562	Neurodegeneration and neuroprotection in Parkinson disease. **2004**, 1, 139	1
561	Parkinson's disease and iron. **2020**, 127, 181-187	25
560	The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease. **2020**, 57, 2959-2980	60
559	Microglial activation in a mouse model of synuclein overexpression. **2008**, 545-557	1
558	Alpha-Synuclein?. **2017**,	1
557	Mitochondrial: A Critical Role in Aging. **2005**, 124-148	1
556	Parkinson's Disease. **2008**, 10-17	3
555	Clinical Neurogenetics. **2012**, 704-734	3
554	Specific Knockdown of Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity. **2020**, 27, 751-762.e4	15
553	Genetic architecture of common non-Alzheimer's disease dementias. **2020**, 142, 104946	16
552	Astrocytes and therapeutics for Parkinson disease. **2010**, 7, 413	1
551	Screening of small molecules using the inhibition of oligomer formation in synuclein aggregation as a selection parameter. **2020**, 3,	4
550	A novel resource for studying function and dysfunction of synuclein: mouse lines for modulation of endogenous Snca gene expression. **2015**, 5, 16615	13

549	CHAPTER 2:Molecular Pathogenesis and Pathophysiology of Parkinson's Disease: New Targets for New Therapies. **2013**, 26-57	1
548	Nanotheranostic agents for neurodegenerative diseases. **2020**, 4, 645-675	1
547	RT-QuIC-based detection of alpha-synuclein seeding activity in brains of dementia with Lewy Body patients and of a transgenic mouse model of synucleinopathy. **2020**, 14, 88-94	10
546	Structures of α-synuclein filaments from multiple system atrophy.	9
545	A conformational switch driven by phosphorylation regulates Ykt6 activity in macroautophagy.	1
544	IPSC-derived midbrain astrocytes from Parkinson's disease patients carrying pathogenic SNCA mutations exhibit alpha-synuclein aggregation, mitochondrial fragmentation and excess calcium release.	1
543	α-Synuclein facilitates clathrin assembly in synaptic vesicle endocytosis.	3
542	Observation of an α-synuclein liquid droplet state and its maturation into Lewy body-like assemblies.	5
541	Genome-Wide Polygenic Risk Score Identifies Individuals at Elevated Parkinson's Disease Risk.	0
540	Seeded assembly in vitro does not replicate the structures of α-synuclein filaments from multiple system atrophy.	1
539	Cryo-EM structure of alpha-synuclein fibrils.	1
538	Expanding Parkinson's disease genetics: novel risk loci, genomic context, causal insights and heritable risk.	51
537	Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms.	6
536	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability.	2
535	Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation.	1
534	Two new polymorphic structures of alpha-synuclein solved by cryo-electron microscopy.	4
533	Cryo-EM structures of α-synuclein fibrils with the H50Q hereditary mutation reveal new polymorphs.	2
532	Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.	7

531	Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression.	3
530	Parkinson disease associated mutation E46K of synuclein triggers the formation of a novel fibril structure.	2
529	Regulation of alpha-synuclein expression: implications for Parkinson's disease. **2003**, 68, 409-15	9
528	Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection. **2017**, 9, 437-440	25
527	Age-dependent nigral dopaminergic neurodegeneration and synuclein accumulation in RGS6-deficient mice. **2019**, 5,	8
526	Thinking laterally about neurodegenerative proteinopathies. **2013**, 123, 1847-55	80
525	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. **2020**, 8, 5	15
524	Parkinson Disease. **2012**, 21-28	0
523	Discovery of functional non-coding conserved regions in the synuclein gene locus. **2014**, 3, 259	6
522	Nigrostriatal dynein changes in A53T alpha-synuclein transgenic mice. **2014**, 3, 68	8
521	shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity. **2016**, 12, e1005995	48
520	C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of Synuclein in a Yeast Model of Parkinson's Disease. **2016**, 12, e1006098	39
519	Formation of toxic oligomeric alpha-synuclein species in living cells. **2008**, 3, e1867	299
518	Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. **2008**, 3, e3394	88
517	Granular assembly of alpha-synuclein leading to the accelerated amyloid fibril formation with shear stress. **2009**, 4, e4177	50
516	Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. **2009**, 4, e5515	270
515	Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. **2009**, 4, e7480	71
514	Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. **2010**, 5, e9956	73

513	Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. **2010**, 5, e12333	80
512	Resistance to MPTP-neurotoxicity in □synuclein knockout mice is complemented by human □synuclein and associated with increased □-synuclein and Akt activation. **2011**, 6, e16706	50
511	14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax. **2011**, 6, e21720	30
510	Improved immunodetection of endogenous □synuclein. **2011**, 6, e23939	96
509	Pre-fibrillar □synuclein mutants cause Parkinson's disease-like non-motor symptoms in Drosophila. **2011**, 6, e24701	31
508	Antibodies against alpha-synuclein reduce oligomerization in living cells. **2011**, 6, e27230	54
507	The role of the Parkinson's disease gene PARK9 in essential cellular pathways and the manganese homeostasis network in yeast. **2012**, 7, e34178	35
506	Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy. **2012**, 7, e34713	49
505	Striatal dopamine transmission is subtly modified in human A53T□synuclein overexpressing mice. **2012**, 7, e36397	22
504	The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. **2012**, 7, e45183	64
503	A spirulina-enhanced diet provides neuroprotection in an □synuclein model of Parkinson's disease. **2012**, 7, e45256	58
502	Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. **2013**, 8, e70274	111
501	Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. **2013**, 8, e71634	73
500	SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening. **2013**, 8, e77711	11
499	Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. **2013**, 8, e81426	57
498	Traumatic brain injury dysregulates microRNAs to modulate cell signaling in rat hippocampus. **2014**, 9, e103948	70
497	Targeted Overexpression of □Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse. **2015**, 10, e0131281	23
496	Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations. **2016**, 11, e0154890	17

495	Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. **2017**, 12, e0181844	15
494	Heritable heading time variation in wheat lines with the same number of Ppd-B1 gene copies. **2017**, 12, e0183745	2
493	Oxyphylla A Promotes Degradation of -Synuclein for Neuroprotection Activation of Immunoproteasome. **2020**, 11, 559-574	8
492	Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease. **2011**, 4, 1-7	9
491	Immunotherapy Targeting Neurodegenerative Proteinopathies: -Synucleinopathies and Tauopathies. **2020**, 13, 11-19	14
490	Long-Term Outcomes of Genetic Parkinson's Disease. **2020**, 13, 81-96	5
489	-GFP Knock-In Mice Reflect Patterns of Endogenous Expression and Pathological Seeding. **2020**, 7,	8
488	Pronounced -Synuclein Pathology in a Seeding-Based Mouse Model Is Not Sufficient to Induce Mitochondrial Respiration Deficits in the Striatum and Amygdala. **2020**, 7,	6
487	Loss of -Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons. **2017**, 4,	10
486	Hsc70 Ameliorates the Vesicle Recycling Defects Caused by Excess -Synuclein at Synapses. **2020**, 7,	13
485	Parkinson Disease: Etiology, Neuropathology, and Pathogenesis. 3-26	45
484	Immunogenetics of Parkinson Disease. 27-44	2
483	From the baker to the bedside: yeast models of Parkinson's disease. **2015**, 2, 262-279	44
482	The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (-syn) oligomerization and secretion. **2017**, 9, 1677-1697	6
481	overexpression disturbs hippocampal gene expression trajectories in midlife. **2018**, 10, 4024-4041	8
480	Dopaminergic neuron injury in Parkinson's disease is mitigated by interfering lncRNA SNHG14 expression to regulate the miR-133b/-synuclein pathway. **2019**, 11, 9264-9279	30
479	Rep1 microsatellite length influences non-motor symptoms in early Parkinson's disease. **2020**, 12, 20880-20887	2
478	Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose. **2015**, 6, 40480-95	10

477	Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. **2008**, 14, 451-64	362
476	Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins. **2013**, 17,	20
475	Parkinson's disease: from genetics to clinical practice. **2013**, 14, 560-7	17
474	The Effects of Variants in the Parkin, PINK1, and DJ-1 Genes along with Evidence for their Pathogenicity. **2017**, 18, 702-714	13
473	PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration. **2016**, 13, 150-63	43
472	Drug targets from genetics: synuclein. **2011**, 10, 712-23	8
471	Cellular models, genomic technologies and clinical practice: a synthesis of knowledge for the study of the mechanisms, diagnostics and treatment of Parkinson's disease. **2017**, XII,	3
470	Traditional Chinese medicine-based neurorestorative therapy for Alzheimer and Parkinson disease. **2019**, 7, 207-222	12
469	Postmortem studies in Parkinson's disease. **2004**, 6, 281-93	48
468	Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. **2011**, 5, 59	281
467	Papel da alfa-sinuclea e da disfun mitocondrial associada doen de Parkinson. **2012**, 20, 273-284	2
466	[Copy number variations in the human genome: their mutational mechanisms and roles in diseases]. **2011**, 33, 857-69	4
465	Neuroprotective effects of lithium on a chronic MPTP mouse model of Parkinson's disease via regulation of synuclein methylation. **2019**, 19, 4989-4997	9
464	The ubiquitous role of mitochondria in Parkinson and other neurodegenerative diseases. **2020**, 7, 43-65	9
463	Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway. **2013**, 8, 3269-74	7
462	Protein Quality Control in Neurodegeneration and Neuroprotection. **2020**, 1-24	3
461	Molecular Interactions of Synuclein, Mitochondria, and Cellular Degradation Pathways in Parkinson's Disease. **2020**, 212-234	1
460	The role of quercetin on the survival of neuron-like PC12 cells and the expression of synuclein. **2015**, 10, 1113-9	29

459	Subcellular localization of alpha-synuclein aggregates and their interaction with membranes. **2018**, 13, 1136-1144	32
458	Small molecules to prevent the neurodegeneration caused by -synuclein aggregation. **2020**, 15, 2260-2261	4
457	Alpha-synuclein truncation and disease. **2012**, 04, 1167-1177	6
456	Polymorphisms in the SNCA Gene: Association with the Risk of Development of the Sporadic Form of Parkinson Disease and the Level of SNCA Gene Expression in Peripheral Blood of Patients from Russia. **2013**, 04, 208-214	5
455	Using induced pluripotent stem cells for modeling Parkinson's disease. **2019**, 11, 634-649	14
454	Dexamethasone induces the expression of LRRK2 and -synuclein, two genes that when mutated cause Parkinson's disease in an autosomal dominant manner. **2013**, 46, 454-9	8
453	Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation. **2019**, 52, 349-359	8
452	Induced pluripotent stem cells for modeling neurological disorders. **2015**, 5, 209-21	28
451	A microRNA negative feedback loop downregulates vesicle transport and inhibits fear memory. **2016**, 5,	20
450	Overriding FUS autoregulation in mice triggers gain-of-toxic dysfunctions in RNA metabolism and autophagy-lysosome axis. **2019**, 8,	49
449	Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy. **2019**, 8,	106
448	Key issues in essential tremor genetics research: Where are we now and how can we move forward?. **2013**, 3,	19
447	Brain regions susceptible to alpha-synuclein spreading. **2021**,	4
446	Biomarkers in Parkinson Disease. **2022**, 155-180	7
445	Examining the Toxicity of -Synuclein in Neurodegenerative Disorders. **2021**, 11,	0
444	Activators of alpha synuclein expression identified by reporter cell line-based high throughput drug screen. **2021**, 11, 19857	
443	CK1BP Reduces -Synuclein Oligomerization and Aggregation Independent of Serine 129 Phosphorylation. **2021**, 10,	
442	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. **2021**, 73, 33-97	2

441	Functions of Intracellular Alpha-Synuclein in Microglia: Implications for Parkinson's Disease Risk. **2021**, 15, 759571	1
440	Targeting Microglial Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease. **2021**, 12, 719807	12
439	A Quantitative Perspective of Alpha-Synuclein Dynamics - Why Numbers Matter. **2021**, 13, 753462	0
438	Postsynaptic synucleins mediate vesicular exocytosis of endocannabinoids.	0
437	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease. **2021**, 16, e0257372	2
436	Parkinson's disease and microRNAs - Lessons from model organisms and human studies. **2021**, 155, 111585	0
435	Genetics of Parkinson's disease. **2004**, 6, 295-301	1
434	The goldilocks genes. Our chromosomes can get sloppy and delete or pick up genes. Researchers are starting to probe how these DNA miscues affect health and longevity. **2004**, 2004, ns8	
433	Parkinsonism, Autosomal Dominant. **2004**, 970-975	
432	Use of C. elegans to Model Human Movement Disorders. **2005**, 111-126	1
431	Mechanisms of degeneration in Parkinson disease. **2005**, 23-30	
430	Genome Variation Influencing Gene Copy Number and Disease. **2005**, 611-637	
429	Genetics Of Parkinson Disease. **2005**, 611-631	
428	Reactive Oxygen and Nitrogen Species. **2005**, 107-119	
427	Methionine Sulfoxide Reductase System. **2005**, 199-212	
426	Que nous apprennent les gnes responsables des formes familiales de maladie de Parkinson ?. **2006**, 190, 485-498	
425	LRRK2-Associated Parkinsonism. **2007**, 45-59	
424	Molecular Pathways of Mitochondrial Dysfunction in Neurodegeneration: the Paradigms of Parkinson's and Huntington's Diseases. **2007**, 193-219	

423	Tremors: Diagnosis and Treatment. **2007**, 451-478	2
422	Environmental and Genetic Interactions: Key to Sporadic Parkinson's Disease?. **2007**, 607-619	
421	Parkin and Neurodegeneration. 211-236	
420	Overview: rodent and fish models of parkinson's disease. **2008**, 219-223	
419	Dissecting the Biochemical Pathways Mediated by Genes Implicated in Parkinson Disease: Induction of DJ-1 Expression in A30P Synuclein Mice. **2008**, 97-112	
418	Cellular and Molecular Mechanisms Underlying Parkinson Disease: The Role of Molecular Chaperones. **2008**, 51-68	
417	Genetic Models of Familial Parkinson's Disease. **2008**, 225-236	
416	Purification and Quantification of Neural synuclein: Relevance for Pathogenesis and Biomarker Development. **2008**, 559-573	1
415	Amyloid Fibril Formation of Natively Unfolded Proteins. 247	
414	Nucleotide Sequence Divergence between Humans and Chimpanzees.	
413	The Shaking Palsy - Advances in Our Understanding of Parkinson's Disease. **2008**,	
412	Cognitive Deficits in Parkinson Disease. **2009**, 1-15	
411	The Genetic Approach to Dementia. **2009**, 1222-1232	
410	Endophenotype Strategy in Epilepsy Genetics. **2009**, 135-149	
409	Parkinson Disease: An Overview of Pathogenesis. **2009**, 159-178	
408	Treating Oxidative Neural Injury: Methionine Sulfoxide Reductase Therapy for Parkinson Disease. **2009**, 193-206	
407	Molecular Biology of Parkinson's Disease. **2009**, 277-289	
406	Disorders with Synuclein Pathology and Parkinsonism.	

405 Neuroprotective Strategies in Parkinson□ Disease. **2009**, 498-508

404 Dopamine and Motor Function in Rat and Mouse Models of Parkinson□ Disease. **2009**, 279-285

403 AD-FTLD Spectrum: New Understanding of the Neurodegenerative Process from the Study of Risk Genes. **2010**, 235-246

402 Alpha-Synuclein. **2010**, 31-34

401 Genetic Basis of Monogenic Forms of Parkinson Disease.

400 Molecular Genetics of Parkinsonism.

399 Cognitive Dysfunction in Genetic Mouse Models of Parkinsonism. **2011**, 485-492

398 The Genetics of Alzheimer□ Disease and Parkinson□ Disease. **2011**, 695-755 0

397 Methodological Strategies to Evaluate Functional Effectors Related to Parkinson□ Disease Through Application of Caenorhabditis elegans Models. **2011**, 31-53

396 Aspects g□□iques. **2011**, 21-31

395 □iopathog□ie. **2011**, 9-19

394 Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease. 455-461

393 Animal Models of Parkinson's Disease: The Non-Motor and Non-Dopaminergic Features. 79-92

392 Cognitive and Behavioral Neurology. **2012**, 161-215

391 Introduction to □Synucleinopathies. 189-193

390 Molecular Diagnosis of Neurogenetic Disorders: General Issues, Huntington's Disease, Parkinson's Disease and Dystonias. 51-60

389 Mutations in Nuclear Genes That Affect Mitochondrial Function in Parkinson□ Disease. **2012**, 43-61

388 Oligomers of □Synuclein in the Pathogenesis of Parkinson□ Disease. **2012**, 189-216

387 Parkinson's disease. **2012**, 81-94

386 Nanoelectrode Arrays for Monitoring and Modulating Nervous System Electrical and Chemical Activity. **2012**, 76-79

385 Advances in the Genetics of Human Tremor. **2013**, 53-78

384 Interaction of Human α-Synuclein with VTI1B May Modulate Vesicle Trafficking. **2012**, 33, 3071-3075 1

383 An Overview of Dementias. **2012**, 21, 75-84

382 Neuropathology of parkinsonism. **2013**, 239-257

381 Animal models of Parkinson's disease and related disorders. **2013**, 281-316

380 Genetics. **2013**, 317-340

379 Neuroscience and the Genomic Revolution: An Overview. **2013**, 1018-1027

378 Dementia with Lewy Bodies. **2014**, 155-177

377 Innate and Adaptive Immune-Mediated Neuroinflammation and Neurodegeneration in Parkinson's Disease. **2014**, 119-142

376 Protein seeding in Alzheimer's disease and Parkinson's disease: Similarities and differences. **2014**, 4, 23

375 Autophagic Pathways and Parkinson Disease. **2014**, 727-751

374 Diabetes. **2014**, 115-146

373 Parkinson Disease. **2015**, 27-40

372 Genetics of Dementia with Lewy Bodies. **2015**, 65-74

371 Conformational Disease and RNA Disease Theory in the Context of Neurodegenerative Diseases. **2015**, 3-22

370 Gene Therapy for Neurological Diseases. **2015**, 1171-1216

369 Parkinson's Disease. **2015**, 263-299

368 Modélisation expérimentale de l'agrégation et de la propagation de l'α-synucléine dans les synucléinopathies. **2015**, 199, 797-808

367 Toxin-Mediated Complex I Inhibition and Parkinson's Disease. **2016**, 115-137 0

366 Extracellular α-Synuclein as a Target for Immunotherapy. **2016**, 73-83

365 Neuropsychological Screening and Advanced Neuropsychological Tests. **2016**, 51-90

364 Findings of 123I-MIBG Cardiac Scintigraphy: Parkinson's Disease and Related Disorders and Others (RBD, Cardiac Diseases, DM, etc.). **2017**, 231-257

363 Age-dependence and aging-dependence: The case of neuronal loss and lifespan in a C. elegans model of Parkinson's disease.

362 Genetics of Movement Disorders. **2017**, 77-92

361 [illegible]
"[illegible] **2017**, 4-14

360 Protein Structure Modeling of Abnormal Genes Associated with PARK 1 and PARK 8 Loci Related to Autosomal Dominant Parkinson's Disease and Docking the Protein(s) with Appropriate Ligands. **2017**, 43-89

359 Drosophila Models of Parkinson's Disease?. **2017**,

358 5 Stem Cells for Parkinson's Disease. **2017**, 101-114

357 Universidad e Hispanidad. Tres décadas de trayectorias entrecruzadas del ministro José Ibáñez Martín y el catedrático exiliado Mariano Ruiz-Funes. **2017**, 77, 263 1

356 Identification of β-synuclein on secretory granules in chromaffin cells and the effects of α- and β-synuclein on BDNF discharge following fusion.

355 Endogenous α-SYN protein analysis from human brain tissues using single-molecule pull-down assay.

354 Advanced Gene-Targeting Methods to Generate Cell Line Models that Preserve Native Regulatory Elements for Efficient High-Throughput Drug Screenings. **2018**, 643-647

353 Prion-Like Propagation in Neurodegenerative Diseases. **2018**, 189-242

352 Inducible alpha-synuclein overexpression affects human Neural Stem Cells behavior.

351	Atxn2-CAG100-knock-in affects mouse lifespan and vestibulo-cerebellar function via neural disconnection.	
350	REM Sleep Behavior Disorder: The Link Between Synucleinopathies and REM Sleep Circuits. **2019**, 625-637	0
349	C. elegans genetic background modifies the core transcriptional response in an α-synuclein model of Parkinson's disease.	
348	Disorders with Synuclein Pathology and P arkinsonism. 1-7	
347	Parkinson-associated SNCA enhancer variants revealed by open chromatin in mouse dopamine neurons.	
346	Chronic corticosterone enhancement aggravates alpha-synuclein brain spreading pathology and substantia nigra neurodegeneration in mice.	0
345	The Use of Co-immunoprecipitation to Study Conformation-Specific Protein Interactions of Oligomeric α-Synuclein Aggregates. **2019**, 23-36	
344	LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.	
343	From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies. **2019**, 2049, 419-444	2
342	Nutraceuticals Role in Stress, Aging, and Neurodegenerative Disorders. **2019**, 288-306	
341	Lewy Body Disease. **2019**, 298-321	
340	Hsc70 Ameliorates the Vesicle Recycling Defects Caused by Excess α-Synuclein at Synapses.	0
339	Intra-mitochondrial proteostasis is directly coupled to alpha-synuclein and Amyloid β1-42 pathology.	
338	The genetic architecture of Parkinson disease in Spain: characterizing population-specific risk, differential haplotype structures, and providing etiologic insight.	1
337	Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions.	
336	Transcriptomic signatures of brain regional vulnerability to Parkinson's disease.	0
335	Misfolded α-synuclein causes hyperactive respiration without functional deficit in live neuroblastoma cells.	
334	Organotypic slice culture model demonstrates interneuronal spreading of alpha-synuclein aggregates.	

333	Mathematical modeling of the role of α-synuclein and dopamine in cell death in Parkinson's disease provides the molecular basis to the toxicity of different point mutations.	
332	Integrated Sequencing & Array Comparative Genomic Hybridization in Familial Parkinson's Disease.	
331	Transgenic mice expressing human alpha-synuclein in noradrenergic neurons develop locus coeruleus pathology and non-motor features of Parkinson's disease.	0
330	Alpha synuclein aggresomes inhibit ciliogenesis and multiple functions of the centrosome.	
329	Microglia Clear Neuron-released α-Synuclein via Selective Autophagy and Prevent Neurodegeneration.	1
328	The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure.	
327	The role of environmental toxins and inflammation in Parkinson's disease pathophysiology: a historical perspective and research-based evidence. **2020**, 39-55	
326	Salivary Biomarkers in Neurologic Diseases. **2020**, 121-152	
325	α-Synuclein-112 impairs synaptic vesicle recycling consistent with its enhanced membrane binding properties.	
324	Chronic α-Synuclein Accumulation in Rat Hippocampus Induces Lewy Bodies Formation and Specific Cognitive Impairments. **2020**, 7,	2
323	Snca-GFP knock-in mice reflect patterns of endogenous expression and pathological seeding.	
322	Robust Sequence Determinants of α-Synuclein Toxicity in Yeast Implicate Membrane Binding.	
321	α-Synuclein Overexpression in SH-SY5Y Human Neuroblastoma Cells Leads to the Accumulation of Thioflavin S-positive Aggregates and Impairment of Glycolysis. **2020**, 85, 604-613	2
320	Characterization of small molecule induced changes in Parkinson's-related trafficking via the Nedd4 ubiquitin signaling cascade.	
319	α-Synuclein facilitates dopamine release during burst firing of substantia nigra neurons in vivo.	
318	stLFRsv: a germline SV analysis pipeline using co-barcoded reads.	
317	A population scale analysis of rare SNCA variation in the UK Biobank.	
316	CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson's disease.	

315	The SNCA-Rep1 Polymorphic Locus: Association with the Risk of Parkinson's Disease and SNCA Gene Methylation. **2020**, 12, 105-110	1
314	Protein structure prediction in the HP model using scatter search algorithm. **2020**,	
313	Neuroprotective mechanisms of red clover and soy isoflavones in Parkinson disease models.	
312	Subcellular-specific alpha-synuclein in Parkinson's disease. **2020**, 175-188	
311	Alpha-synuclein gene and Parkinson's disease. **2020**, 19-34	
310	Parkinson disease and related disorders. **2020**, 19-30	1
309	DNA sequencing and other methods of exonic and genomic analyses. **2020**, 109-120	
308	Deep Brain Stimulation for Parkinson Disease. **2020**, 171-191	
307	Animal Models in Neuro Ophthalmology. **2020**, 401-426	
306	Executive Summary of the 2019 International Conference of Korean Dementia Association: Exploring the Novel Concept of Alzheimer's Disease and Other Dementia: a Report from the Academic Committee of the Korean Dementia Association. **2020**, 19, 39-53	1
305	Alpha-synuclein and neuroinflammation in Parkinson's disease. **2020**, 431-446	1
304	Introduction and Basic Concepts in Stem Cell Research and Therapy: The Facts and the Hype. **2020**, 1-36	
303	Progression of symptoms in Parkinson's disease. **2020**, 3-20	0
302	Targeted attenuation of elevated histone marks at SNCA alleviates synuclein in Parkinson disease.	
301	SCA4 locus-associated gene Ronin (Thap11) increases Ataxin-1 protein levels and induces cerebellar degeneration in a mouse model of ataxia.	
300	Mitochondria-mitochondria interaction networks show altered topological patterns in Parkinson disease.	0
299	Pronounced synuclein pathology in a seeding-based mouse model is not sufficient to induce mitochondrial respiration deficits in the striatum and amygdala.	
298	A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. **2021**, 12, 705407	5

297	An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels. **2021**, 1	2
296	Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function. **2021**, 11, 21946	0
295	Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies. **2022**, 202, 108870	3
294	Spontaneous Formation of Lewy Bodies in a Rodent. **2005**, 321-329	
293	Early Behavioral Phenotypes in Mouse Models of Huntington's and Parkinson's Diseases. **2005**, 349-359	
292	Parkinson's Disease and Related Disorders. **2006**, 199-212	
291	Neurogenetics in Parkinson's Disease. **2008**, 9-16	
290	Novel Proteins in α-Synucleinopathies. **2009**, 207-224	
289	Genetics of Parkinson disease. **2004**, 1, 235-242	
288	Polyphenols as Potential Therapeutic Drugs in Neurodegeneration.	0
287	Modeling multifunctionality of genes with secondary gene co-expression networks in human brain provides novel disease insights.	
286	Presynaptic accumulation of α-synuclein causes synaptopathy and progressive neurodegeneration.	
285	Gene-corrected Parkinson's disease neurons show the A30P alpha-synuclein point mutation leads to reduced neuronal branching and function.	0
284	Understanding the Pathogenesis Involved in Parkinson's Disease and Potential Therapeutic Treatment Strategies. **2020**, 20, 88-102	3
283	Familial occurrence of dementia with Lewy bodies. **2004**, 12, 179-88	8
282	Genetic neuropathology of Parkinson's disease. **2008**, 1, 217-31	63
281	Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies. **2008**, 2, 41-9	4
280	Molecular chaperones in Parkinson's disease--present and future. **2011**, 1, 299-320	27

279	Detecting highly differentiated copy-number variants from pooled population sequencing. **2013**, 344-55	6
278	Protein aggregation and degradation mechanisms in neurodegenerative diseases. **2013**, 2, 1-14	120
277	Translational inhibition of -synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. **2019**, 8, 1-15	9
276	Modeling synucleinopathies in rodents. **2021**, 2, 65-154	0
275	Spreading of alpha-synuclein pathology from the gut to the brain in Parkinson's disease. **2021**, 2, 155-191	
274	Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an -arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity.. **2022**, 3, 96-111	2
273	Parkinson's Disease Modification through Abl Kinase Inhibition: An Opportunity. **2021**,	2
272	Rescue of -synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking. **2021**,	5
271	Ca2+ administration prevents -synuclein proteotoxicity by stimulating calcineurin-dependent lysosomal proteolysis. **2021**, 17, e1009911	0
270	Assembly of -synuclein and neurodegeneration in the central nervous system of heterozygous ́M83 mice following the peripheral administration of -synuclein seeds. **2021**, 9, 189	2
269	Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model.. **2021**, 13,	0
268	Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease. **2021**, 1	
267	-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox. **2021**, 11, 196	1
266	A novel mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein fibrils and recapitulates its pathological diversity.	0
265	Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors. **2021**, 2, 1-63	
264	Alpha-Synuclein ́Toxicity: An Insight on Controversial Issues. **2021**, 1-18	
263	Proteostasis impairment and ER stress as a possible target to treat Parkinson's disease. **2021**, 2, 245-260	
262	Alpha synuclein, the culprit in Parkinson disease, is required for normal immune function.. **2022**, 38, 110090	9

261	Intermediates of -synuclein aggregation: Implications in Parkinson's disease pathogenesis.. **2021**, 281, 106736	5
260	The protective role of exercise against age-related neurodegeneration.. **2021**, 74, 101543	4
259	Animal models of brain-first and body-first Parkinson's disease.. **2021**, 163, 105599	3
258	Microarray Genotyping Identifies New Loci Associated with Dementia in Parkinson's Disease.. **2021**, 12,	1
257	Pathogenic mechanisms of cytosolic and membrane-enriched -synuclein converge on fatty acid homeostasis.. **2022**,	2
256	Longitudinal Study of SNCA Rep1 Polymorphism on Executive Function in Early Parkinson's Disease.. **2022**,	
255	T cells, -synuclein and Parkinson disease.. **2022**, 184, 439-455	0
254	Passive Immunization in Alpha-Synuclein Preclinical Animal Models.. **2022**, 12,	1
253	Entstehung und Pr ention altersassoziierter neurodegenerativer. **2022**, 335-356	
252	Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells.. **2022**, 59, 1273	5
251	Reduced synaptic activity and dysregulated extracellular matrix pathways are common phenotypes in midbrain neurons derived from sporadic and mutation-associated Parkinson disease patients.	0
250	Insights into the multifaceted role of circular RNAs: implications for Parkinson's disease pathogenesis and diagnosis.. **2022**, 8, 7	2
249	Quantifying regional -synuclein, amyloid , and tau accumulation in lewy body dementia.. **2022**,	2
248	Therapeutics in the Pipeline Targeting -Synuclein for Parkinson's Disease.. **2022**, 74, 207-237	8
247	Alpha-synuclein and cortico-striatal plasticity in animal models of Parkinson disease.. **2022**, 184, 153-166	1
246	Targeting -Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models.. **2021**, 12, 786835	0
245	DNA Methylation: A Promising Approach in Management of Alzheimer's Disease and Other Neurodegenerative Disorders.. **2022**, 11,	4
244	Nanoparticles in Combating Neuronal Dysregulated Signaling Pathways: Recent Approaches to the Nanoformulations of Phytochemicals and Synthetic Drugs Against Neurodegenerative Diseases.. **2022**, 17, 299-331	2

243	Roles of Synuclein and Disease-Associated Factors in Models of Parkinson's Disease.. **2022**, 23,	1
242	Living in syn: Tackling aggregates in Parkinson's disease.. **2022**, 110, 351-352	1
241	The amyloid state of proteins: A boon or bane?. **2022**, 200, 593-617	0
240	Up and Down Synuclein Transcription in Dopamine Neurons Translates into Changes in Dopamine Neurotransmission and Behavioral Performance in Mice.. **2022**, 23,	0
239	Coupling comprehensive pesticide-wide association study to iPSC dopaminergic screening identifies and classifies Parkinson-relevant pesticides.	1
238	Modulation of miR-181 influences dopaminergic neuronal degeneration in a mouse model of Parkinson's disease.. **2022**, 28, 1-15	1
237	Parkinson's Disease: From Genetics to Molecular Dysfunction and Targeted Therapeutic Approaches. **2022**,	0
236	Protein folding in 3D lattice HP model using a combining cuckoo search with the Hill-Climbing algorithms. **2022**, 108564	1
235	Cortical neuronal differentiation is not impaired by elevated levels of synuclein in human pluripotent stem cells.	
234	Involvement of molecular chaperone in protein-misfolding brain diseases.. **2022**, 147, 112647	2
233	Impact of endolysosomal dysfunction upon exosomes in neurodegenerative diseases.. **2022**, 105651	0
232	Pathological syn aggregation is mediated by glycosphingolipid chain length and the physiological state of syn in vivo. **2021**, 118,	4
231	Mitochondrial Phenotypes in Parkinson's Diseases-A Focus on Human iPSC-Derived Dopaminergic Neurons.. **2021**, 10,	1
230	Mitochondrial dysfunction in protein conformational disorders. **2018**, 97, 703-713	1
229	Regulation of membrane dynamics by Parkinson's disease-associated genes. **2018**, 97, 715-725	2
228	Parkinson's disease: what the model systems have taught us so far. **2018**, 97, 729-751	3
227	Language impairment in primary progressive aphasia and other neurodegenerative diseases. **2019**, 98,	1
226	Immunotherapeutic interventions in Parkinson's disease: Focus on Synuclein.. **2022**, 129, 381-433	0

225	Recent Update on the Development of Leucine- Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.. **2022**,	1
224	Gene Co-expression Analysis of the Human Substantia Nigra Identifies ZNHIT1 as an SNCA Co-expressed Gene that Protects Against -Synuclein-Induced Impairments in Neurite Growth and Mitochondrial Dysfunction in SH-SY5Y Cells.. **2022**, 1	
223	Human -synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy.. **2022**, 12, 79	1
222	S-Nitrosylation of p62 Inhibits Autophagic Flux to Promote -Synuclein Secretion and Spread in Parkinson's Disease and Lewy Body Dementia.. **2022**,	3
221	Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson's Disease.. **2022**, 15, 805087	2
220	Characterization of altered molecular mechanisms in Parkinson disease through cell type-resolved multi-omics analyses.	
219	Chicago sky blue 6B inhibits -synuclein aggregation and propagation.. **2022**, 15, 27	
218	Occurrence of Total and Proteinase K-Resistant Alpha-Synuclein in Glioblastoma Cells Depends on mTOR Activity.. **2022**, 14,	0
217	Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer's disease: review, recommendation, implementation and application.. **2022**, 17, 17	2
216	O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and -Synuclein Proteinopathies.. **2022**,	0
215	Repurposed Agents in Alzheimer Disease Drug Development. **2022**, 54-61	
214	-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity.. **2022**, 119, e2109617119	3
213	Distribution of -Synuclein Aggregation in the Peripheral Tissues.. **2022**, 1	0
212	Recombinant pro-CTSD (cathepsin D) enhances SNCA/-Synuclein degradation in -Synucleinopathy models.. **2022**,	1
211	Effects of Cannabidiol on Parkinson's Disease in a Transgenic Mouse Model by Gut-Brain Metabolic Analysis.. **2022**, 2022, 1525113	
210	-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.. **2022**,	1
209	Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.. **2022**, 79, 174	3
208	Propagation of tau and -synuclein in the brain: therapeutic potential of the glymphatic system.. **2022**, 11, 19	0

207	Neurons with Cat's Eyes: A Synthetic Strain of Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions.. **2022**, 12,	2
206	Change in the Oligomeric State of Synuclein Variants in Living Cells.. **2022**,	1
205	Human organotypic brain model as a tool to study chemical-induced dopaminergic neuronal toxicity.. **2022**, 105719	2
204	Alpha-SYNUCLEINOPATHY reduces NMNAT3 protein levels and neurite formation that can be rescued by targeting the NAD+ pathway.. **2022**,	0
203	Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases.. **2022**, 155, 105307	1
202	Autophagy system as a potential therapeutic target for neurodegenerative diseases.. **2022**, 155, 105308	0
201	Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action.. **2022**, 149, 112877	11
200	The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches.. **2022**, 119243	2
199	Synuclein Overexpression Increases Dopamine D2/3 Receptor Binding and Immune Activation in a Model of Early Parkinson's Disease.. **2021**, 9,	1
198	Lipotoxicity Downstream of Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?. **2021**, 12,	1
197	Neuropathology and molecular diagnosis of Synucleinopathies.. **2021**, 16, 83	10
196	Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice.. **2021**, 1	0
195	Whole genome sequencing-based copy number variations reveal novel pathways and targets in Alzheimer's disease.. **2021**,	0
194	CHAPTER 1. Etiology and Pathogenesis of Parkinson Disease. 1-26	1
193	OUP accepted manuscript.	0
192	Neuroglial Senescence, Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson's Disease.. **2022**, 16, 824191	1
191	A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses Synuclein Toxicity.. **2022**, 1	0
190	Biology in balance: human diploid genome integrity, gene dosage, and genomic medicine.. **2022**,	3

189 Synaptic vesicle binding of □synuclein is modulated by □- and □synucleins.. **2022**, 39, 110675 0

188 Transcriptome and Proteome Analysis in LUHMES Cells Overexpressing Alpha-Synuclein.. **2022**, 13, 787059 0

187 Parkinson’s disease and the spectrum of Lewy body disease. 10-26

186 Synucleinopathies. 149-175

185 CHAPTER 11. At the Intersection Between Mitochondrial Dysfunction and Lysosomal Autophagy: Role of PD-Related Neurotoxins and Gene Products. 325-388

184 Factors Affecting the Fibrillation of □Synuclein, a Natively Unfolded Protein. 265-285

183 Image_1.JPEG. **2020**,

182 Image_2.JPEG. **2020**,

181 Image_3.JPEG. **2020**,

180 Data_Sheet_1.docx. **2020**,

179 Data_Sheet_1.docx. **2020**,

178 Image_1.pdf. **2018**,

177 DataSheet1.pdf. **2018**,

176 Image_1.pdf. **2020**,

175 Data_Sheet_1.pdf. **2018**,

174 Data_Sheet_2.docx. **2018**,

173 Data_Sheet_3.docx. **2018**,

172 Data_Sheet_1.docx. **2018**,

171	Data_Sheet_1.PDF. **2020**,	
170	Image_1.JPEG. **2019**,	
169	Image_2.JPEG. **2019**,	
168	Image_3.JPEG. **2019**,	
167	Image_4.JPEG. **2019**,	
166	Image_5.JPEG. **2019**,	
165	Image_6.JPEG. **2019**,	
164	Data_Sheet_1.PDF. **2019**,	
163	Presentation_1.pdf. **2020**,	
162	Reduction of the □synuclein expression promotes slowing down early neuropathology development in the model of Parkinson's disease.. **2022**, 1-10	
161	Nutraceuticals Role in Stress, Aging, and Neurodegenerative Disorders. **2022**, 83-97	
160	A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity.. **2022**, 8, eabn0044	0
159	Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation. **2022**, 12, 655	0
158	Second Sphere Interactions in Amyloidogenic Diseases.. **2022**,	3
157	Comparative Analysis of the Relative Fragmentation Stabilities of Polymorphic Alpha-Synuclein Amyloid Fibrils. **2022**, 12, 630	
156	Toward Novel [F]Fluorine-Labeled Radiotracers for the Imaging of □Synuclein Fibrils.. **2022**, 14, 830704	
155	Ultrastructural and biochemical classification of pathogenic tau, □synuclein and TDP-43.. **2022**, 143, 613-640	1
154	Macroautophagy in CNS health and disease.. **2022**,	3

153	The aging immune system in Alzheimer's and Parkinson's diseases.. **2022**, 1	1
152	Cross-species genetic screens identify transglutaminase 5 as a regulator of polyglutamine-expanded ataxin-1.. **2022**, 132,	1
151	Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.	
150	Lewy Body-Associated Proteins A-Synuclein (a-syn) as a Plasma-Based Biomarker for Parkinson Disease. **2022**, 14,	0
149	mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.. **2022**, 101, 154125	0
148	Molecular mechanisms of amyloid formation in living systems.	3
147	Human Brain-Based Models Provide a Powerful Tool for the Advancement of Parkinson Disease Research and Therapeutic Development. **2022**, 16,	0
146	Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies. **2022**, 14,	0
145	Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein. **2022**, 8,	
144	Library-Derived Peptide Aggregation Modulators of Parkinson Disease Early-Onset Synuclein Variants.	0
143	Loss of GBA in zebrafish leads to dopaminergic neurodegeneration, but overexpression of synuclein does not further worsen degeneration. **8**, Publish Ahead of Print,	
142	An Isogenic Collection of Pluripotent Stem Cell Lines With Elevated Synuclein Expression Validated for Neural Induction and Cortical Neuron Differentiation. **2022**, 10,	
141	Neuroinflammation in Parkinson Disease Putative Pathomechanisms and Targets for Disease-Modification. **2022**, 13,	3
140	Synuclein Analysis in Adult Xenopus laevis. **2022**, 23, 6058	0
139	Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases.	0
138	Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function. **2022**, 10,	0
137	Alpha-Synuclein Aggregation Pathway in Parkinson Disease: Current Status and Novel Therapeutic Approaches. **2022**, 11, 1732	3
136	Structures of tau and synuclein filaments from brains of patients with neurodegenerative diseases. **2022**, 105362	0

135	Induced pluripotent stem cells: a tool for modeling Parkinson disease. **2022**,	1
134	Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. **2022**, 10,	0
133	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. 13,	0
132	Pathogie et physiopathologie de la maladie de Parkinson. **2022**, 29-38	
131	Crosstalk Between Autophagy and Nutrigenomics in Neurodegenerative Diseases. **2022**, 175-199	
130	The Parkinson disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. **2022**, 185, 2035-2056.e33	5
129	Lipase regulation of cellular fatty acid homeostasis as a Parkinson disease therapeutic strategy. **2022**, 8,	1
128	Plasticity of Membrane Binding by the Central Region of Synuclein. 9,	1
127	Psychosis in Parkinson Disease: A Lesson from Genetics. **2022**, 13, 1099	1
126	Detailed insight into the pathophysiology and the behavioral complications associated with the Parkinson's disease and its medications. **2022**, 8,	
125	Structural conversion of synuclein at the mitochondria induces neuronal toxicity.	
124	The Role of AlphSynuclein in Mouse Models of Acute, Inflammatory and Neuropathic Pain. **2022**, 11, 1967	0
123	Expanding the HPSE2 Genotypic Spectrum in Urofacial Syndrome, A Disease Featuring a Peripheral Neuropathy of the Urinary Bladder. 13,	0
122	Deep phenotyping for precision medicine in Parkinson's disease. **2022**, 15,	0
121	Retrograde axonal autophagy and endocytic pathways are parallel but separate in neurons.	
120	Cryo-EM structures of synuclein filaments from Parkinson disease and dementia with Lewy bodies.	0
119	Autophagy in health and disease: From molecular mechanisms to therapeutic target. **2022**, 3,	7
118	Liquid-liquid Phase Separation of Synuclein: A New Mechanistic Insight for Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis. **2022**, 167713	3

117	TNF-α promotes α-synuclein propagation through stimulation of senescence-associated lysosomal exocytosis.	1
116	Functional and Pathological Effects of α-Synuclein on Synaptic SNARE Complexes. **2022**, 167714	3
115	Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease. **2022**, 119,	1
114	Joint Computational/Cell-Based Oligomerization for Screening Inhibitors of Tau Assembly: A Proof-of-Concept Study. **2022**, 1-13	0
113	New Perspectives on Immune Involvement in Parkinson's Disease Pathogenesis. **2022**, 1-7	
112	Parkinson disease and other synucleinopathies. **2023**, 253-274	
111	Crosslink between mutations in mitochondrial genes and brain disorders: implications for mitochondrial-targeted therapeutic interventions. **2023**, 18, 94	2
110	Gene-Based Therapeutics for Parkinson's Disease. **2022**, 10, 1790	1
109	α-Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid-Binding Property.	0
108	Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies. **2022**, 8,	5
107	Trial of Cinpanemab in Early Parkinson's Disease. **2022**, 387, 408-420	16
106	Stable Cavitation Interferes with Aβ1-42 Oligomerization. **2022**, 62, 3885-3895	1
105	N-Terminal Acetylation of α-Synuclein Slows down Its Aggregation Process and Alters the Morphology of the Resulting Aggregates.	3
104	Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson's disease patients. **2022**, 8,	1
103	Genome-wide analysis of Structural Variants in Parkinson's Disease using Short-Read Sequencing data.	0
102	NLRP3 inflammasome in neurodegenerative disease. **2022**,	5
101	Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease. **2022**, 23, 8586	0
100	An innovative biodevice towards monitoring of miR-153 using specific DNA immobilized on the surface of poly(chitosan) decorated AgNPrs/GQDs-CysA conductive nano-ink: Early-stage diagnosis of Parkinson's disease using biosensor technology. **2022**, 286, 116017	0

99	Development of autophagy enhancers for Parkinson disease therapy. **2022**, 305-320	0
98	Pathological structural conversion of synuclein at the mitochondria induces neuronal toxicity. **2022**, 25, 1134-1148	6
97	Genetics and Pathogenesis of Parkinson's Syndrome. **2023**, 18,	1
96	Identifying the Template for Oligomer to Fibril Conversion for Amyloid- (1-42) Oligomers using Hamiltonian Replica Exchange Molecular Dynamics.	0
95	Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain synuclein oligomers without adverse effects. **2022**, 8,	1
94	Effects of N-terminal acetylation on the aggregation of disease-related synuclein variants. **2022**, 167825	0
93	Precision Medicine in Parkinson Disease: From Genetic Risk Signals to Personalized Therapy. **2022**, 12, 1308	0
92	Structures of synuclein filaments from human brains with Lewy pathology.	5
91	Sequestration of Inflammation in Parkinson Disease via Stem Cell Therapy. **2022**, 23, 10138	0
90	Retrograde axonal autophagy and endocytic pathways are parallel and separate in neurons. JN-RM-1292-22	1
89	Regulation of Parkinson disease-associated genes by Pumilio proteins and microRNAs in SH-SY5Y neuronal cells. **2022**, 17, e0275235	0
88	Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding. **2022**, 8,	0
87	Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective.	0
86	Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping.	0
85	Microbiota- Brain-Gut-Axis Relevance to Parkinson Disease: Potential Therapeutic Effects of Probiotics.. **2022**, 28,	0
84	NLRP3 inflammasomes: A potential target to improve mitochondrial biogenesis in Parkinson's disease. **2022**, 934, 175300	1
83	Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in human midbrain dopaminergic neurons.	0
82	Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications. **2022**, 13,	0

81	Surgical Management of Synucleinopathies. **2022**, 10, 2657	0
80	Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy. **2022**, 8,	1
79	Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson's disease in Drosophila. **2022**, 11,	1
78	A Conceptual Study on the Peripheral Clearance of Brain-Derived α-Synuclein in Humans. **2022**, 1-8	0
77	Cellular Models of Alpha-Synuclein Aggregation: What Have We Learned and Implications for Future Study. **2022**, 10, 2649	0
76	Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease. **2022**, 13, 1937	2
75	Selective neurodegeneration generated by intravenous α-synuclein pre-formed fibril administration is not associated with endogenous α-synuclein levels in the rat brain.	0
74	Large-scale Rare Variant Burden Testing in Parkinson's Disease Identifies Novel Associations with Genes Involved in Neuro-inflammation.	0
73	Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease.	0
72	Future of Monoclonal Antibody Therapy in Parkinson's Disease. 097275312211363	0
71	DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers. **2022**, 13,	1
70	Elevated alpha-synuclein attenuates phagocytosis in SNCA triplication human iPSC-derived neuron:microglia co-cultures.	0
69	Neuroprotective potential of an Ayurvedic compound "Ras Sindoor" on Drosophila melanogaster model of Parkinson's disease.	0
68	The complex role of inflammation and gliotransmitters in Parkinson's disease. **2023**, 176, 105940	0
67	Pyrogallol, Corilagin and Chebulagic acid target the "fuzzy coat" of alpha-synuclein to inhibit the fibrillization of the protein. **2022**, 12, 35770-35777	0
66	A perspective on Drosophila genetics and its insight into human neurodegenerative disease. 9,	0
65	Regulation of Alpha-Synuclein Gene (SNCA) by Epigenetic Modifier TET1 in Parkinson Disease. **2022**, 26, S85-93	0
64	Intronic enhancers of the human SNCA gene predominantly regulate its expression in brain in vivo. **2022**, 8,	1

63	Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson disease in midbrain dopaminergic neurons. **2022**, 8,	1
62	Automated algorithm development to assess survival of human neurons using longitudinal single-cell tracking: Application to synucleinopathy. **2022**,	0
61	NewSNCAmutation and structures of synuclein filaments from juvenile-onset synucleinopathy.	0
60	Cross-omics integration shows cortex-wide synaptic dysfunction at later stages of Alzheimer disease.	0
59	Ultrastructural Study of Dopaminergic Axon Terminals. **2023**, 3-29	0
58	Anti-synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson's disease. **2022**, 105969	1
57	The Role of Lipid Domains and Physical Properties of Membranes in the Development of Age-Related Neurodegenerative Diseases. **2022**, 16, 268-281	0
56	AAV-mediated Expression of a Novel Conformational Anti-Aggregated Synuclein Antibody Prolongs Survival in a Genetic Model of Synucleinopathies.	0
55	Overexpression-Induced Synuclein Brain Spreading.	1
54	Genetic inactivation of the USP19 deubiquitinase regulates a-synuclein ubiquitination and inhibits accumulation of Lewy body like aggregates in mice.	0
53	Interaction Between the Glymphatic System and Synuclein in Parkinson Disease.	0
52	Role of synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson disease.	2
51	The role of the endolysosomal pathway in synuclein pathogenesis in Parkinson disease. 16,	0
50	ATP13A2 Gene Silencing in Drosophila Affects Autophagic Degradation of A53T Mutant Synuclein. **2023**, 24, 1775	0
49	Animal Models of Parkinson's Disease. **2011**, 86-112	0
48	Animal Models and the Pathogenesis of Parkinson's Disease. **2011**, 113-161	0
47	Intracellular Signaling Pathways in Parkinson's Disease. **2011**, 247-282	0
46	Synuclein Toxicity in Drosophila melanogaster Is Enhanced by the Presence of Iron: Implications for Parkinson Disease. **2023**, 12, 261	1

45	Deficiency of RAB39B Activates ER Stress-Induced Pro-apoptotic Pathway and Causes Mitochondrial Dysfunction and Oxidative Stress in Dopaminergic Neurons by Impairing Autophagy and Upregulating Synuclein.	0
44	Evaluating the mouse neural precursor line, SN4741, as a suitable proxy for midbrain dopaminergic neurons.	0
43	Increased Levels of the Parkinson Disease-Associated Gene ITPKB Correlate with Higher Expression Levels of Synuclein, Independent of Mutation Status. **2023**, 24, 1984	0
42	Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue.	0
41	Nuclease-dead S.aureusCas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in patient-derived stem cell model of Parkinson disease.	0
40	Studies on alpha-synuclein and islet amyloid polypeptide interaction. 10,	0
39	The role of structural variations in Alzheimer disease and other neurodegenerative diseases. 14,	0
38	Role of rodent models in advancing precision medicine for Parkinson's disease. **2023**, 3-16	0
37	Interneuronal In Vivo Transfer of Synaptic Proteins. **2023**, 12, 569	0
36	Single-Molecule Two-Color Coincidence Detection of Unlabeled alpha-Synuclein Aggregates. **2023**, 62,	0
35	Characterization of altered molecular mechanisms in Parkinson disease through cell type esolved multiomics analyses. **2023**, 9,	0
34	Unraveling the Complex Interplay between Alpha-Synuclein and Epigenetic Modification. **2023**, 24, 6645	0
33	Beta2-adrenoreceptor agonists and long-term risk of Parkinson's disease. **2023**, 110, 105389	0
32	Alpha-Synuclein Toxicity: An Insight on Controversial Issues. **2022**, 1489-1506	0
31	Genome-Wide Analysis of Structural Variants in Parkinson Disease.	1
30	The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson Disease. **2023**, 66, 2282-2307	0
29	Dysregulation of astrocytic Ca2+ signaling and gliotransmitter release in mouse models of synucleinopathies. **2023**, 145, 597-610	0
28	Single-Molecule Two-Color Coincidence Detection of Unlabeled alpha-Synuclein Aggregates. **2023**, 135,	0

27	Impaired Autophagic-Lysosomal Fusion in Parkinson's Patient Midbrain Neurons Occurs through Loss of ykt6 and Is Rescued by Farnesyltransferase Inhibition. **2023**, 43, 2615-2629	0
26	Synuclein Conformational Strains as Drivers of Phenotypic Heterogeneity in Neurodegenerative Diseases. **2023**, 168011	0
25	Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson Disease. **2023**, 12, 621	0
24	Lewy Body-like Pathology and Loss of Dopaminergic Neurons in Midbrain Organoids Derived from Familial Parkinson Disease Patient. **2023**, 12, 625	0
23	Evaluating the mouse neural precursor line, SN4741, as a suitable proxy for midbrain dopaminergic neurons.	0
22	LRRK2: Genetic mechanisms vs genetic subtypes. **2023**, 133-154	0
21	Alpha-synuclein oligomers activate NFAT proteins modulating synaptic homeostasis and apoptosis.	0
20	Mechanisms of Glucocerebrosidase Dysfunction in Parkinson Disease. **2023**, 168023	0
19	New SNCA mutation and structures of synuclein filaments from juvenile-onset synucleinopathy. **2023**, 145, 561-572	0
18	Proteins and transcriptional dysregulation of the brain extracellular matrix in Parkinson disease: A systematic review.	0
17	Corynoxine B targets at HMGB1/2 to enhance autophagy for synuclein clearance in fly and rodent models of Parkinson's disease. **2023**,	0
16	Genetic testing for Parkinson disease in clinical practice.	0
15	Genetics of Neurogenic Orthostatic Hypotension in Parkinson Disease, Results from a Cross-Sectional In Silico Study. **2023**, 13, 506	0
14	Detection of rare genetic variations in the promoter regions of the ATG16L gene in Parkinson's patients. **2023**, 804, 137195	0
13	A Pilot Study of Ex Vivo Human Prefrontal RNA Transcriptomics in Parkinson Disease.	0
12	Microglia Mediated Neuroinflammation in Parkinson Disease. **2023**, 12, 1012	0
11	Genetic Evidence for Endolysosomal Dysfunction in Parkinson Disease: A Critical Overview. **2023**, 24, 6338	0
10	Cognitive heterogeneity in Parkinson disease: A mechanistic view. **2023**,	0

9	In silico investigation of the structural stability as the origin of the pathogenicity of -synuclein protofibrils. 1-13	0
8	Enhancing Conformational Sampling for Intrinsically Disordered and Ordered Proteins by Variational Autoencoder. **2023**, 24, 6896	0
7	Histone Deacetylase 4 Inhibition Reduces Rotenone-Induced Alpha-Synuclein Accumulation via Autophagy in SH-SY5Y Cells. **2023**, 13, 670	0
6	Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of -Synuclein in Parkinson Disease. **2023**, 11, 1187	0
5	Disrupting the -synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson disease. **2023**, 14,	0
4	Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms.	0
3	Cntnap4 partial deficiency exacerbates -synuclein pathology through astrocyte-microglia C3-C3aR pathway. **2023**, 14,	0
2	Concomitant protein pathogenesis in Parkinson disease and perspective mechanisms. 15,	0
1	A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides. **2023**, 14,	0